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Hematopoietic stem cell transplantation (HSCT) is a therapy for many diseases, 
however, development of graft versus host disease (GVHD) severely limits the successful 
use of HSCT. Pre-transplant conditioning including total body irradiation (TBI) causes 
tissue damage and cytokine production that activates antigen presenting cells (APCs). 
This change triggers monocyte differentiation to macrophages that present alloantigen 
to T cells during early GVHD. A better understanding of monocytes/macrophages 
activation during the early phase of alloresponse is needed. This study evaluated 
monocyte/macrophage function during the early phase alloresponse by measuring 
surface marker expression in whole blood mixed leukocytes reaction (MLR). To simulate 
GVHD inflammatory conditions, IFN-γ or IL-4 were added. In response to the allogeneic 
cells in MLR culture (day 1 and 2), monocytes/macrophages showed significant up-
regulation of CD86, HLA-DR, CD64, C3aR and CD204 demonstrating strong 
monocyte/macrophages   activation, accompanied by secretion of TNF-α, IFN-γ, IL-2 and 
IL-6 (day 2), and T cell activation (day 3). Unexpectedly, IFN-γ addition to MLR culture 
did not affect co-stimulatory potential or antigen presentation, it instead induced 
significant up-regulation of CD64 expression, suggesting stimulation of phagocytosis and 
pathogen defence. Whereas, IL-4 addition significantly up-regulated co-simulation and 
Ag presentation (day 2), reducing T cell alloreactivity on day 3. Spleen tyrosine kinase 
(SYK) phosphorylation regulates monocytes/macrophages activation, thus the SYK 
pathway is a potential therapeutic target for MLR and GVHD. Data in this study showed 
that the highly selective SYK inhibitor, PRT0603, modulated monocyte/macrophage 
activation in MLR culture by significantly reducing CD64 (FcγRI) expression, antigen 
presentation and T cell alloreactivity. In MLR IFN-γ and MLR IL-4 the anti-SYK effects on 
monocyte/macrophages function were modest. However, a subsequent decrease in T 
cells alloreactivity was observed in MLR IFN-γ culture due to PRT0603 treatment. More 
importantly, a significant reduction in cytokine production was observed in all treated cell 
cultures. This reduction could stop the inflammatory cycle and prevent the development 
of allogeneic response in GVHD. 
3 
 
Table of Contents: 
Abstract: ................................................................................................................... 2 
Table of Contents: .................................................................................................... 3 
Table of figures: ....................................................................................................... 9 
Table of tables: ...................................................................................................... 11 
Acknowledgements: ............................................................................................... 12 
Author’s declaration: .............................................................................................. 13 
Abbreviations: ........................................................................................................ 14 
1 Introduction: ............................................................................................... 20 
1.1 Haematopoietic stem cell transplantation: ....................................................... 20 
1.2 Graft-versus-host-disease: ................................................................................. 20 
1.3 Human monocytes: .............................................................................................. 22 
1.4 Macrophages: ....................................................................................................... 24 
1.4.1 Macrophage polarisation: .............................................................................................. 25 
1.4.1.1 Pathogen recognition: .................................................................................. 28 
1.4.2 Antigen processing and presentation: ......................................................................... 29 
1.4.2.1 FcγRI (CD64):.............................................................................................. 30 
1.4.3 FcγRIIB (CD32B): ........................................................................................................... 31 
1.4.4 Co-stimulatory molecule (CD80/CD86): ..................................................................... 32 
1.4.5 Recognition of apoptotic cells by macrophages: ....................................................... 33 
1.4.6 Scavenger receptor A (CD204): ................................................................................... 34 
1.4.7 Scavenger receptor B (CD36): ..................................................................................... 35 
1.4.8 Complement receptors: ................................................................................................. 36 
1.4.9 CD11b: ............................................................................................................................. 37 
1.5 T cell response: .................................................................................................... 38 
1.5.1 T cells activation markers CD69 and CD25: .............................................................. 39 
1.5.2 Th1/ Th2 cells in acute GVHD: ..................................................................................... 41 
4 
1.6 Pathophysiology of acute GVHD: ...................................................................... 42 
1.6.1 The conditioning regimen phase: ................................................................................. 42 
1.6.1.1 Allogeneic reaction in conditioning regimen: ................................................ 42 
1.6.2 The activation phase of alloresponse: ......................................................................... 43 
1.6.3 The effector phase of allorespons: ............................................................................... 44 
1.6.4 Cytokines involved in GVHD pathophysiology: .......................................................... 44 
1.6.4.1 Interferon gamma (IFN-γ): ........................................................................... 46 
1.6.4.2 Interleukin-6 (IL-6): ...................................................................................... 47 
1.6.4.3 Interleukin-4 (IL-4): ...................................................................................... 48 
1.7 Current strategies to control GVHD: ............................................................... 49 
1.8 Mixed leukocytes reaction MLR: ........................................................................ 51 
1.9 Limitations of using animal models: ................................................................. 52 
1.10 Spleen tyrosine kinase: ....................................................................................... 53 
1.10.1 SYK inhibition: ................................................................................................................ 56 
1.11 Hypothesis:........................................................................................................... 59 
1.12 Aims: ..................................................................................................................... 59 
1.13 Objectives: ............................................................................................................ 59 
2 Material and Methods: ............................................................................... 60 
2.1 Materials: .............................................................................................................. 60 
2.1.1 Reagents, chemicals, and supplier information: ........................................................ 60 
2.1.2 Flow cytometer antibodies: ........................................................................................... 61 
2.1.3 Cell culture complete media: ........................................................................................ 62 
2.1.4 Consumables for tissue culture: ................................................................................... 62 
2.1.5 Stimulus/inhibitor reconstitution: .................................................................................. 62 
2.1.5.1 Recombinant human IFN-γ protein: ............................................................. 62 
2.1.5.2 Recombinant human IL-4 proteins: .............................................................. 63 
2.1.5.3 PRT0603 SYK inhibitor: ............................................................................... 63 
2.1.6 ELISA: .............................................................................................................................. 63 
2.1.6.1 Reagent diluent and washing buffer: ............................................................ 63 
5 
2.1.7 Samples: .......................................................................................................................... 63 
2.2 Methods: ............................................................................................................... 63 
2.2.1 Buffy coat sample: .......................................................................................................... 63 
2.2.2 Samples preparation:..................................................................................................... 64 
2.2.3 Cell count: ........................................................................................................................ 64 
2.2.4 Preparation of responder cells (Res) and stimulatory cells: .................................... 64 
2.2.5 Cell culture preparation: ................................................................................................ 65 
2.2.5.1 Culture the responder cells (Res): ............................................................... 65 
2.2.5.2 Mixed leukocyte reaction (MLR) preparation: ............................................... 66 
2.2.6 Stimulating cells culture: ............................................................................................... 66 
2.2.6.1 Optimising IFN-γ concentration: ................................................................... 66 
2.2.6.2 Optimising IL-4 concentration: ..................................................................... 67 
2.2.6.3 MLR stimulated with IFN-γ and IL-4: ............................................................ 67 
2.2.6.4 Responder cells stimulated with IFN-γ and IL-4: .......................................... 67 
2.2.7 Inhibiting the stimulated cells cultures: ....................................................................... 68 
2.2.7.1 Inhibition of MLR IFN-γ and MLR IL-4 with anti-SYK: .................................. 68 
2.2.7.2 Inhibition of Res IFN-γ and Res IL-4 with anti-SYK: ..................................... 68 
2.2.8 Flow cytometer: .............................................................................................................. 69 
2.2.9 Cell surface phenotyping:.............................................................................................. 69 
2.2.10 Controls: .......................................................................................................................... 70 
2.2.11 Fc blocking: ..................................................................................................................... 71 
2.2.12 Cell viability test: ............................................................................................................. 71 
2.2.13 Cytokine quantification: ................................................................................................. 71 
2.2.13.1 Sample collection: ....................................................................................... 71 
2.2.13.2 Cytokine quantification by enzyme-linked immunosorbent assay (ELISA): . 72 
2.2.14 Statistical analysis: ......................................................................................................... 72 
3 Results (Part 1): .......................................................................................... 76 
3.1 Introduction: ......................................................................................................... 76 
3.2 Results: ................................................................................................................. 79 
6 
3.2.1 Investigating the early phase of allogeneic reaction in two-way MLR:..................... 79 
3.2.2 Analysis of monocytes/macrophages co-stimulation capacity: ............................... 80 
3.2.3 Analysis of monocytes/macrophages Ag-presentation capacity: ............................ 80 
3.2.4 Analysis of the Fc receptor expression on CD14+in the early phase of MLR: ......... 80 
3.2.5 Analysis of scavenger receptors on monocytes/macrophages in early phase 
MLR: ................................................................................................................................. 82 
3.2.6 Analysis of C3aR expression on CD14+ in the early phase of MLR:..................... 83 
3.2.7 Analysis of CD11b expression on monocytes/macrophages in the early phase of 
MLR: ................................................................................................................................. 83 
3.2.8 Analysis of T cell activation in the allogeneic setting: ............................................... 84 
3.2.9 Measurement of cytokines in allogeneic media: ........................................................ 85 
3.2.10 Effects of the inhibition of the SYK pathway in monocytes/ macrophages in MLR 
culture: ............................................................................................................................. 88 
3.2.11 Analysis of the effects of the SYK inhibitor on CD3+ and CD4+ T cells: .............. 89 
3.2.12 Analysis the inhibitory effect of PRT0603 SYK on the production of inflammatory 
cytokines: ......................................................................................................................... 91 
3.3 Discussion (Part 1): ............................................................................................. 94 
4 Results (Part 2): ........................................................................................ 106 
4.1 Introduction: ....................................................................................................... 106 
4.2 Results: ............................................................................................................... 107 
4.2.1 Optimising the IFN-γ concentration: .......................................................................... 107 
4.2.2 Monocytes/macrophages co-stimulation capacity in MLR culture with addition of 
IFN-γ: ............................................................................................................................. 108 
4.2.3 Monocytes/macrophages Ag presentation capacity in MLR culture with added 
IFN-γ: ............................................................................................................................. 109 
4.2.4 Analysis of CD64 (FCγRI) and CD32B (FCγRIIB) expression on monocytes 
CD14+ in MLR treated with IFN-γ: ............................................................................ 110 
4.2.5 Analysis of CD36 and CD204 expression on CD14+in the presence  of allogeneic 
cells and IFN-γ: ............................................................................................................. 111 
7 
4.2.6 Analysis of Ca3R expression on CD14+ in the presence of allogeneic cells and 
IFN-γ: ............................................................................................................................. 112 
4.2.7 Analysis of CD11b expression on CD14+ monocytes in the presence of 
allogeneic cells and IFN-γ: .......................................................................................... 113 
4.2.8 Activation of T cells in MLR treated with 100 ng/ml IFN-γ: .................................... 114 
4.2.9 Measurement of cytokines in MLR treated with IFN-γ: ........................................... 117 
4.2.10 Effects of SYK inhibitor on CD14+ in MLR treated with IFN-γ: ............................. 119 
4.2.11 Effects of SYK inhibitor on T cell activity in MLR treated with IFN-γ: ................... 121 
4.2.12 Measuring cytokines concentrations in MLR culture treated with IFN-γ and   SYK 
inhibitor: ......................................................................................................................... 123 
4.3 Discussion (Part 2): ........................................................................................... 125 
5 Results (Part 3): ........................................................................................ 137 
5.1 Introduction and aims: ...................................................................................... 137 
5.2 Results: ............................................................................................................... 138 
5.2.1 Optimising IL-4 concentration:.................................................................................... 138 
5.2.2 Monocyte/macrophage co-stimulation capacity in MLR culture in the presence of 
IL-4 cytokine: ................................................................................................................. 139 
5.2.3 Monocyte/macrophage Ag presentation in early MLR culture with addition of IL-4 
cytokine: ......................................................................................................................... 140 
5.2.4 Analysis of monocytes/macrophages CD64 and CD32B expression in early MLR 
with addition of IL-4 cytokine: ..................................................................................... 140 
5.2.5 Analysis of monocytes/macrophages scavenger receptors in MLR culture treated 
with IL-4 cytokine: ........................................................................................................ 142 
5.2.6 Analysis of C3aR expression on CD14+ monocytes in the presence of allogeneic 
cells and MLR IL-4: ...................................................................................................... 142 
5.2.7 Analysis of CD11b expression on CD14+ monocytes in the presence of 
allogeneic cells and IL-4 cytokine: ............................................................................. 143 
5.2.8 Analysis of T cell activity in MLR treated with IL-4 cytokine: ................................. 144 
5.2.9 Measurement of cytokines in MLR culture treated with IL-4: ................................ 147 
5.2.10 Analysis of the effects of SYK inhibitor on monocytes/macrophages in MLR 
8 
treated with IL-4: ........................................................................................................... 149 
5.2.11 Analysis of the effects of SYK inhibitor on T cell activity in the ............................. 151 
presence of MLR and IL-4 cytokine: ........................................................................................... 151 
5.2.12 Measuring cytokine concentrations in MLR treated with IL-4 and SYK inhibitor:153 
5.3 The effects of SYK inhibitor when MLR is unmodified compared to the MLR 
culture in presence of IFN-γ and IL-4: ............................................................. 155 
5.3.1 Evaluation of the inhibitory effects of PRT0603 on monocytes/ macrophages: . 155 
5.3.2 Evaluation of the inhibitory effects of PRT0603 on T cells and cytokine 
concentrations: ............................................................................................................. 156 
5.4 Discussion (Part 3): ........................................................................................... 159 
6 General discussion: ................................................................................. 169 
7 Limitations and future work: .................................................................. 180 
7.1 Limitations: ......................................................................................................... 180 
7.2 Future work: ....................................................................................................... 182 
8 Appendix: .................................................................................................. 184 
8.1 T cells gating strategies: ................................................................................... 184 
8.2 Analysis of CD3 T cells activity (in MLR, MLR SYK, Res and Res SYK): .... 184 
8.3 Analysing the expression of CD86 on CD14+ monocyte/macrophages (in 
MLR, MLR SYK, Res and Res SYK): ................................................................ 185 
8.4 Analysing the expression of CD64 on CD14+ monocyte/macrophages (in 
MLR, MLR IFN-γ, Res and Res IFN-γ): ............................................................. 186 
8.5 CD4+CD25+ T cells activation analysis before and after SYK treatment (MLR 
IFN-γ, Res IFN-γ, MLR IFN-γ SYK and Res IFN-γ SYK): ................................ 186 
8.6 Analysing the expression of CD32 on CD14+ monocyte/macrophages (in 
MLR, MLR IL-4, Res and Res IL-4): .................................................................. 187 
8.7 CD3+CD69+ T cells activation analysis before and after SYK treatment (MLR 
IL-4, Res IL-4, MLR IL-4 SYK and Res IL-4 SYK): ........................................... 187 
9 References: ............................................................................................... 188 
9 
Table of figures: 
 
Figure 1. 1: Monocyte’s classification based on CD14, CD16 and CCR2 expression. .............. 23 
Figure 1. 2: Macrophage polarisation based on IL-4 and IFN-γ stimulus: ................................. 26 
Figure 1. 3: CD14 activation of tyrosine kinase SYK and its downstream effector PLCγ2 through 
an ITAM-containing receptor. ............................................................................................ 54 
Figure 1. 4: The Fcγ receptors downstream signalling pathways: ............................................ 55   
Figure 2. 1: Responder and stimulatory cell preparation and cell counting. .............................. 65 
Figure 2. 2: Res and MLR preparation and incubation: ............................................................ 66 
Figure 2. 3: Res IFN-γ/IL-4 and MLR IFN-γ /IL-4 preparation diagram: ..................................... 68 
Figure 2. 4: Figure: inhibiting Res IFN-γ and MLR IFN-γ by anti-SYK diagram: ........................ 69 
Figure 2. 5: Quantile-Quantile plot (QQ plot)  ........................................................................... 73 
Figure 3. 1: Analysis of monocyte viability and CD14+ expression……………………...79 
Figure 3. 2: Analysis of A) CD86, B) HLA-DR, C) CD64, D) CD32B expression on CD14+ 
monocytes measure by flow cytometer after one (D1) and two days (D2) of incubation. .... 81 
Figure 3. 3: Analysis of A) CD36, B) CD204, C) C3aR and D) CD11b expression on CD14+ 
monocytes measured by flow cytometry after one (D1) and two days (D2) of incubation. . 84 
Figure 3. 4: Analysis of T cells activation measured by flow cytometry after three days of 
incubation. ........................................................................................................................ 85 
Figure 3. 5: Measuring inflammatory cytokines in MLR cultures after two days of incubation. .. 87 
Figure 3. 6: Analysis of A) CD86, B) HLA-DR and C) CD64 expression on CD14+ in MLR culture 
with/without SYK inhibitor. .................................................................................................. 89 
Figure 3. 7: T cells inhibition in the presence of SYK inhibitor on D3 of incubation. ................... 91 
Figure 3. 8: Concentrations of inflammatory cytokines in MLR cultures after two days of 
incubation in the presence of SYK inhibitor. ....................................................................... 93 
Figure 4. 1: Analysis of the level of expression (MFI) for A) CD86, B) HLA-DR and C) CD64 on 
CD14+ monocytes measured by flow cytometry after one (D1) and two days (D2) of 
incubation…………………………………………………………………………………………108 
Figure 4. 2: Analysis of expression levels on CD14+ monocytes after IFN-γ stimulation after D1 
and D2 of incubation. A) CD86, B) HLA-DR, C) CD64, D) CD32B. ................................. 111 
Figure 4. 3: Analysis of the expression CD36, CD204, C3aR and CD204 on CD14+ monocytes 
after IFN-γ stimulation on D1 and D2 of incubation. ........................................................ 114 
Figure 4. 4: Analysis T cells activation measured by flow cytometry after three days (D3) of 
incubation. ...................................................................................................................... 116 
Figure 4. 5: Measuring inflammatory cytokines on D2 of incubation with/without IFN-γ     
treatment. ....................................................................................................................... 118 
Figure 4. 6: Analysis of A) CD86, B) HLA-DR and C) CD64 expression on CD14+ monocytes 
on D1 and D2 of incubation in the presence of IFN-γ, MLR and SYK inhibitor. ............... 120 
Figure 4. 7: Analysis of T cell activation by flow cytometry on D3 of incubation with IFN-γ and 
SYK inhibitor. .................................................................................................................. 122 
Figure 4. 8: Measuring proinflammatory cytokines on D2 of incubation in the presence of 
allogeneic cells, IFN-γ and SYK inhibitor. ........................................................................ 124 
Figure 5. 1: Analysis of the level of (MFI) expression on CD14+ monocytes by flow cytometry 
after D1 and D2 of incubation in the presence of with IL-4. A) CD86, B) HLA-DR and C) 
CD64…………………………………………………………………………...……………………139 
10 
Figure 5. 2: Analysis of expression on CD14+ monocytes by flow cytometry on D1 and D2 of 
incubation in the presence of allogeneic cells (MLR) and cytokine.IL-4. .......................... 141 
Figure 5. 3: Analysis of expression on CD14+ monocytes by flow cytometry after D1 and D2 of 
incubation in the presence of allogeneic cells/MLR and IL-4 cytokine. ........................... 144 
Figure 5. 4: Analysis T cells activation by flow cytometry on D3 of incubation with/without 
addition of IL-4. ................................................................................................................ 146 
Figure 5. 5: Measuring cytokines by ELISA on D2 of incubation in MLR culture with/without IL-4.
 ....................................................................................................................................... 148 
Figure 5. 6: Analysis of the expression CD86, HLA-DR and CD64 on CD14+ 
monocytes/macrophages by flow cytometry on D1 and D2 of incubation with/without IL-4 
and anti- SYK. ................................................................................................................. 151 
Figure 5. 7: Analysis of T cells activation by flow cytometer on D3 of incubation in the presence 
of  MLR, IL-4 and anti-SYK. ............................................................................................. 152 
Figure 5. 8: Measuring cytokines by ELISA on D2 of incubation in the presence of MLR, IL-4 
and anti-SYK. ................................................................................................................. 154 
Figure 5. 9: Comparing the precent of inhibition of A) CD86, B) HLA-DR and D) CD64 
expression after SYK inhibitor treatment: ........................................................................ 156 
Figure 5. 10: Comparing the potency of inhibition of A) T cells activation B) cytokine 
concentration after the SYK inhibitor treatment: .............................................................. 158 
 
Figure S1. 1: Analysis of lymphocytes viability, CD3 + and CD4+ expression. ....................... 184 
Figure S1. 2: Analysis of CD3 T cells activation by flow cytometer on D3 of incubation. ......... 184 
Figure S1. 3: Flow cytometry histograms that present expression of CD86+ on CD14+ in four 
experimental conditions on D2 of cell culture. ................................................................. 185 
Figure S1. 4: Flow cytometry histograms that present expression of CD64+ on CD14+ in four 
experimental conditions on D2 of cell culture. ................................................................. 186 
Figure S1. 5: Analysis of CD4 T cells activation by flow cytometer on D3 of incubation. ......... 186 
Figure S1. 6: Flow cytometer histograms presenting expression of CD14+CD32+ in four 
conditions on D1of incubation. ......................................................................................... 187 


















Table of tables: 
 
Table 1. 1: Human-monocyte subtypes and their function: ....................................................................... 24 
 
Table 2. 1: Details of the chemicals and reagents . .................................................................................. 60 
Table 2. 2: Details of antibodies used for flow cytometry. . ....................................................................... 61 





First and foremost, prayers and thanks to Almighty Allah for his blessing throughout 
my research journey. 
I would like to express my deep sincere appreciation to my director of study Dr. 
Stipo Jurcevic, for his continuous support, motivation, and immense knowledge. It 
was great privilege to study under your guidance. He taught me the methodology 
to carry out my research and to present my work as clearly as possible. 
I would like to pay special thanks to my sponsors, princess Noura bint 
Abdulrahman University and the Saudi Arabian minister of education for their 
generous funding of my scholarship. 
I am extremely grateful to my parents Kamal & Abeer for their prayers, love, 
kindness and caring. Thank you for always being there for me, may Allah protect 
and bless you. 
I am deeply thankful to my one and only Mohammad who supported me 
emotionally and financially during this journey, I would like to thank him for his love, 
kindness, and patience. I am extending my thanks to my partners during this trip, 
my sunshine Faisal and Abdulrahman, my life is beautiful because of you. May 
Allah protect you, I wish to see you happy and successful in your life. 
I express my thanks to my sisters Deena, Nejoud, Aljouharah and my brother 
Ahmad, I am blessed to have you in my life. 
I am dedicating this thesis to the memory of my grandfather Suleiman Alkhuraiji, 
for being my first English teacher. 
13 
Author’s declaration: 
I hereby declare that this thesis is my own original work, this work has not been 
submitted to any institution for basis of any degree or professional qualification 
before. 





Ab  Antibody 
Ag  Antigen 
aGVHD Acute Graft versus host disease 
AIRE          Autoimmune regulator 
APCs Antigen presenting cells 
AKT  Protein kinase B 
BA1  β-Arrestin 1 
BCR  B cells receptor 
BM  Human bone marrow 
BMT  Bone marrow transplant 
C3aR Complement receptor 3a 
CB  Cord Blood 
CCR2 C-C chemokine receptor type 2 
CD  Cluster of differentiation 
cDC  Conventional dendritic cells 
cGVHD Chronic Graft versus host disease 
CRP  C-Reactive Protein 
CSF-1 Colony stimulating factor-1 
 CTLA-4 Cytotoxic T lymphocyte-associated protein-4 
CXCR1 C-X-C motif chemokine receptor 1 
15 
D Day 
DAMP Damage-associated molecules 
DC Dendritic Cells 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
F4/80 1 EGF-like module-containing mucin-like hormone receptor-like 
FceR1 High-affinity IgE receptor 
FcγR Fc gamma receptor 
FcR Fc receptor 
FSC Forward scatter light 
Fas L Fas ligand 
G-CSF Granulocyte stimulating factor 
GM-CSF Granulocyte monocyte colony stimulating factor 
GVHD Graft versus host disease 
GVL Graft versus leukaemia 
GVT Graft vs. tumour 
HBsAg Hepatitis B infection 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigens 
HLA-DR Human leukocyte antigen – DR isotype 
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HSCT Haematopoietic stem cell transplantation 
Hsp70 Heat shock protein 70 
ICAM-1 Intercellular adhesion molecule 1 
IFN-γ Interferon γ 




IL-4R Membrane IL-4 receptor 
IL-6R Membrane IL-6 receptor 
iNOS Inducible nitric oxide synthase 
IRF-1 Interferon regulatory factor-1 
ITAM Immunoreceptor-activating motif 
JAK Janus kinase 
JNK2 Jun N-terminal protein kinase 2 
LDL Low-density lipoprotein 
LIMP-2 Lysosomal integral membrane protein–2 
LOX Lectin-like oxidized low-density lipoprotein receptor 
LPS Lipopolysaccharide 





Lymphatic vessel endothelial hyaluronan receptor 1 
 
V-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
MAPK Mitogen-activated protein kinases 
MARCO Macrophage receptor with collagenous structure 
M-CSF Monocyte colony stimulating factor 
MDSC Myeloid derived suppressor cells 
MerTK MER Proto-Oncogene, Tyrosine Kinase 
MFI Median fluorescence intensity 
MHC Major histocompatibility 
miHA Minor histocompatibility antigen 
MLR Mixed leukocyte reaction 
moDCs Monocyte-derived dendritic cells 
MSC Mesenchymal stromal cell 
mTEC Medullary thymic epithelial 
NF-κB Nuclear factor κB 
NK Natural killer cells 
NO Nitric oxide 
NOD Nucleotide-binding oligomerization domain 
PAMPs Pathogen associated molecular patterns 
PAMPS Pathogen molecular pattern 
PBMCs Peripheral blood mononuclear cells 
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PBS Phosphate buffered saline 
PD-L1 Program cell death ligand 1 
PGJ2 Prostaglandin J2 
PPARγ Peroxisome proliferator–activated receptor γ 
PRRs Pattern-recognition receptors 
PS Phosphatidy serine 
RBCs Red blood cells 
ROI Reactive oxygen intermediates 
RT Room temperature 
sIL-6R Soluble IL-6 receptor 
SIRPA Signal regulatory protein alpha 
SR-A Scavenger receptor 
SRB-1 Scavenger receptor B-1 
SSC Side scatter light 
STAT Signal transducer and activator of transcription 
SYK Spleen tyrosine kinase 
T reg Regulatory T cells 
TAP Transporter associated with antigen processing 
TBI Total body irradiation 
Tc cytotoxic T cells 
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TCR T cell receptor 
TGFB Transforming growth factor beta 
Th T helper 
Th1 Type 1 T helper cells 
Th2 Type 2 T helper cells 
TLRs Toll-like receptor 
TNF-α Tumour necrosis factor-α 




1.1 Haematopoietic stem cell transplantation: 
One of the key life-saving therapies for malignant and haematological diseases is 
allogeneic hematopoietic stem cell transplantation (HSCT) (Shlomchik et al., 
1999, Markey et al., 2014, Blazar et al., 2013, Koehn et al., 2015, Hill et al., 2018). 
Essentially, hematopoietic stem cells (HSC) are collected from a health donor and 
transplanted into the host, to allow them to produce healthy blood cells (Welniak 
et al., 2007, Aveni et al., 2015). There are three different sources of HSCs, bone 
marrow (BM), cord blood (CB) and harvesting cells from the peripheral blood 
(Smith & Wagner, 2009). The latter is feasible after administration of granulocyte 
stimulating factor (G-CSF) to the donor, which induces mobilisation of HSCs from 
BM into the blood stream (Welniak et al., 2007, Aveni et al., 2015). One of the 
main limitations of using HSCT as a therapy is that there is a high risk of 
developing graft versus host disease (GVHD), which causes high mortality rates 
in patients after their transplant (Ferrar et al., 1991, Welniak et al., 2007, Markey 
et al., 2014, Blazar et al., 2013, Koehn et al., 2015, Hiller et al., 2018, Nguyen et 
al., 2018, Drobyski et al., 2018). In GVHD, the immune cells from the graft target 
the host patient’s tissue (Ferrar et al., 1991). In order to decrease the incidence of 
GVHD and to maintain graft survival, the patients should undertake chemotherapy 
and irradiation before transplantation, which is known as a conditioning regimen, 
and after the HCST they should take immunosuppressive drugs for an extended 
period of time to control the immune response (Ferrar et al., 1991, Welniak et al., 
2007, Hiller et al., 2018, Ganetsky et al., 2019). 
1.2 Graft-versus-host-disease: 
Although Mathe and his colleagues (1963) succeeded in performing the first BM 
transplantation, the patient developed a chronic immune reaction, which was 
characterised by weight loss and cutaneous inflammation (Mathe et al., 1963). 
Subsequently, Billingham (1966) discovered that there are three elements 
necessary for the development of the detrimental immune response after 
transplantation known as GVHD. Firstly, the graft contains immune cells, the host 
is immune-compromised, so they will not reject the transplant, and the lastly the 
donor and host tissue express different human leukocyte antigens (HLA), also 
known as major histocompatibility complex (MHC) molecules (Billingham et al., 
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1966, Atkinson et al., 1990). The HSCT patients preparation protocol involves a 
conditioning regimen, that removes the patient’s stem cells and maintains space 
for the donor graft cells for engraftment (Blazar et al., 2013). However, this causes 
severe inflammation that results in T cells-interaction with antigen presenting cells 
(APCs) through MHC molecules to generate a cytokine storm that results in GVHD 
(Ferrar et al., 1991, Blazar et al., 2013). Interestingly, patients who received 
matched MHC HSCT grafts can also develop GVHD, which highlights the 
importance of there being no differences between the host and donor minor 
histocompatibility (miHA) antigens, as multiple miHA antigens may stimulate a 
strong immune response, leading to development of GVHD (Ferrar et al., 1991, 
Shlomchik et al., 1999 , Shlomchik, 2007). GVHD is an allo-immune disease which 
develops after HSCT; donor T cells recognise mismatched polymorphic human 
leukocyte antigen complexes and/or miHA antigens on both donor or host APCs 
(Shlomchik et al., 1999, Shlomchik, 2007). Based on the time of the disease onset 
after transplantation, GVHD can be classified as either acute or chronic, if the 
symptoms appear within 100 days after HSCT, it is considered as acute GVHD 
(aGVHD), and the typical symptoms include skin rash and gastrointestinal disease 
(Ferrar et al., 1991, Shlomchik, 2007, Blazar et al., 2013, Zhang et al., 2017). 
However, in chronic GVHD (cGVHD), the disease onset can appear within a year 
after HSCT, and the immune cells will target all body tissues (Shlomchik, 2007, 
Blazar et al., 2013). It is widely accepted that donor T cells, host and donor APCs 
play a critical role in developing GVHD, however, other studies have suggested 
that T cells are also essential in fighting against leukaemia, which known as the 
graft versus leukaemia (GVL) effect, which suggests the immune response is 
complicated and needs further study (Dazzi and Goldman, 1999, Nguyen et al., 
2015). 
aGVHD is a lethal complication after HSCT and is the most common cause of 
mortality and morbidity post-transplant (Ferrar et al., 1991, Blazar et al., 2013, 
Zhang et al., 2017). Patients who survive in the first 100 days are then at a high 
risk of developed cGVHD (Ferrar et al., 1991). This highlights the need to better 
understand the complicated mechanism of this disease to maintain effective GVL, 
prevent GVHD, and to have a strong therapeutic effect of allogeneic HSCT (Lee 
et al., 2005, Nguyen et al., 2018, Ganetsky et al., 2019). 
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1.3 Human monocytes: 
In 1960 van Furth and Cohn described monocytes as circulatory white blood cells 
(WBCs) and classified them as mononuclear cells (Furth and Cohn., 1960). 
Monocytes are mainly generated in the BM from myeloid precursor cells and 
represent around 4 % of the total leukocyte cell count (Furth and Cohn., 1960, 
Tacke & Randolph, 2006, Castano et al., 2011, Lee et al., 2017). The half-life   of 
monocytes is relatively short, about 3 days in human circulation (Tacke & 
Randolph, 2006). Monocytes can be regarded as precursor cells that give rise to 
macrophages, dendritic cells (DC) and osteoclast. Macrophages and DCs 
maintain body homeostasis and have critical role in the innate immune response 
(Tacke & Randolph, 2006, Sprangers et al., 2016). The monocytes in circulation 
are a heterogeneous, functionally diverse population of cells that can be divided 
into three sets in (Figure 1.1) based on expression of the cluster of differentiation 
14 (CD14) a lipopolysaccharide receptor (LPS) and CD16 the IgG receptor 
(FcγRIII). The classical monocytes (CD14++CD16-), non-classical monocytes 
(CD14+CD16++) and intermediate monocytes (CD14++CD16+) (Belhareth and Meg 
2015, Boyettel et al., 2016, Sprangers et al., 2016, Lee et al., 2017, Collin et al., 
2018, Zhong et al., 2019). Monocytes are further classified based upon their 
adhesion molecules and chemokine receptors: each subpopulation has a 
particular function; the classical monocytes (CD14++CD16-) mainly count 90-95 % 
of monocytes count, express C-C chemokine receptor type 2 (CCR2), CD62L (L- 
selectin) and FcγRI (CD64) and are rapidly recruited to injured tissues during 
inflammation to phagocytose dead cells and remove microorganisms (Tacke & 
Randolph, 2006, Sprangers et al., 2016, Lee et al., 2017). Prolong response of 
classical monocytes result in tissue damage due to inflammation (Sprangers et 
al., 2016). The intermediate monocytes (CD14++CD16+) are 10 % of total 
monocytes which lack of CCR2, highly express MHC-II and FcγRII (CD32) and 
recruited in the later stages of inflammation to enhance antigen presentation, 
secretion of anti- inflammatory cytokines like IL-10 and transforming growth factor 
TGF-β to initiate wound healing and tissue repair (Tacke & Randolph, 2006, 
Sprangers et al., 2016, Lee et al., 2017). The non-classical monocytes (CD14- 
CD16++) lack of CCR2 make up 10 % of monocytes surveying the endothelium as 
part of the innate immune response (Tacke & Randolph, 2006). Classical, 
intermediate, and non-classical monocytes make important contributions to 
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innate immune response with different functions (Sprangers et al., 2016). As 
presented in (Table 1.1) the classical phenotype migrates to the site of infection 
to start antimicrobial response through phagocytosis (Sprangers et al., 2016). The 
intermediate monocytes maintain Ag presentation and regulate apoptosis. 
Whereas the nonclassical monocytes lose the expression of CD14, and mainly 
initiate wound healing and tissue repair (Sprangers et al., 2016). It has been 
reported that in GVHD patients the percentage of classical monocytes decreases, 
while the numbers of intermediate and non-classical monocytes increased (Heller 
et al., 2017). Interestingly, it has been reported that the presence of monocyte- 
derived cells in the recipient blood after organ transplantation will suppress 
immunological rejection and improve graft survival (Ochando et al., 2015). This 
tolerance could be induced by blocking of co-stimulatory molecules on monocytes, 
which prevents interaction with T cells and may cause defects in T cell proliferation 
(Ochando et al., 2015). Thus, although monocytes have a crucial role in 
inflammation and the initiation of the alloresponse, they could regulate 
inflammation and mediate tolerance (Wu et al., 2019). This study investigated the 
role of activated monocytes in an allogenic culture and evaluate the therapeutic 
strategy by targeting the spleen tyrosine kinase (SYK) pathway in monocytes to 
induce immune tolerance.  
 
Figure 1. 1: Monocyte’s classification based on CD14, CD16 and CCR2 expression.  
A) classical monocytes that express CD14++ CD16- CCR2+ CD64+ B) Intermediate monocytes 
express CD14++ CD16+ CCR2- CD32+ MHCII+CD86+ and C) Non-classical -monocytes phenotype 
express CD14dim CD16++ CCR2- MHCII+.  Created with BioRender.com
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Classical  CD14++CD16- CCR2high CX3CR1low Antimicrobial response 
through phagocytosis 
Intermediate  CD14+ CD16+ CCR2 low CX3CR1high Ag presentation 
Regulate apoptosis 




Macrophages are myeloid cells, they are classified as mononuclear phagocytic 
cells and considered as professional APCs. However, they are unlike monocytes 
in some ways, as they are non-migratory cells that stay in the tissues and carry 
out their effector and phagocytic functions only in the surrounding area, meaning 
the activities of inflammatory macrophages are tissue specific (Shechter et al., 
2009, Murray & Wynn., 2012, Varol et al., 2015). There are two origins of 
macrophages; the first type comprises the majority of the tissue macrophage 
populations, which develop prenatally and are known as embryonic derived 
macrophages (Belhareth, 2015, Varol et al., 2015, Sprangers et al., 2016). These 
cells are characterised as independent cells and different from the other 
hematopoietic cells; they are in charge of cleaning tissue debris which results from 
tissue development and remodelling (Shechter et al., 2009, Varol et al., 2015, 
Sprangers et al., 2016). The second type of macrophages originate from  adult 
monocytes that infiltrate to inflamed tissues and are termed adult tissue 
macrophages or monocyte-derived macrophages (Varol et al., 2015, Sprangers 
et al., 2016). Phenotypical variations between macrophages from the two different 
origins have been reported: the tissue resident macrophages highly express 
CD64, MER Proto-Oncogene, C mer Tyrosine Kinase (MerTK), CD14 and EGF-
like module-containing mucin-like hormone receptor-like 1 (F4/80) with a long life 
span (Belhareth, 2015, Sprangers et al., 2016). In contrast, monocyte-derived 
macrophages show little expression of CD64, MerTK, CD14 and F4/80 and have 
a short life span (Belhareth, 2015, Tacke & Ranndolph, 2006).  Macrophages play 
an essential role in inflammation by expressing chemokine receptors and secreting 
cytokines to activate neutrophils, monocytes and to recruit T cells (Varol et al., 
2015). Macrophages are different from monocytes, as they are 5 to 10 times 
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bigger in size, with increased complexity and have a greater phagocytic capacity 
(Duque & Descoteaux, 2014). Macrophages are tissue specific cells, which mean 
that these cells can acquire organ-specific functions based on their location, which 
can help to maintain tissue homeostasis (Varol et al., 2015). The growth factor 
granulocyte monocyte colony stimulating factor (GM- CSF) and IL-34 are essential 
to regulate the development, differentiation, function, and proliferation of 
macrophages (Sprangers et al., 2016, Belhareth, 2015). The growth factors 
provided to the macrophages by the tissues they reside in, can   enhance tissue-
specific functions of the macrophages, meaning that the local environment can 
influence macrophages function (Sprangers et al., 2016). There are eight 
macrophage phenotypes based on the site of residence, for example, Kupffer cells 
are macrophages located in the liver, microglia are macrophages found in the 
brain tissue, alveolar macrophage-based in the alveolar of the lungs, osteoclast 
reside in the bone, peritoneal macrophage are found in the peritoneal cavity, 
mammary gland macrophages in the breast, and gut macrophages are located in 
the abdomen (Varol et al., 2015, Sprangers et al., 2016). Inflammatory 
macrophages are highly phagocytic cells that are capable of capturing the 
pathogen and presenting it to T cells; they can also release lytic factors and 
proteinases to the extracellular environment to help with the breakdown of 
invading pathogens (Martinez and Gordon., 2014). Studies have shown that 
transforming growth factor beta (TGFβ) production by inflammatory macrophages 
is involved in tissue fibrosis production in cGVHD (Alexander et al., 2014). 
1.4.1 Macrophage polarisation: 
Monocytes and macrophages are essential components of the innate immune 
response (Belhareth, 2015, Murray, 2017). In response to pathological infection 
many monocytes produced from the BM travel to the site of infection and   these 
monocytes will proliferate to form monocyte-derived macrophages (Belhareth, 
2015, Murray, 2017). Based on the type, number of cytokines present in the 
microenvironment, and the time of exposure, macrophages undergo the process of 
phenotypical polarisation into classical M1 and alternative M2 (Wang et al., 2014, 
Belhareth, 2015, Obrine et al., 2019). The two subsets have   opposite functions 
(Figure 1.2), M1 mainly have a protection role from pathogens such as viruses, 
bacteria and have anti-tumour activity (Murray & Wynn, 2012, Belhareth, 2015). 
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In contrast, M2 maintain tissue repair and anti-inflammatory reaction by releasing 
IL-10 (Murray & Wynn, 2012, Belhareth, 2015). M1 macrophages are 
characterised by high antigen (Ag) presentation, increased production of IL-12, IL-
23, nitric oxide (NO) and reactive oxygen intermediates (ROI) (Murray, 2017). On 
the other hand, M2 macrophages perform the protection   function by upregulation 
of mannose receptors, scavenger receptors A, CCR2, C- X-C motif chemokine 
receptor 1 (CXCR1) and CXCR2, M2 also release ornithine and polyamines (Wang 
et al., 2014). Interestingly, M1 and M2 polarisation can be reversed during normal 
physiological and pathological conditions (Wang et al., 2014). It is thought that the 
classical monocytes give rise to M1 macrophages, whereas CD16+ monocytes 
give rise to M2 macrophages (Shechter et al., 2009). 
There are three elements on cellular level that control macrophage polarisation: 
the extrinsic pathway, intrinsic pathway, and tissue microenvironment (Obrine et 
al., 2019). In vivo extrinsic polarisation of M1 phenotype is stimulated by interferon 
γ (IFN-γ) released from the type 1 T helper cells (Th1) cells also ligands that bind 
to the toll-like receptors (TLR) at the surface of macrophages (Obrine et al., 2019). 
However, type 2 helper T (Th2) cells release IL4 and IL-13, which stimulates M2 
polarisation which is presented in (Figure 1.2) (Obrine et al., 2019). 
 
Figure 1. 2: Macrophage polarisation based on IL-4 and IFN-γ stimulus:  
Polarisation of macrophages with IFN-γ results in the classical M1 subtype that mainly control 
antimicrobial response and activates the Th1 response. However polarising macrophages with IL-
4 results in alternative activated M2 that controls tissue repair, The Th2 response and 
immunosuppression. Created with BioRender.com 
During inflammation, the important factor that enhances monocytes differentiation 
to macrophages and their further polarization is the alteration of surface marker 
expression which make cells more sensitive and   responsive to cytokines (Murray, 
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2017). In contrast, in vitro extrinsic polarization is maintained by culturing the 
macrophages with polarizing cytokines to generate a M1 or M2 phenotype to  
mimic what  happens in  vivo. Studies in vitro of monocytes cultured with GM-
CSF and LPS, IFN-γ and tumour necrosis factor-α (TNF-α) have shown that they 
will acquired M1 morphology, however, if monocytes are cultured with monocyte 
colony stimulating factor (M-CSF), IL-4, IL- 10, IL-13, and vitamin D, then the 
monocytes will give rise to the M2 macrophages (Martinez and Gordon, 2014, 
Obrine et al., 2019). In addition, hypoxia and lactate   production within a tumour 
are non-cytokine extrinsic pathways that may control macrophage polarization 
(Murray, 2017). It has been reported that macrophages   adapt to the surrounding 
environment; hypoxia which is one of the characteristics of the inflamed tissue will 
stimulate M1 activation by increasing gene expression of pro-inflammatory 
cytokines and enhanced anti-microbial or anti-tumour functions (Wang et al., 
2014, Murray, 2017).The second pathway that controls macrophage polarization 
is known as the intrinsic pathway and is focused on the developmental origin of 
the macrophages  (Murray, 2017). Macrophages originate from two sources and 
each cell type has a different role in the tissue they are found in, for example 
microglia originate in the embryo, they maintain tissue homeostasis, remodelling, 
and removal of dead cells, microglia mainly are located in the central nervous 
system (Belhareth, 2015). After birth most of the embryonic macrophages are 
replaced by monocyte-derived macrophages except for microglia cells, which are 
monocyte independent (Murray, 2017). This replacement occurs depending on 
time and the type of tissue  microenvironment; in gut the transformation occurs 
within few days after birth, whereas alveolar macrophages need months to years 
for the full replacement to occur (Murray, 2017).  
Interestingly, in a healthy person most tissues will have a mix of embryonic and 
monocyte-derived macrophages, however in a transplant patient all tissue 
resident macrophages are replaced by monocyte-derived macrophages due to the 
effect of irradiation or chemotherapy (Murray, 2017). As   macrophage subtypes 
have opposite functions, the switching from one phenotype to another is controlled 
by strict pathway signals at the molecular level, such as the interferon regulatory 
factors (IRF) and signal transducer and activator of transcription (STAT) signalling 
pathway that controls M1 and M2 switching mainly   by IFN-γ and by TLR signalling 
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(Wang et al., 2014). IFN-γ type 1 which activates STAT1 and enhances production 
of inducible nitric oxide synthase (iNOS) will skew macrophages towards M1 type 
(Obrine et al., 2019). However, stimulation of the IRF/STAT pathway with anti-
inflammatory or Th2 cytokines, such as IL-4 and IL-13 via STAT6, will skew 
macrophages toward M2 phenotype (Murray, 2017, Obrine et al., 2019). Indeed, 
impaired M1 switching may result in chronic inflammatory (Obrine et al., 2019) and 
autoimmune disease (Murray & Wynn, 2012). Human macrophages and mouse 
macrophages are polarised by using different signalling pathways (Murray, 2017). 
This highlights the importance of developing in vitro models from human 
monocytes to assess the effects of blocking specific pathways in the GVHD 
response (Wang et al., 2014). The aim of this study was to optimise a human in vitro 
model of GVHD, using in vitro extrinsic pathway activation by (IFN-γ and IL-4), 
evaluate monocytes/macrophage function (co-stimulation, Ag presentation, 
activation, capturing apoptotic cells, adhesion, and differentiation) by measuring 
the expression of surface markers.  
1.4.1.1 Pathogen recognition: 
Viruses and bacterial products are the standard stimulators for monocytes and 
macrophages (Neefjes et al., 2011, Wu et al., 2019). Microorganisms display 
pathogen associated molecular patterns (PAMPs), which are recognised by 
pattern-recognition receptor (PRRs) present on myeloid cells and some epithelial 
cells (Neefjes et al., 2011, Wu et al., 2019). The cellular PRRs include CD14, 
mannose receptors, nucleotide-binding oligomerization domain (NOD)- like 
receptors, scavenger receptors and Toll like receptor (TLRs), which are all 
expressed by monocytes and macrophages (Jiménez-Dalmaroni et al., 2016). 
This recognition is the first line of defence against microorganisms, dead cells and 
is also essential for initiation of the immune response (Murray & Wynn, 2012, 
Duque & Descoteaux, 2014, Jiménez-Dalmaroni et al., 2016, Wu et al., 2019). 
CD14 is a human monocyte marker, known to be the first identified PRR (Wu et 
al., 2019). CD14 is a phosphoinositolglycan-linked cell surface receptor expressed 
on monocytes and macrophages that binds to LPS present on gram negative cell 
walls, which helps to activate the innate immune response (Lin et al.,  2004, Neefjes 
et al., 2011, Wu et al., 2019). The TLR are type I glycoprotein, include 10 
members; they are surface or cytoplasmic receptors which can recognise virus, 
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bacteria, or fungi components (Jiménez-Dalmaroni et al., 2016). TLR1, 2, 4, 5, 6 
and 10 are present on the cell surface and recognise PAMPs, whereas TLR 3, 7, 
8 and 9 are found intracellularly and maintain detection of the presence of foreign 
RNA and DNA within the infected cell (Jiménez-Dalmaroni et al., 2016). CD14 
helped to transfer LPS to TLR4 to form a complex and allowed internalisation of 
the TLR4 complex (Wu et al., 2019). The CD14/TLR4 complex activated spleen 
tyrosine kinase (SYK) through ITAMs that activated the downstream effector 
phospholipase Cγ 2 (PLCγ2), which resulted in generation of inositol triphosphate 
(IP3) release, influx of Ca2+  from intracellular store result in internalisation of 
CD14/ TLR4 complex (Wu et al., 2019). Studies have shown the importance of 
LPS as a key molecule that activates the GVHD response, the presence of this 
molecule can result in monocyte and macrophage activation (Deeg, 2001). Ag 
recognition, phagocytosis, Ag processing and peptides presentation via MHCI and 
MHCII on the surface of monocytes/macrophages, important in the initiation of 
GVHD as they can lead to recognition of antigens by the T cells, and this can 
trigger the adaptive immune response (Deeg, 2001, Blazer et al., 2013, Boyette 
et al., 2016). 
1.4.2 Antigen processing and presentation: 
In order to stimulate immune response, professional APCs need to recognise, 
process non-self-antigens, and present digested material (amino acids) via MHC 
class I and class II to CD8+ and CD4+ T cells respectively, which results in the 
development of the adaptive immune response (Duque & Descoteaux, 2014, Rock 
et al., 2016, Wieczorek et al., 2017). MHCI and MHCII are polymorphic proteins 
because they are expressed from three different gene regions MHCI (HLA-A, HLA-
B and HLA-C) MHCII (HLA-DR, HLA-DP and HLA-DQ) (Wieczorek et al., 2017). 
There are two antigen processing pathways based on the origin of  the 
pathogen: the endogenous and exogenous pathway (Rock et al., 2016, Wieczorek 
et al., 2017, Junker et al., 2020).In the endogenous pathway, the virus antigen or 
cancer cells with mutant sequence are presented within the host-nucleated cells 
and the antigen is broken down to peptides in the proteosome to form peptides 
of 8-9 amino acids (Rock et al., 2016, Wieczorek et al., 2017, Junker et al., 2020). 
These peptides are transferred to the endoplasmic reticulum (ER) through the 
transporter associated with antigen       processing (TAP) channel. After that, the 
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MHCI molecules will bind to the peptide   and transport it to the cell surface of APCs 
to present the peptide to CD8+ T cells (Neefjes et al., 2011, Rock et al., 2016, 
Wieczorek et al., 2017, Junker et al., 2020). In contrast, the exogenous pathway 
occurs when pathogens are endocytosed from the surrounding environment by 
PRRs or Fc receptors to form endocytic vesicles (Neefjes et al., 2011, Rock et 
al., 2016). These vesicles are then acidified, which leads to pathogen 
degradation and produces peptides of 10-20 amino acids long, and at the same 
time the MHCII molecules are generated in the ER and vesicles are formed 
(Neefjes et al., 2011, Rock et al., 2016, Junker et al., 2020). The two types of 
membrane vesicles will fuse together to facilitate the antigen peptides loading to 
the MHCII (Neefjes et al., 2011, Rock et al., 2016).  Ultimately, the vesicle will fuse 
with the cell surface membrane to express the MHC-peptide complex and display 
it to CD4+ T cells (Neefjes et al., 2011, Rock et al., 2016). Monocytes and 
macrophages can process both endogenous and exogenous antigens and 
present the antigen-derived peptide fragments either to CD4+ and CD8+ T cells 
(Rock et al., 2016).  
1.4.2.1 FcγRI (CD64): 
Fc receptors mediate important links between innate and adaptive immune 
response, as Fcγ R mainly recognise opsonised Ag coated with IgG or immune 
complex (IC), the crosslinking results in IC internalisation, processing of the Ag, 
presenting via MHCII to activate T cells (Junker et al., 2020). The FcγR family 
include both activation receptors like FcγR I, FcγRIIa, FcγRIIc, FcγRIIIa and the 
inhibitory receptor like FcγRIIb (Brandsma et al., 2018). 
FcγRI known as CD64 which is a transmembrane glycoprotein found on 
monocytes, macrophages, and neutrophils, with a high binding affinity for the IgG 
complex (Hepburn et al., 2004, Akinrinmade et al., 2017). As CD64 mainly binds 
to IgG1, IgG3 and IgG4 isotypes (Junker et al., 2020). Many studies have reported 
elevated CD64 on activated macrophages and monocytes during chronic 
inflammation (Hepburn et al., 2004, Delneste et al., 2003, Akinrinmade et al., 
2017, Lau et al., 2018). Interestingly, CD64 is involved in autoimmune diseases 
(Brandsma et al., 2018). For example, CD64 expression was elevated in circulated 
monocytes in rheumatoid arthritis patients (Hepburn et al., 2004). More 
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importantly ligation of CD64 with IgG-IC complex result in internalisation, 
processing of the Ag proteins, leads to Ag presentation via MHCII (Brandsma et 
al., 2018, Junker et al., 2020). CD64 intracellular signalling is involved in ITAM 
phosphorylation and spleen tyrosine kinase (SYK family) recruited to the ITAM 
domain, this intracellular signalling affects cellular function, such as enhancing 
degranulation, phagocytosis, cytokine, and inflammatory mediator release (Junker 
et al., 2020). CD64 has gained attention in recent years as a potential target for 
reducing inflammation (Akinrinmade et al., 2017). Blockage of CD64 with anti- 
CD64 reduced Ag presentation to T cells (Junker et al., 2020). Targeting CD64 
with anti-CD64 showed promising results in treating acute myeloid leukaemia by 
chemotherapy (Young et al., 2019). It has been reported that monocytes cultured 
with IFN-γ, IL-4 and GM-CSF upregulate CD64 and shift monocyte differentiation 
from DCs to macrophages (Delneste et al., 2003). Treating peripheral blood 
mononuclear cell (PBMC) with IFN-γ polarises macrophages to the M1 type and 
upregulates CD64 expression. Whereas IL-4 treatment down regulates CD64 
expression (Akinrinmade et al., 2017). Targeting of CD64 by anti-CD64 is a 
potential therapeutic approach to block M1 formation,  maintain the M1/M2 balance 
that allows tissue healing after chronic inflammation (Akinrinmade et al., 2017). A 
study reported CD64 as an activation  marker found in APCs in a skin biopsy from 
GVHD patients (Kerkhof et al., 2011). There is limited data that links expression of 
CD64 on CD14+ monocytes/macrophages and  aGVHD (Kerkhof et al., 2011). 
Thus, in this study the level of CD64 expression was measured in two-way mixed 
leukocyte reaction (MLR) as activation marker, and further targeting the SYK 
pathway through FCγRI tested by highly specific SYK inhibitor to evaluate the 
therapeutic approach in the histo-incompatible model. 
1.4.3 FcγRIIB (CD32B): 
CD32 is expressed on DCs, monocytes and monocytes derived macrophages, it 
is a Fcγ cell membrane receptor protein (FcγRII) that has a medium-low affinity for 
IgG and has been shown to play a vital role in antibody mediated immune 
regulation (Bhatnagar et al., 2014, Anania et al., 2019, Zhao et al., 2019). There 
are three different CD32 isoforms expressed on human cells, such as monocytes 
and natural killer (NK) cells; CD32A and CD32C which are activating receptors 
and CD32B which is an inhibitory receptor (Bhatnagar et al., 2014). CD32A is the 
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most prevalent and abundant activating CD32 on macrophages and monocytes, 
whereas the inhibitory CD32B is expressed only in relatively low levels on 
neutrophils, monocytes, and macrophages, and has higher levels of expression 
on B cells (Zhao et al., 2019, Anania et al., 2019). In human monocytes both 
cytokines (IL-4 and IL-10) induce the expression of CD32B, and down regulate 
CD32A expression that mainly linked to macrophage deactivation (Zhao et al., 
2019, Anania et al., 2019). CD32 can aggregate IgGs by cross-linking them and 
this activates a range of effector responses, which is dependent on crosstalk 
between TLR and FcRs with local cytokine environment that control CD32 
expression (Anania et al., 2019).  
Studies of asthma and rheumatoid arthritis patients have shown that CD32, and 
especially CD32B, may be crucial in modulating the allergic immune response by 
regulating monocyte activity in response to allergic inflammation mediated by IL- 
4/IL-4Rα signalling (Anania et al., 2019 and Zhao et al., 2019). An imbalance 
between activation and inhibition FcγR functions can predispose patients to pro-
inflammatory, autoimmune diseases (Anania et al., 2019). Patients with GVHD 
have increase expression of inflammatory cytokines IL-6, TGF-β, TNF-α, IFN-γ 
and IL- 1β, with decreased expression of anti-inflammatory cytokines including IL-
10, and upregulation of CD32A expression on B cells, granulocytes, monocytes, 
and subpopulation of macrophages (Zdziarski et al., 2018). Limited data available 
regarding expression of inhibitory CD32B and allogeneic response. As such, in this 
study  CD32B was selected as inhibitory marker to investigate the expression of 
CD32B in the early allogeneic response. 
1.4.4 Co-stimulatory molecule (CD80/CD86): 
The B7 family, CD80 and CD86, are co-stimulatory molecules for T cells 
expressed on the surface of APCs including monocytes and macrophages 
(Deneys et al., 2001, Zheng et al., 2004, Ke et al., 2016, Zeiser et al., 2016). 
Generally, CD80 and CD86 are ligands for CD28 and cytotoxic T lymphocyte- 
associated protein-4 (CTLA-4) on T cell surfaces and are involved in T cell 
activation or tolerance (Ke et al., 2016). Interestingly, CD80 and CD86 are not 
expressed on the surface of APCs at the same level; their crystal structures show 
CD80 is present as a dimeric structure that can bind to three ligands: CD28, CTLA- 
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4 and program cell death ligand 1 (PD-L1), whereas CD86 molecules are present 
as monomers and they can only bind to CD28 or CTLA-4 (Ke et al., 2016). It has 
been reported that CD80 binding with CTLA-4 is more efficient than binding with 
CD86, meaning CD80 has high affinity for CTLA-4, which mainly induces immune 
tolerance by production of IL-10 and TGF-β from the APCs or upregulation of Treg 
CD4+CD25+ Foxp cells, whereas CD86 preferentially binds to CD28 activating 
immune reactions (Zhang et al., 2006, Zeiser et al., 2016). Consequently, APCs 
that expressed high levels of CD86 could impair Treg function, and the expression 
of CD86 on the surface of APCs is mainly upregulated by danger signals like LPS 
or  IFN-γ signals (Deneys et al., 2001, Zheng et al., 2004, Zeiser et al., 2016). This 
study focused on upregulation of CD86 expression on CD14+, as critical step in T 
cells co-stimulation, in MLR with Th1 or Th2 cytokines. 
1.4.5 Recognition of apoptotic cells by macrophages: 
Programmed cell death, which is known as apoptosis, is a vital process to maintain 
tissue haemostasis (Maderna & Godson, 2003, Gregory & Devitt 2004, Nagata, 
2018). Everyday millions of cells generated in human body and millions die based 
on the cells type and life span (Nagata, 2018). Apoptotic cells are rapidly   cleared 
by macrophages and DCs to avoid release of intracellular component and maintain 
tissue haemostasis (Maderna & Godson, 2003, Gregory & Devitt 2004, Martinez 
et al., 2020). The clearance of apoptotic cells mainly occurs in BM, spleen, and 
liver (Hufford & Ravichandran, 2013, Nagata, 2018). The efficient clearance of 
apoptotic cells by phagocytic cells reduced proinflammatory response (Gorden & 
Pluddemann et al., 2018, Nagata et al., 2018). Whereas defects in apoptotic cell 
clearance and accumulation, results in auto-Ag that drive autoimmune 
diseases (Maderna & Godson, 2003). 
The clearance process is divided in to three stages known as “find me, eat me, 
and don’t eat me” signals. find me signals like: Fractalkine, ATP, Uridine, and 
sphingosine I phosphate that mainly chemoattract phagocyte. Don’t eat me signal 
include: CD31, CD47 which expressed in all healthy cells (Maderna & Godson, 
2003, Gorden & Pluddemann, 2018). Whereas phosphatidyl serin (PS) exposer 
and loss of phospholipid rearrangements on the cell surface play a significant role 
in apoptotic cell recognition (Maderna & Godson, 2003, Gorden & Pluddemann, 
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2018). PS exposure in the outer cell surface is considered as “eat me” signal; β-
arrestin 1 (BA1)-1 receptors on the macrophage cell surface bind to PS on the 
apoptotic cell surface, and carbohydrate changes on the apoptotic cells can be 
recognise by scavenger receptors expressed on macrophage cell surfaces 
(Gorden & Pluddemann, 2018). Interestingly, a few days after inflammation 
responses, monocytes and activated macrophages undergo apoptosis (Gorden & 
Pluddemann, 2018). In this study, to detect the apoptotic cells, all samples were 
stained with Annexin V that mainly binds to PS, and all Annexin V positive cells 
were considered as apoptotic cells and excluded from the rest of the experiment. 
This thesis evaluated monocyte/macrophage recognition of apoptotic cells during 
the allogeneic response by measuring the level of expression of scavenger 
receptors (CD36 and CD204) and measure the expression of C3aR and Fc 
receptors to evaluate ability of monocytes to opsonize Ag within histo-incompatible 
model. 
1.4.6 Scavenger receptor A (CD204): 
Scavenger receptors (SRs) are members of the PRRs family, there are 10 classes 
of SR from A-J (Pombinho et al., 2018). SRs are expressed on neutrophils, 
macrophages, DCs and B cells (Pombinho et al., 2018). SR-A contain five 
members they name as A because of structural similarity all have trimeric 
transmembrane, intracellular N terminus, short cytoplasmic tail including: SR-A1, 
macrophage receptor with collagenous structure (MARCO), cellular stress 
response (CSR), SR with C-type lection (SRCL) and SR-A member 5 (SCARA5, 
Kelley et al., 2014). This report focused on SRA-1, which is known as CD204, and 
is expressed on macrophages and DCs involve in the innate immune response 
(Seimon et al., 2006, Murray & Wynn, 2012, Martinez et al., 2020). CD204 can 
bind to different varieties of ligands, they recognise bacterial cell wall components 
like LPS, and lipoteichoic acid viral component (Pombinho et al., 2018). The 
ligation of CD204 results in phagocytosis, inflammatory responses, and secretion 
of cytokines, like TNF-α (Pombinho et al., 2018). More importantly, CD204 is 
involved in the uptake of apoptotic cells (Maderna & Godson, 2003, Kelley et al., 
2014). Neonatal microglia promote apoptotic clearance through ligation of PS with 
SRA (Maderna & Godson, 2003). The CD204 receptor shows a dual function as 
they contribute to the inflammatory response against pathogens and could be 
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involve in protecting the host (Kelley et al., 2014). Binding to oxidised low- density 
lipoproteins (oxoLDL) and PS expressed on apoptotic cells (Gorden & 
Pluddemann, 2018). Monocytes/macrophages infiltrate and accumulate in 
different organs causing tissue specific fibrosis and resulting in cGVHD in mice 
and patients (Konmua et al., 2018). The host alveolar macrophages were replaced 
with donor non-classical and intermediate monocytes that highly expressed 
CD204 and were significantly increased in patients with severe lung fibrosis in 
cGVHD (Knouma et al., 2018). Thus, controlling the expression of CD204 on 
surface of monocytes/macrophages could prevent tissue-specific pathology in 
cGVHD (Konmua et al., 2018). The high levels of CD204 expression on 
monocytes/macrophages is linked to a poor prognosis of cGVHD in HSCT patients 
(Knouma et al., 2018). Furthermore, aGVHD is characterised by the strong 
inflammatory response and cells death, this study has investigated the expression 
of CD204     to evaluate the ability of monocytes to capture apoptotic cells in 
allogeneic culture. 
1.4.7 Scavenger receptor B (CD36): 
SRB-1, also known as CD36 is a membrane glycoprotein expressed on 
mononuclear phagocytes including DCs, macrophages, microglia, cardiac 
myocytes, hepatocytes, platelets and adipocytes and some epithelia (including gut, 
kidney, and breast) (Silverstein & Febbraio, 2009, Wang & Li, 2019). On 
phagocytes, CD36 functions to recognizes specific oxidised lipoproteins and 
phospholipids and plays a key role in internalisation of modified LDLs (via 
activation of peroxisome proliferator–activated receptor γ (PPARγ) the nuclear 
hormone receptor), certain bacterial and fungal pathogens, and apoptotic cells, 
which contributes to atherothrombotic diseases and inflammatory responses 
(Silverstein & Febbraio, 2009, Wang & Li, 2019). CD36 has been shown to 
recognise PS to regulate clearance of apoptotic cells (Perry et al., 2018). CD36 
expression in macrophages is reduced by viral infection however, IL-4 can induce 
CD36 expression in macrophages by activating the PPARγ ligand prostaglandin 
J2 (PGJ2) and intracellular lipoxygenase result in anti-inflammatory response 
(Cooper et al., 2016, Wang & Li, 2019). Treatment with IFN-γ has been shown to 
inhibit CD36 and CD14 expression, but increase expression of CX3CR1, CD16 and 
HLA-DR on monocytes (Zhong et al., 2019). Phagocytosis is particularly important 
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in cardiac wound healing to remove apoptotic neutrophils and necrotic 
cardiomyocytes; the process involves CD36 upregulation, and targeting CD36 
reduces macrophage phagocytosis (Daseke et al., 2020). CD36 works by 
recognising specific lipoprotein and lipid components of bacterial cell walls 
(especially mycobacterial and staphylococcal organisms), erythrocytes infected 
with malaria, β-glucans on fungal species, which then triggers opsonin-
independent pathogen internalisation (Silverstein & Febbraio, 2009). Interestingly, 
CD36 showed a protective role in skin infections by generating a host anti-
inflammatory response (Pombinh et al., 2018). In GVHD, patients are often found 
to have skin rashes (Kanuma et al., 2018). CD36 expressed on DCs from mice 
have been shown to be involved in allo- tolerance, and reduction of CD36 
expression was associated with GVHD (Perry et al., 2018).  
There is an association between the severity of GVHD, increase  production of pro-
inflammatory cytokines and activation immunoregulatory intracellular signalling 
cascades through CD36. As CD36 upregulation initiating allo-tolerance that limits 
the pathogenesis of as GVHD (Juric et al., 2017). The data about the exact role of 
CD14+CD36+ in early allogeneic response were limited. As such CD36 expression 
was selected to evaluate the clearance of apoptotic cells by 
monocytes/macrophages  in in vitro model of GVHD. 
1.4.8 Complement receptors: 
Complement receptors play an essential role in pathogen recognition and immune 
complex clearance (Eredi et al., 1991, Nguyen et al., 2015). Complement 
activated products and their receptors develop during the innate and adaptive 
immune responses (Nguyen et al., 2015, Mathern and Heeger, 2015). C3a and 
C5a are anaphylatoxins that mainly bind to complement receptor 3a (C3aR) and 
complement receptor 5a (C5aR), respectively (Nguyen et al., 2015). C3aR and 
C5aR are seven transmembrane spanning G protein coupled receptors (Mathern 
and Heeger, 2015). C3aR is mainly expressed on the surface of T cells, 
monocytes, macrophages, neutrophils, and basophils, whereas C5aR is 
expressed on T cells neutrophils and platelets (Eredi et al., 1991, Cravedi et al., 
2013). C3aR and C5aR provide essential signals for APCs survival, maturation, 
and differentiation, they are also involved in signals that promote T cells priming, 
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which results in T cells differentiation and proliferation (Nguyen et al., 2015). C3aR  
and C5aR on APCs promote APC activation via up-regulation of CD86 expression 
and control cytokine production, as such C3aR and C5aR considered as APC 
activation markers (Cravedi et al., 2013).C3a, C5a ligation with C3aR and C5aR 
favour the inflammatory response by increasing vasodilation, chemokines, 
cytokines, promotes macrophage activation, engulfing of the organism, and 
intracellular killing to present Ag to T cells (Mathern & Heeger, 2015). Interestingly, 
APCs that express high levels of C3aR and C5aR activate T cells to   differentiate 
in to Th1 and type 17 T helper (Th17) cells that suppress Treg formation (Nguyen 
et al., 2018). Also ligation of C3aR and C5aR results in monocyte derived DC 
activation (Li et al., 2012), elevation of CD86 and HLA-DR levels, secretion of 
inflammatory cytokines including IL-6 and TNF-α that initiate aGVHD development 
(Li et al., 2012, Nguyen et al., 2018). More importantly ligation of C3aR, C5aR can 
result in kidney transplant rejection due to allo-reactive T cells response (Mathern 
& Heeger, 2015). Studies has revealed that C3aR and C5aR deficiency on APCs 
reduces T cell priming and decreases the onset of  aGVHD (Nguyen et al., 2015, 
Mathern & Heeger, 2015). Blocking of C3aR and C5aR inhibit T cell activation and 
proliferation (Cravedi et al., 2013). Targeting C3aR, C5aR on mice DCs lowers the 
Ag presentation, with reduced     HLA-DR expression, APCs activities, and 
decreased IFN-γ (Nguyen et al., 2015). Currently, there  are limited data on the 
expression of C3aR, on human monocytes and  their role in aGVHD, therefore 
more study is required. Thus, in this thesis the levels of C3aR+CD14+ expression 
measured to evaluate the role of  C3aR during early allogeneic response in two-way 
MLR. 
1.4.9 CD11b: 
CD11b is expressed on granulocytes, lymphocytes, monocytes, monocyte- 
derived cells including DCs, and some resident macrophages (Ochando et al., 
2016, Fendl et al., 2018). Human tissue-resident macrophages express MHCII, 
CD68, CD33 and CD11b under homeostatic conditions (Ochando et al., 2016). 
CD11b is an important marker for differentiating between different subsets of 
macrophages; CD11blowF4/80+ macrophages express greater numbers of pro-
inflammatory M1 markers (including CD11c, CD86 and MHC-II), whereas 
CD11bhighF4/80+ express greater numbers of M2 markers with a high phagocytic 
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activity (Ma et al., 2019). CD11b is crucial for cell adhesion, phagocytosis of 
pathogens, phagocytosis of apoptotic cells, and complement-opsonised cells by 
monocytes, but this process does not always involve inflammation (Lukácsi et al., 
2017, Gavin et al., 2019).  
During cell migration, CD11b, along with CD11c, becomes concentrated in the 
podosome adhesion ring in human phagocytes, which confirms the important role 
of CD11b in migration (Lukácsi et al., 2017). Monocytes and macrophages in 
circulation can be mobilised and activated by the interaction of CD11b and IL-4 
(Baba et al., 2020). CD11b selected in this study to evaluate monocytes/ 
macrophages differentiation state in two-way MLR. 
1.5 T cell response: 
Naïve T cells are produced from the thymus, after positive and negative selection. 
Consequently, they can recognise non-self Ag which is presented by APCs to 
generate an immune response against the pathogen (Neefjes et al., 2011, Rock 
et al., 2016, Wieczoret et al., 2017). Most APCs are in the secondary lymphoid 
organs; all pathogen-infected cells in the peripheral sites are transported to the 
lymph nodes or the spleen. APCs will engulf the pathogen, then process and 
present the peptides to the naïve T cells via MHC molecules (Murray & Wang 
2012, Deretic et al., 2013, Rock et al., 2016, Wieczoret et al., 2017). The activation 
of naïve T cells usually involves three essential signals; the initial signal comes 
from the interaction between the T cell receptor (TCR) on both CD4+ and CD8+ and 
the peptide antigen present via MHCII and I on the surface of APCs (Neefjes et al., 
2011, Ka et al., 2016). The later signal after TCR activation is co- stimulation as 
the absence of co-stimulation leads to T cells apoptosis; naïve T cells express 
CD28, which is a receptor for CD80, and CD86 expressed on the APCs (Neefjes 
et al., 2011, Ka et al., 2016). Importantly, binding of CD28 to CD86 enhances T cell 
proliferation (Ka et al., 2016). CD28 and B7(CD80/CD86) binding up-regulates 
CTLA-4 on T cell surfaces, which later competes with CD28 to bind with B7 
resulting in T cell inhibition, leading to immune tolerance (Blazar et al., 1994, Ka 
et al., 2016). There are other costimulatory molecules upregulated on T cells 
during activation, including T cell co-stimulator (ICOS/CD278), members of the 
TNF ligand/TNF receptor family, such as CD40 ligand (CD154; TNFSF5), CD30 
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(TNFRSF8), CD137 (TNFRSF9) and OX40 (CD134; TNFRSF4) (Deretic et al., 
2013, Zeiser et al., 2016). It has been reported that activation of CD8+ T cells 
requires co-stimulation signals from CD70 and CD137, unlike CD4+ T cells, which   
rely on CD28 and B7 co-stimulatory signals (Deretic et al., 2013, Zeiser et al., 
2016). The third crucial step for activating T cells are interactions with cytokines, 
including IL-12 and other cytokines essential for T cell survival, proliferation, and 
differentiation. This includes cytokines that share a common gamma chain 
(CD132), which forms a complex receptor for six cytokines, IL2, IL-4, IL-7, IL-9, 
IL-15, and IL-21 that are present on all lymphocytes, including T cells (Hechinger 
et al., 2015, Zeiser et al., 2016). 
Interestingly, CD4+ cells are further classified into Th1, Th2, Th9, Th17, Th22 and 
Treg cells based on their cytokine profile and the type of infectious agent (Ouyang 
et al., 2012, Rahimi et al., 2019). Naïve T cells will differentiate into Th1 if they 
recognize intracellular infection, whereas T cells will differentiate into Th2 after 
extracellular pathogen recognition (Romagnani, 1999, Rahimi et al., 2019). Th1 
cells secrete IFN-γ, IL-2 and TNF-α, which activate cell mediated immunity and 
macrophage phagocytic activity, whereas, Th2 cells mainly produce IL-4, IL-5, IL- 
6, IL-9 IL-10, IL-13, and IL-25, which down regulate macrophages functions, 
increase antibody production and eosinophil recruitment (Romagnani, 1999, 
Rahimi et al., 2019). IL-23 prime Th17 cells to secrete the cytokines IL-17, IL-21, 
and IL-22, which play a crucial role in the defence against extracellular pathogens 
(Ouyang et al., 2012). Balance in cytokine secretion from Th is essential as an 
unbalanced Th1/Th2 secretion is associated with many diseases, including 
inflammatory bowel disease, allergic and ectopic diseases (Rahimi et al., 2019). 
1.5.1 T cells activation markers CD69 and CD25: 
T cells express many surface markers based on their activation stage (Bajnok et 
al., 2017). An early activation marker is the glycoprotein receptor (CD69), that is 
induced soon after TCR/CD3 ligation with MHC molecules and activating 
cytokines, CD69 levels remain elevated on the surface of T cells from 3 hours up 
to 72 hours post activation (Sancho et al., 2005, Han et al., 2009, Bajnok et al., 
2017, Cibrian et al., 2017). Interestingly, resting T cells did not express CD69 
(Sancho et al., 2005, Han et al., 2009, Cibrian et al., 2017). CD69 have short 
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cytoplasmic domains binds to JAK3, a ligand to specific carbohydrate binding 
protein known as Galectin-1 (Gal-1) which is expressed by DCs and macrophages 
(Cibrian et al., 2017). Activation of CD69 plays an essential role in T cells 
proliferation and survival   during the proinflammatory response (Han et al., 2009, 
Bajnok et al., 2017).CD69   could control T cells migration to the lymph node and 
inflamed tissue, as such T cells expressing CD69 are mainly not found in the 
circulation (Cibrian et al., 2017). CD69 could negatively regulate T cell activity, as 
ligation of CD69 to calprotectin activate STAT3 result in transcription of TGF-β 
gen, TGF-β later secreted by activated T cells reduced Ag presentation by APCs 
which impairs T cells polarisation more importantly maintain Treg differentiation 
(Sancho et al., 2005). CD4+CD69- failed to develop into Treg (Sancho et al., 2005, 
Cibrian et al., 2017). The late activation marker of T cells is the alpha chain trimeric 
IL-2 receptor prominent surface receptor expressed on lymphocytes (CD25), 
which is induced 24 hours post TCR activation in response to IL-2, and results in 
T cells activation and releasing more IL-2 (Yarkoni et al., 2014, Bajnok et al., 
2017). Interestingly, CD25 remain on the surface of T cells for a few days (Bajnok 
et al., 2017). CD25 is up-regulated due to cytokines released by 
monocytes/macrophages or in responds to substances such as oxoLDL (Bajnok 
et al., 2017). Many lymphocytes subsets express CD25 on their surface, including 
regulatory T cells, effector, and memory T cells (Bajnok et al., 2017). It has been 
reported that incomplete depletion of T cells with CD25 and CD69 produced a 
good clinical picture of GVHD (Yarkoni et al., 2014). It has been demonstrated 
that T cells after activation with MHC will go through apoptosis by ligation of the 
Fas/Fas ligand. Defects of Fas expression will result in accumulation of activated 
T cells that caused autoimmune damage (O’Flaherty et al., 2000). This study aimed  
to measure MFI value of CD25 and proportion of % CD69 expression on CD3+ 
and CD4+, to evaluate T cells allo-activity in MLR. Based on the well-established 
characteristics of this molecules, CD69 is regarded as an early activation marker 
for T cells that is rapidly up-regulated on the cell surface (Han et al., 2009). 
However, it is difficult to detect difference in the levels of CD69 expression (MFI 
values), and there is no clear correlation between the level of CD69 expression 
and the strength of T cell activation (Han et al., 2009). In contrast, after activation 
CD25 becomes up-regulated on the surface of T cells, and the level of expression 
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of this marker (detected by changing MFI values-brightness) corresponded to the 
level of activation. Thus, measuring CD25 level of expression (MFI values) and 
the proportion of CD69 positive cells (CD69%) were informative and meaningful 
markers that reflect T cells activation for this study. Indeed, numerous studies 
have analysed T cell activity based on the proportion (%) of CD69 positive cells 
and changes in MFI levels for CD25 expression to show the key features of T cells 
activation (Han et al., 2009, Bajnok et al., 2017, Via et al., 2017). 
1.5.2 Th1/ Th2 cells in acute GVHD: 
It is thought that during HSCT, donor T cells are primed by APCs, leading to 
activation and differentiation toward Th and cytotoxic T (Tc) cells, and both T cell 
subtypes controlled developing of a GVHD (Wyscoki et al., 2005, Blazar et al., 
2013, Avin et al., 2015, Koehn et al., 2015, Zeiser et al., 2016, Heller et al., 2017, 
Hong et al., 2020). More importantly, T cells migrate to lymphoid organs and 
tissue, T cells can be primed by different APCs at both sites (Yarkoni et al., 2014). 
It has been reported that the incomplete removal of activated T cells that 
expressed CD25 and CD69 affect GVHD development (Yarkoni et al., 2014). As 
previously mentioned, three signals are essential to activate donor T cells to 
undergo the different stages of activation (naïve, effector and memory) and to 
initiate aGVHD, starting with activation of TCR, followed by co-stimulatory/ co-
inhibitory signals and interaction with cytokines (Zeiser et al., 2016). T cell 
activation is controlled by the location and the type of APCs, the kind of antigen or 
peptide presented via the MHC complex, and the capacity for direct peptide 
recognition (Zeiser et al., 2016). The classical concept was that donor Th cells are 
primed by host APCs which can further differentiate into Th1, Th2, and Th17 cells 
that migrate towards target organs such as skin, liver, and intestine (Avin et al., 
2015, Zeiser et al., 2016, Hong et al., 2020). Th1 cells-controlled cell mediate 
immunity like cytokine secretion IFN-γ, IL-2 and TNF-α (Raphael et al., 2014), and 
these cytokines are essential to induce antigen presentation by APCs and recruit 
effector T cells during the activation phase of aGVHD (Aveni et al., 2015, Hong et 
al., 2020). However, Th2 controlled humeral response has been reported to be 
involved in tissue repair (Raphael et al., 2014). Th2 released cytokines such as 
IL-4, IL-5 and IL-13 which may lower the risk of GVHD (Aveni et al., 2015). 
Excessive secretion of Th1 cytokine results in tissue damage whereas excessively 
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production of Th2 result in hypersensitivity (Raphael et al., 2014). It has been 
reported that T cells mediated tissue damage controlled by monocytes or 
macrophages and their microenvironment (Hashimoto et al., 2011). 
1.6 Pathophysiology of acute GVHD: 
During transplantation, mononuclear phagocytes from the donor organ can 
migrate into the recipient’s secondary lymphoid organs, and when activated 
initiate the acute inflammatory cascade, which causes secondary tissue injury, for 
example, activated DCs alter their cytokine, adhesion molecule and co-stimulatory 
receptor expression to allow them to migrate into lymphoid tissues and stimulate 
T cells, and this can contribute to initiation of allograft rejection (Ochando, 2016). 
It has been demonstrated that there are three phases involved in aGVHD: firstly, 
the conditioning regimen, then T cell activation, and finally the effector phase 
(Ferrara et al., 1991, Deeg, 2001, Markey et al., 2014). 
1.6.1 The conditioning regimen phase: 
Before the allogeneic HSCT procedure, patients will take immune suppressor 
drugs and undergo total body irradiation (TBI), which can result in gastrointestinal 
tissue damage (Ferrara et al., 1991, Deeg, 2001, Wysocki et al., 2005, Blazer et 
al., 2013, Hong et al., 2020).  
1.6.1.1 Allogeneic reaction in conditioning regimen: 
After TBI, the patient’s T cells, NK cells and neutrophils are quickly destroyed, and 
the number of DC and B cells are also reduced in the lymph nodes 48 hours after 
TBI (Hashimoto et al., 2011). However, the patient’s macrophages can persist for 
many weeks, which may explain the importance of the host macrophages in the 
pathogenesis of GVHD (Hashimoto et al., 2011). The conditioning regimen mainly 
leads to exposure in the body to normal bacterial flora products, such as LPS, and 
many studies have highlighted the importance of releasing LPS to circulation and 
the initiation of aGVHD (Deeg,H 2001, Wysocki et al., 2005, Blazer et al., 2013). 
LPS released activates  APCs from haematopoietic sources including B cells, DCs 
and monocytes/macrophages, and non-haematopoietic sources such as 
endothelial cells (Chakraverty & Sykes 2007, Zeiser et al., 2016). Activated APCs 
show upregulation of TLR4, the LPS receptor, on their surface followed by a 
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cytokine storm in aGVHD (Cooke et al., 2001, Blazer et al., 2016). As such the 
serum levels    of pro-inflammatory cytokines, such as, IL-1β, IL-6 and TNF-α 
become elevated (Deeg,H 2001, Wysocki et al., 2005, Hong et al., 2020). 
Monocytes/macrophages can infiltrate tissue in response to the inflammatory 
response and many studies confirmed the role of monocytes in aGVHD occurrence 
(Markey et al., 2014, Hong et al., 2020). Activated Monocytes/macrophages up-
regulate the expression of adhesion molecules, MHC, co-stimulatory molecules in 
their surface ready to prime T cells (Deeg,H 2001, Wysocki et al., 2005, Markey et 
al., 2014, Duque & Descoteaux, 2014). 
Koehn et al. (2015) reported that after conditioning the dead cells would release 
ATP which binds to APCs via endogenous damage- associated molecules 
(DAMPs) leading to inflammasome activation (Koehn et al., 2015). When the 
inflammasome is activated the numbers of myeloid-derived suppressor cells will 
be reduced, which may increase the chance of developing GVHD (Koehn et al., 
2015).  
1.6.2 The activation phase of alloresponse: 
In this phase, alloantigen recognition stimulates donor T cell activation, 
proliferation, differentiation, and migration of effector T cells from the lymphoid 
tissues to target tissues, such as the skin, gastrointestinal tract, and the liver 
(Markey et al., 2014). Post-HSCT, both donor and host APCs process and present 
peptides to the donor T cells; several studies have confirmed that donor APCs 
have a role in allogeneic T cell activation (Chakraverty & Sykes, 2007, Markey et 
al., 2014). Direct presentation occurs when the donor T cells interact with APCs 
from the host, leading to a proliferation of Th1 CD4+ and Tc CD8+ cells 
(Chakraverty & Sykes, 2007). The Th1 cells then secrete cytokines, including IL- 
2 and IFN-γ, which are important in inducing antigen presentation and recruitment 
of effector T cells, and this phase is crucial for the progression of GVHD 
(Chakraverty & Sykes, 2007, Blazer et al., 2013). In addition, IL-2 is considered as 
T cells factor because it induces T cells to differentiate and to form CD8+ T cells 
(Chakraverty & Sykes, 2007, Markey et al., 2014). However, cross-presentation, 
develops when the donor T cells recognize host allogeneic antigens presented 
indirectly by donor APCs (Matte et al., 2004, Koyama et al., 2015). Interestingly, 
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antigen presentation may occur via host non- hematopoietic cells like myofibroblast 
to activate donor T cells (Zeiser et al., 2016, Hechinger et al., 2015). As there is 
evidence that the activation phase by macrophages is important in the  initiation of 
GVHD, this study focused on evaluation of monocyte-derived macrophages 
activation, cytokine production and their interaction with T cells using an in vitro 
model of GVHD. 
1.6.3 The effector phase of allorespons: 
This last phase, occurs when the allo-reactive T cells (CD4+ and CD8+) in 
response to   chemokines and adhesion molecules target the patient's organs, 
including the skin, liver, and intestine, causing tissue damage, which is the main 
characteristic  of aGVHD (Wysocki et al., 2005, Blaze et al., 2013, Markey et al., 
2014, Zeiser et al., 2016, Hill et al., 2018). 
1.6.4 Cytokines involved in GVHD pathophysiology: 
Cytokines are small, soluble proteins that regulate cellular communication (Duque 
& Descoteaux, 2014). The main function of cytokines is to control the immune 
response in health and disease; each cytokine binds to a specific surface receptor 
to mediate cellular signalling and influence cell function (Duque & Descoteaux, 
2014). More importantly, GVHD pathophysiology is characterised by the presence 
of a cytokine   storm (Ferrar et al., 1991, Blazer et al., 2013, Zhang et al., 2017, 
Drobyski et al., 2018). 
Due to patient tissue damaged after irradiation, activated T cells, APCs and NK 
cells will release pro-inflammatory cytokines, such as IFN-γ, which up-regulate 
MHCI and MHCII expression on the surface of professional APCs, including 
monocytes/macrophages. These respond to the initial inflammatory stimulation by 
releasing significant amounts of TNF-α and IL-1β, which leads to APCs 
maturation, expression of co-stimulatory molecules, and further cytokine release. 
This contributes to T cell activation targeting organs and induces GVHD symptoms 
(Deeg, 2001, Chakraverty & Sykes 2007, Markey et al., 2013, Zhang et al., 
2017).Clinical symptoms of aGVHD like weight loss, diarrhoea, and skin rashes, 
are mainly due to Th1 and pro-inflammatory cytokines like IFN-γ, TNFα, IL-2, IL-
1β and nitric oxide (Blazer et al., 2013, Zhang et al., 2017, Hong et al., 2020). 
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TNF-α is pro-inflammatory cytokine released from macrophages and activated 
Th1 and is involved in acute inflammation (Deeg, 2001, Duque & Descoteaux, 
2014). Releasing of TNF-α in the liver caused vasodilation, stimulated T cells, 
neutrophil recruitment, and monocytes infiltration (Duque & Descoteaux, 2014). In 
aGVHD, TNF-α upregulated co-stimulation by monocytes/macrophage followed 
by priming of T cells (Chakraverty & Sykes 2007, Markey et al., 2013, Zhang et 
al., 2017). In addition, TNF-α caused cell apoptosis and necrosis, which was 
associated with tissue damage and resulted in a GVHD symptoms such as liver 
and intestinal tissue damage (Kumar et al., 2017). Low concentrations of TNF-α 
followed HST used to lower the risk of aGVHD (Deeg, 2001). Priming of TNF-α 
could induce Treg functions and lower incidence of aGVHD (Kumar et al., 2017). 
IL-2 is one of the key secretory cytokines that act as T cells growth factor, that 
controls activation and proliferation. IL-2 may control the resistance to apoptosis 
by up-regulation of anti-apoptotic markers Bcl-2 or Bcxl-xL on T cells (Blazar et al., 
2013, Bajnok et al., 2017, O’Flaherty et al., 2000). During GVHD, IL-2 levels are 
increased early post transplantation (Deeg, H 2001). IL-2 is secreted from Th1 
cells and NK cells to stimulate T cell activation, differentiation and proliferation, 
secretion of TNF-α from macrophages, and enhanced APCs recruitment to 
mediate skin and gut damage (Chakraverty & Sykes 2007, Kumar et al., 2017). It 
has been reported that IL-2 controlled Treg formation is associated with 
immunotolerance (Blazar et al., 2013, Bajnok et al., 2017). Anti-IL-2 therapy 
successfully lowers the incidence of GVHD (Deeg,H 2001). Interestingly, low 
concentrations of IL-2 were associated with Treg proliferation and low GVHD 
development (Blazar et al., 2013, Kumar et al., 2017). 
IL-1 β pro-inflammatory cytokines are produced by several cell types, including 
monocytes, macrophages, Th1 cells, B cells and NK cells (Chakraverty & Sykes 
2007, Ferrara et al., 2009). IL-1β stimulated histamine release that resulted in 
vasodilation and enhance APCs recruitment to the inflamed tissue to promote Th 
differentiation (Duque & Descoteaux, 2014). It has been reported that patients with 
severe forms of aGVHD have higher levels of IL-1β when compared with patients 
with mild symptoms of aGVHD, which confirms the association between IL-1β, 
inflammation and GVHD pathology (Ferrara et al., 2009). 
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In contrast, there are many other cytokines that could lower the GVHD 
development such as, IL-10 and IL-4 that are mainly produced  by Th2 cells (Deeg, 
H 2001, Kumar et al., 2017). IL-10 and IL-4 could control GVHD formation by 
inhibiting Th1 cytokine production cytokines like IL-2, IL-6 and TNF-α (Deeg, H 
2001, Kumar et al., 2017).  
Nevertheless, the clinical pathology of GVHD relies on the alloreactive T cells 
activities after recognising polymorphic Ag on monocytes/macrophages, which 
causes T cells activation and  differentiation due to local cytokines (Kumar et al., 
2017). This study stimulated monocytes/macrophages in alloresponse with two 
different modulating cytokines (IFN-γ and IL-γ4) to evaluate 
monocytes/macrophages activation and their interaction with T cells followed by 
measuring TNF-α, IFN-γ, γ and IL-6 concentrations as an indication of allogeneic 
inflammatory response. 
1.6.4.1 Interferon gamma (IFN-γ): 
Interferons (IFNs) are known as viral interfering agents classified as type I and 
type II, based on their binding receptor, IFN-γ belongs to the type II IFN family  (Lee 
& Ashkar, 2018). The IFN-γ receptor (IFN γ -R) consists of two heterodimer   chains, 
IFNγ-R1 and IFNγ-R2; notably, IFNγ-R1 is expressed on all haematopoietic cells, 
whereas IFNγ-R2 is highly expressed on myeloid and B cells with variable 
expression on T cells, which is upregulated during T cells activation (Lee & Ashkar, 
2018). Importantly, IFN-γ activate cells via Janus kinase (JAK1 and JAK2) 
/phosphorylation of STAT1 signalling pathway (Gregory et al., 2000, Lee & 
Ashkar, 2018). Based on the relatively high level of IFN-γR expression on the cell 
surface, IFN-γ/JAK/STAT1 may be able to control cellular proliferation or 
apoptosis activity (Gregory et al., 2000, Lee & Ashkar, 2018). 
IFN-γ is mainly produced by CD4+ T helper cells and NK cells, and plays crucial 
role in activating immune cells, including CD8+ Tc cells, B cells and APCs (Wang 
& Yang., 2014, Lee & Ashkar, 2018, Rahimi et al., 2019). However, this cytokine 
is also produced locally by APCs in the early phase of innate immune response, 
resulting in cell self-activation and nearby cells activation, meaning IFN-γ can 
control both innate and adaptive immune reactions (Schroder et al., 2004, Wang 
& Yang., 2014, Lee & Ashkar, 2018). IFN-γ is also known as macrophage 
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activation factor as IFN-γ is produced when the cells are activated by antigens, 
mitogens, and allo-antigens (Lee & Ashkar, 2018). IFN-γ stimulated   macrophages 
to up-regulate the expression of complement receptors to mediate phagocytosis 
(Lee & Ashkar, 2018). It has been reported that IFN-γ stimulates polarisation of 
macrophages towards the high phagocytic, high Ag presentation M1 subtype via 
TLR binding and activation of the STAT1 signalling pathway to produce pro-
inflammatory cytokines like: IL-12, IL-1β and TNF-α (Wang et al., 2014, Lee et al., 
2017, Obrine et al., 2019). Most immune cells express IFN-γ receptors, and they 
up-regulate the MHCI and II molecules, TLR, IgG class switching, and induced 
chemokines in response to activation by IFN-γ (Wang & Yang, 2014, Raphael et 
al., 2014). Interestingly, IFN-γ plays important role in GVHD; the TBI and 
conditioning regimen results in high amount of IFN-γ, as mentioned earlier it is 
secreted by activated donor Th1 cells (Chakraverty & Sykes, 2007, Rahimi et al., 
2019). This enhances apoptosis of intestinal epithelial cells leading to damage in 
the gut and increased production of proinflammatory cytokines such as TNF-α 
from APCs during innate immune reaction in the early phase of aGVHD (Wang 
&Yang, 2014). Interestingly, IFN-γ showed protective role by controlling T cells 
trafficking to the lymph node, increased T cells apoptosis and controlling 
differentiation of T cells (Raphael et al., 2014). Therefore, IFN-γ concentrations 
were measured in MLR culture, also IFN-γ was selected as a stimulus to activate 
monocytes/ macrophages in the in vitro model of histo- incompatibility in this 
thesis. 
1.6.4.2 Interleukin-6 (IL-6): 
IL-6 is pleiotropic cytokine that has proinflammatory and anti-inflammatory 
functions (Duque & Descoteaux, 2014). IL-6 is produced by several cells   including 
monocytes, macrophages and DCs during acute inflammation, however, T cells are 
the main source of IL-6 during chronic inflammation (Ferrara et al., 2001, Tvedt et 
al., 2017). IL-6 is involved in acute and chronic inflammation and autoimmune 
diseases (Tvedt et al., 2017). IL-6 receptors exist in two forms, the membrane IL-
6 receptor (IL-6R) and soluble IL-6 receptor (sIL-6R) and both receptors rely on 
glycoprotein (gp)130 (John, 2012, Drobyski et al., 2018). IL-6R is mainly found on 
hepatocytes, neutrophils, naïve T cells, monocytes, and macrophages (Drobyski 
et al., 2018). Notably cells that do not express the previous receptor essentially 
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bind to IL-6 via sIL-6R, which is known as trans- signalling (Tvedt et al., 2017). 
Binding of IL-6 to sIL-6R with gp130 leads to pro- inflammatory reactions, whereas 
complexes of IL-6 with IL-6R and gp130 result in   an anti-inflammatory response 
and tissue repair (John, 2012), which confirms the role of IL-6 in activating 
monocytes in the pro-inflammatory phase (Duque & Descoteaux, 2014). 
Interestingly IL-6 is released by classical monocytes in response to M-CSF 
(Boyette et al., 2016). Several studies have confirmed the elevation of IL-6 in 
early aGVHD (Tvedt et al., 2017, Drobyski et al., 2018). IL-6 mainly controls the 
severity of GVHD and blocking the IL-6R lowers the severity of aGVHD and saves 
the graft vs. tumour (GVT) after BMT (Drobyski et al., 2018). Interestingly, in 
aGVHD, IL-6 mainly mediated GI tissue damage (Drobyski et al., 2018). IL-6 in 
GVHD is produced by damaged cells after chemotherapy and irradiation, or donor 
T cells, and the IL-6 stimulates the production of other cytokines like IL-1β and 
TNF-  (Deeg, 2001, Tvedt et al., 2017, Drobyski et al., 2018). IL-6 is essential in 
GVHD as it controls maturation and proliferation of T and B cells by up-regulating 
production of Th2, Th17 and down regulating Tregs (Tvedt et al., 2017). M1 
activated macrophages mainly release IL-6, TNFα, IL-12, IL-1β and nitric oxide 
(Obrine et al., 2019, Hong et al., 2020), therefore in this study IL-6 concentration 
was measured in MLR. 
1.6.4.3 Interleukin-4 (IL-4): 
IL-4 is an anti-inflammatory cytokine that is produced by CD4+ Th2 cells, 
basophils, mast cells and NK cells (Lee et al., 2017, Harms et al., 2019). It controls 
monocytes/macrophages maturation and polarization, B cell activation and IgG 
IgE class switching (Lee et al., 2017, Harms et al., 2019). IL4 is produced during 
asthma and the inflammation results in down regulation of the pro-inflammatory 
cytokines produced by monocytes and macrophages (Bonder et al., 1999, Deeg, 
2001). IL-4 can bind to two subunit receptors, the type I receptor (IL- 4Rα/γc) and 
the type II receptor (IL-4Rα) (Junttila, 2018). Interestingly the type II  receptor IL-
4Rα is shared by the cytokine IL-13 (Junttila, 2018). IL-4 ligation with the type I 
receptor activates downstream signal through JAK1, JAK3 and phosphorylation 
of STAT6 resulting in Th2 and monocytes activation (Junttila, 2018). IL-4 induces 
Ag presentation by expression of HLA-DR on the monocytes surface, but that 
activation results in reduced secretion of TNF-α by human monocytes (Rousset et 
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al., 1988, Velde et al., 1990). Interestingly, IL-4 induced HLA-DR, CD86 
expression in both classical and intermediate monocytes, HLA- DR expression 
was found more in the intermediate subtype with anti-inflammatory response, which 
resulted in CD4 Th2 cells proliferation (Lee et al., 2017). More importantly IL-4 
polarise macrophages towards M2 with tissue repair function (Lee et al., 2017, 
Junttila, 2018, Obrien et al., 2019). Several studies have confirmed the role  of high 
concentrations of IL-4 in aGVHD tolerance (Deeg, 2001, Via et al., 2017, Tvedt et 
al., 2017). Study by Via and his colleagues showed that treating un-irradiated mice 
with 3-10 µg IL-4 reduced donor CD4, CD8 T cells allogeneic response. The study 
showed that early administration of high dose (10 µg) of IL-4 reduce acute GVHD 
without inducing chronic GVHD (Via et al., 2017). Notably, the high, non-
physiological levels of IL-4 were needed to achieve pharmacological effects in 
GVHD setting.  
It has been reported that IL-4 antagonise the inflammatory cytokines that are 
essential in aGVHD, including IFN-γ, and reduce T cells alloresponse (Blazar et 
al., 2013, Via et al., 2017). There are limited data about the effects of IL-4 on 
monocytes/macrophages function in the early stage of allogeneic culture. Thus, IL-
4 was selected as stimulus, to evaluate the anti- inflammatory response of 
monocytes/macrophages in two-way MLR model. 
1.7 Current strategies to control GVHD: 
Over the last decades of HSCT, the primary goal was to minimise the risk of GVHD 
and maintain the graft survival. The patients age, condition regimen and source of 
HSCT are factors that could control GVHD induction (Markey et al., 2014, Blazar 
et al., 2013, Ganetsky et al., 2019). The stronger condition regimen caused more 
tissue injury which resulted in inflammation that favoured GVHD (Blazar et al., 
2013, Drobyski et al., 2018). Currently, the first line of treatment to prevent GVHD 
is immunosuppressive drugs, however the main limitation is that patients will be 
at high risk of infection with high incidence of relapse (Ferrara et al., 2009, Blazar 
et al., 2013, Hill et al., 2018). The immunosuppressive regimen aimed to down- 
regulate TCR signalling pathway and that can be achieved by using calcineurin 
inhibitors like cyclosporin A, which was introduced in 1980s and became the 
prominent drug to control T cell alloresponse and in GVHD prophylaxis (Storb et 
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al., 1989, Zieser et al., 2016). Furthermore, in the 1990s tacrolimus (FK-506) was 
developed to control GVHD and transplant rejection by reducing IL-2 and 
maintaining Treg formation in response to TGFβ (Zieser et al., 2016). Steroids 
were used to treat inflammatory disease including aGVHD however some patients 
develop steroid resistance (Reinhardt et al., 2017, Hill et al., 2018). Interestingly, 
both steroid and calcineurin inhibitors reduced IL-2 which is essential for T cells 
activation and proliferation (Markey et al., 2014). Targeting IL-2 receptor induced 
Treg formation (CD4+CD25+ FoxP3+), proven to be beneficial in murine models 
and human clinical trials. Tregs can prevent GVHD, as they could deactivate allo-
reactive T cells after HSCT during activation phase (Wysocki et al., 2005, Markey 
et al., 2014, Blazar et al., 2013). More importantly, Sirolimus is rapamycin inhibitor 
used as front-line therapy in older aGVHD patients who cannot tolerate steroid 
treatment or for patients who develop steroid resistance (Zieser et al., 2016, Hill 
et al., 2018). 
Furthermore, Belatacept and Abatacept are nontoxic reagents available in clinical 
trial provided for patients who intolerance of calcineurin, to block co-stimulation 
like CD80, CD86, CTLA-4 and CD28 (Markey et al., 2014). It has been reported 
that the T cell response in aGVHD is mainly controlled by proinflammatory 
cytokines through JAK2 signalling, it has been demonstrated that kinase inhibitors 
that target JAK2 could control the T cells alloresponse (Hill et al., 2020). Ruxolitinib 
is a JAK1/JAK2 inhibitor used in mouse models showed promising results in 
controlling aGVHD by reducing proinflammatory cytokines and formation of Treg 
(Hill et al., 2018). Preclinical studies for Tocilizumab (which is humanized anti-IL- 
6 receptor have shown promise, as IL-6 is essential cytokine involved tissue 
damage in gastrointestinal track (GI) in GVHD (Drobyski et al., 2018, Ganetsky et 
al., 2019). IL-6 controls T cell proliferation, trafficking to GI and anti-apoptosis 
(Drobyski et al., 2018, Ganetsky et al., 2019). As such, a combination of 
Tocilizumab with a GVHD standard immunosuppressor show therapeutic effects 
in controlling GVHD (Drobyski et al., 2018, Ganetsky et al., 2019). Fostamatinib is 
SYK inhibitor (discuss in detail 2.11 and 2.12) that has been used in murine model 
and showed reduction of GVHD (Hill et al., 2018). It has been demonstrated that 
activation of innate response through TLR4 caused cytokine storm in aGVHD, and 
that mutation of the TLR4 gene showed promising results in controlling aGVHD in 
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a mouse model (Blazar et al., 2013). Furthermore, TLR9 signalling through MyD88 
induced aGVHD, whereas MyD88 inhibitor reduced the innate immune response 
and could result in a lower risk of aGVHD (Blazar et al., 2013). Interestingly, T 
cells could be activated in GVHD even after controlling TLR (Blazar et al., 2013). 
As mentioned earlier, APCs control Ag presentation in GVHD, targeting or 
depletion of a single type of APCs could control  GVHD (Blazar et al., 2013). Most 
of the cellular therapies in the clinical trial phase  demonstrated promising results 
by suppressing alloresponse in GVHD targeted lymphocytes (Ferrara et al., 2009, 
Blazar et al., 2013). However, there are limited studies that targeted 
monocytes/macrophages function to control GVHD. 
From this perspective, this thesis hypothesised that targeting adult monocytes 
derived macrophages by inhibiting SYK signalling through FcγRI may lower 
antigen presentation, and this could produce promising results in respect of the 
down-regulation of allo-reactive T cells after HSCT, as this would reduce the 
incidence of aGVHD. 
1.8 Mixed leukocytes reaction MLR: 
Mixed leukocyte reaction (MLR) is mainly used to detect the level of mismatched 
before organ and stem cells transplants to predict the rejections (O’Flaherty et al., 
2000, Bromelow et al., 2000, Reinsomen, 2010). MLR used mainly to allow 
measuring of   T cell activation and proliferation (Bromelow et al., 2000). There are 
two types of culture   for MLR, in one-way MLR stimulatory cells are irradiated and 
treated with drug or   inhibitor, then the responder cells are added so in this model 
only one population (responder cells) are allowed to proliferate (Reinsomen, 
2010). In two-way MLR, which was established by Bain et al. (1964), two 
populations are mixed with all immune component cells, which results in an 
allogeneic reaction, interestingly both cellular populations could proliferate 
(Reinsomen, 2010). Two-way MLR is used to detect mismatch among individuals, 
one population will disappear after 3 weeks, however the second population will 
proliferate and survive strongly (Reinsomen, 2010). The allogeneic reaction in 
two-way MLR is more complex (Sato et al., 1999). Post-transplant the graft will 
contain immune components that could leave the graft and migrate in the 
recipient's circulation (Smith & Wang 2009, Reinsomen, 2010). Some protocols 
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used murine splenocytes as stimulatory cells (Han et al., 2009, Highfill et al., 2010, 
Ke et al., 2016). Other studies used PBMC as a stimulator population (Bromelow 
et al., 2000). It has been reported that whole blood MLR will most likely mimic the 
human immune response better than using PBMC (Bromelow et al., 2000). In this 
report, two random mismatched samples collected from healthy donors were 
mixed as two-way MLR. Unlike other  protocols that mainly use two-way MLR to 
measure T cells proliferation, or isolate monocytes (Han et al., 2009, Highfill et al., 
2010), this thesis analysed monocytes/macrophages function and T cell activities 
in two-way MLR saving cellular interaction that could reflect the allogeneic 
response. 
1.9 Limitations of using animal models: 
Mouse models are regularly used to test drug efficacy, therapeutic options, or to 
study immunological reactions during transplantation (Blazar et al., 2013). 
Although many drugs succeed in mice models, they fail in human systems due to 
immunological reaction differences between these two species. Basically, human 
and mice differ in terms of life span, size, behaviour, and innate and adaptive 
immune reactions (Murray & Wyn, 2011, Heitbrock. L, 2014). One of the 
important variations in the innate immune system between human and mice is the 
WBC count; in mice species the lymphocyte count is 75-90 % of the total WBCs 
count, neutrophils are about 10-20 % and monocytes only make up 2-4 %. 
However, in humans the ratio of neutrophil is higher, with a count of around 50-70 
% of the total WBCs, lymphocytes are 20-40 % and monocytes make up 1-10 % 
(Zschaler et al., 2014). In addition, there is a recognised variation between the two 
species especially in respect of the source of monocytes and macrophages 
(Murray, 2017). For instance, monocytes are the major source of macrophages in 
humans, however, BM-derived, or peritoneal cavity macrophages are the main 
source of macrophages in mice, which is due to different polarisation agents 
(Murray, 2017). There are also differences in expression of cell surface markers 
on human and mouse monocytes (Zschaler et al., 2014). As mentioned above, 
there are three functional human monocyte subsets identified based on cell 
surface marker CD14/CD16 expression, whereas monocytes in mice are 
classified into two different populations based on expression of Ly6C, CCR2 and 
CX3CR1 (Sprangers et al., 2016). The Ly6C+, CCR2high, CX3CR1low monocytes 
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can be treated as classical and intermediate monocytes in humans, whereas the 
Ly6C-, CCR2low, CX3CR1high monocytes can be treated as non-classical 
monocytes in humans (Sprangers et al., 2016). Although CD16+ human 
monocytes and Ly6C+ share some similarities they are not identical (Heitbrock, 
2014). These differences may contribute to the variation in immunological 
reactions between humans and mice for specific stimuli or treatments (Blazar et 
al., 2013, Kenney et al., 2016). 
Humanised mouse models have been developed to overcome the differences in 
immunological reactions between mice and humans; the most commonly used 
model is immune-deficient mouse with a mutation in the IL-2 receptor common 
gamma chain (IL-2γ), xenografted with human innate or adaptive cells (Zschaler 
et al., 2014, Kenney et al., 2016). IL-2γ receptor is the main receptor that binds to 
cytokines IL2, IL4, IL7, IL9, IL15 and IL21, and use of this model will eliminate the 
adaptive immune cells from host and enhance the human grafted cells (Brehm 
and Shultz., 2012).Although humanised mouse models have been used to help 
test many drugs in preclinical settings and they also allow for a better 
understanding of the mechanisms of allogeneic rejection (Brehm and Shultz., 
2012). The current humanised model did not show human markers on the surface 
of monocytes and macrophages, and these could have a crucial role in graft 
rejection (Brehm and Shultz., 2012). This highlights the need to develop an in vitro 
model of GVHD to allow the study of the functional potential of human monocytes 
and macrophages in an allogeneic reaction. 
1.10 Spleen tyrosine kinase: 
Spleen tyrosine kinase (SYK) is an intracellular 72 kDa, non-receptor cytoplasmic 
tyrosine kinase involved in several signalling pathways within immune cells, 
including T cells, B cells, monocytes, macrophages and DCs (Wysocki et al., 
2005, Yi et al., 2014, Coffy et al., 2017, Hill et al., 2018). SYK is involved in 
processing downstream signals from cell surface receptors such as TLR, FcR, B 
cells receptors (BCR) and chemokine receptors (Leonhardt et al., 2012, Flynn et 
al., 2015). Importantly, activation of these receptors is thought to be involved in 
the development of GVHD pathology (Leonhardt et al., 2012, Yi et al., 2014, Flynn 
et al., 2015, Hill et al., 2018). Notably, CD14 and FcR on monocytes/macrophages 
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are involved in activation of SYK downstream signals that are essential to mediate 
inflammatory responses by monocytes/macrophages (Yi et al., 2014). As 
presented in (Figure 1.3) CD14 helps in binding LPS to TLR4, this interaction 
activated SYK downstream signalling in monocytes/macrophages resulting in 
CD14, TLR4 endocytosis and internalisation (Yi et al., 2014, Wu et al., 2019). 
Binding of CD14 to LPS promotes endocytosis of CD14/TLR4 complex, 
phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM). Then 
activated tyrosine kinase SYK will activate phospholipase Cγ (PLCγ) leading to 
generation of phosphoinositide 3-kinase (P13K), resulting in influx of extracellular 
Ca2+ and causing CD14 TLR4 receptors internalisation by IRF phosphorylation 
(Wu et al., 2019).  
 
Figure 1. 3: CD14 activation of tyrosine kinase SYK and its downstream effector PLCγ2 through 
an ITAM-containing receptor.  
PLCγ2 promotes the influx of extracellular Ca2+ and transports the TLR4 dimer to the endosome. 
In the endosome TLR4 induces TRIF activation following RIP-1 and TRAF3 recruitment. RIP-1 
activates the TAK1 complex and Caspase 8 and the connected MAPK and NFκB. TRAF3 recruits 
downstream adaptors for IRF3 phosphorylation. (Note : this figure is published by Wu et al., 2019 
CD14: Biology and role in the pathogenesis of disease - ScienceDirect).  
Similarly, the cross-linking of the FcγR to their ligands will generate signal through 
SYK as presented in (Figure 1.4). The ligation of the FcR triggers phosphorylation 
of the cytoplasmic domain through ITAM. Afterwards, the SRC family kinase (Lyn, 
Src, Fyn, Feg and Hck) starts tyrosine phosphorylation of the ITAMs in the 
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cytoplasmic domains of these receptors. This is followed by recruitment of SYK-
family kinases, resulting in activation of PLCγ. Activation of PLCγ causes an 
increased in intracellular calcium. This leads to phagosomes formation by 
membrane remodelling and actin cytoskeleton rearrangements. Then 
phagosomes fuse with lysosomes, releasing reactive oxygen species which is 
crucial for digestion of engulfed particles in phagosomes. Thus, activated 
monocytes/macrophages, up-regulate phagocytosis, Ag uptake, and 
internalisation of pathogens during inflammation that involves SYK signalling 
(Ghazizadeh et al., 1995, Poe et al., 2018). This is followed by up-regulation of 
co-stimulatory molecules and enhanced Ag presentation (Flynn et al., 2015). In 
addition, SYK activation controls the migration of myeloid cells to the site of 
infection to perform antigen uptake in response to the chemotactic CX3CL1, which 
is expressed in inflamed tissues (Gevery et al., 2005, Flynn et al., 2015). More 
importantly, SYK activation in monocytes/macrophages induced proinflammatory 
cytokines production including TNF-α, IL-6, IL-12 and the proinflammatory 
mediator NO (Yi et al., 2014, Hill et al., 2018). Thus, this study aims to control 
monocytes/macrophages allogenic response by inhibiting SYK signalling. 
 
Figure 1. 4: The Fcγ receptors downstream signalling pathways: Signalling -mediated by ITAM 
involves sequential action of SFKs (red) and SYK kinases (green). Antibody Fc domains are used 
to aggregate the receptors, which causes SFKs Phosphorylation of the ITAM residues (green) on 
the receptor-associated γ-chains. The ITAM tyrosine phosphorylation allows SYK SH2 domains 
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association, which result in activation and unfolding of the SYK enzyme. Additionally, 
phosphorylation of sites between the kinase domain of SYK and the C-terminal SH2 domain by 
SFKs also causes SYK enzymatic activation. The activated SYK can then phosphorylates other 
substrates, including adaptor-type proteins, for example SLP-76 (brown), which then recruits 
additional molecules, including Grb-2 (pink), phospholipase Cγ (PLCγ) (turquoise), Vav (pale blue), 
Gads (pink) and ADAP (pale turquoise) (adhesion and degranulation promoting adaptor protein), 
this result in stimulation of downstream pathways, including mitogen-activated protein kinase 
(MAPK) activation and actin polymerisation. This can result in cytokine production, phagocytosis 
and degranulation respiratory burst (Not: this figure is published by Berton et al., 2005 Src and Syk 
kinases: key regulators of phagocytic cell activation - ScienceDirect). 
1.10.1 SYK inhibition: 
SYK inhibitors, tested in murine models, showed promising results in controlling 
autoimmune diseases such as rheumatoid arthritis and systemic lupus 
(Braselmann et al., 2006, Leonhardt et al., 2011, Hill et al., 2018). Fostamatinib, 
and Entospletinib are orally available SYK inhibitors in early phase II clinical trials 
for human (Reilly et al., 2011), mainly their therapeutic approach is in targeting the 
SYK pathway through BCR on B cells malignancy, by inhibiting ATP 
phosphorylation in SYK and Y352 regions (Hill et al., 2018). 
SYK activation is a fundamental element for B cells migration and survival (Yi et 
al., 2014), and in murine cGVHD (Flynn et al., 2015). B cells collected from cGVHD 
patients showed activated SYK signalling (Poe et al., 2018). Studies have shown 
that Fostamatinib (non-specific SYK inhibitor) can effectively reduce B cell 
activation in cGVHD (Flynn et al., 2015). Interestingly, 4 µM of Fostamatinib in a 
murine model showed promising results by deactivation of DCs and successfully 
reduced T cells alloresponse, with  reduction of IFN-γ, IL-6 concentration, which 
resulted in lowered GVHD and GVL (Leonhardt et al., 2012). It has been reported 
that daily treatment of Fostamatinib   interfered with the expression of co-
stimulatory molecules, such as CD80, CD86, MHCI and MHCII in DCs, in a mouse 
model of cGVHD (Leonhardt et al., 2012, Flynn et al., 2015). Another study used 
Entospletinib anti-SYK treatment early after HSCT in a murine model, which 
showed a reduction of the skin manifestations in GVHD (Poe et al., 2018). It has 
been reported that PRT062607, an oral small SYK inhibitor, selectively inhibits 
BCR and Fc γ RI on APCs; 1 nM of PRT062607 successfully inhibited SYK 
phosphorylation after BCR activation in chronic lymphoid leukaemia, which proves 
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its effectiveness and induce cellular apoptosis (Spurgeon et al., 2013). It has been 
reported that targeting SYK on macrophages may show a therapeutic effect in 
cGVHD (Flynn et al., 2015). In autoimmune diseases, the IgG mediated response 
involved SYK activation which    control myeloid cells Ag presentation, blocking of 
SYK defect Ag recognition, Ag presentation and suppression of T cells activation 
(Kato et al., 2017).  
Although Fc receptors require the presence of antibodies for efficient antigen 
capture, in GVHD  it is feasible that both allogeneic and self-antigens could trigger 
the generation of   specific antibodies and cause this reaction (Claude et al., 2005). 
Furthermore, it is becoming increasingly evident that autoimmunity, including 
auto-antibodies may play a significant role in GVHD development (Claude et al., 
2005). As FcR are expected to contribute to the efficient capture and presentation 
of auto- antigens in GVHD (Im et al., 2017, Hong et al., 2020). Meaning targeting 
FcR signalling on monocytes/macrophages using small molecule SYK inhibitors 
may show therapeutic approach (Hong et al., 2020). SYK inhibition can inhibit 
cytoskeletal rearrangement, which is essential for monocytes/macrophages 
phagocytosis (Braselmann et al., 2006). The therapeutic effect of anti SYK has 
been extensively study in B cells as a treatment option for cGVHD, with little data 
about targeting SYK on monocytes/macrophages through FcγR in aGVHD. 
Monocytes/macrophages are an interesting target due to their role in the early 
phase of priming T cells, which is essential for the development of aGVHD. 
PRT062067 is known as P505-15 (Hoellenriegel et al., 2012), a highly selective 
SYK inhibitor, that completely suppresses BCR, FcR in blood samples collected 
from heathy donors and rheumatoid arthritis patients (Coffey et al., 2017). In this 
study, PRT0603 was selected as parent compound of PRT062607 suitable for in 
vitro model testing. PRT0603 also known as PRT318,  is a highly selective SYK 
inhibitor that successfully targeted FcγR SYK downstream signals in platelets to 
treat Heparin induced thrombocytopenia using mice model (Reilly et al., 2011). 
PRT0603 inhibits SYK after BCR cross-linked causing CLL cells apoptosis and 
inhibiting chemotaxis (Hoellenriegel et al., 2012). Although Fostamatinib, and 
Entospletinib are widely used SYK inhibitors, they are both non-selective and have 
significant off target effects, including inhibition of FMS-related tyrosine kinase 3 
(FLT-3), Lck, Janus kinase 1 and 3, and c-kit (Spurgeon et al., 2012, Coffey et al., 
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2017). The nonspecific binding could be the cause of several side effects seen 
with Fostamatinib treatment in rheumatoid arthritis clinical trials, including 
hypertension, diarrhoea, nausea, headache, dizziness vomiting, dyspepsia, and 
arthralgia (Kang et al., 2019). This highlights the need for long term follow up 
study, to evaluate the efficacy of Fostamatinib (Kang et al., 2019).  In contrast, 
PRT0603 is a highly selective SYK inhibitor that shows therapeutic potential in 
rheumatoid arthritis and thrombocytopenia patients by inhibiting SYK signalling 
through BCR on B cells and FcRs on platelets. Although there is broader reactivity 
of non-selective SYK inhibitors such as Fostamatinib and Entospletinib which 
could produce therapeutic effects in cancer and autoimmunity, it is important to 
determine exact contribution of SYK inhibition to the pathological process in a 
particular disease such as GVHD. This would provide an insight into the disease 
mechanisms and also define the therapeutic effects of the selective targeting of 
the single pathway. Indeed, the use of Fostamatinib, or Entospletinib would 
produce questions about the exact mode of their action and the role of inhibition 
of individual signalling pathways that are affected as these are non-selective 
inhibitors.  
The downstream signalling via CD14 and FcRs on monocytes/macrophages is 
controlled by SYK activation was described in section 1.10. This study evaluates 
the therapeutic potential of PRT0603 to control the early allogeneic response by 
monocytes/macrophages. This could be achieved by inhibition of the 
phosphorylation of SYK in the SYK-dependent FcγRs mediated activity in 
monocytes/macrophages in mismatched MLR. This could modulate early co-
stimulation and Ag-presentation by monocytes/macrophages, leading to 
diminished alloresponse in the histo-incompatible model. Although the data 
collected in this report may not reflect the physiological condition in MHC matched 
patients, the data could demonstrate the potential of highly selective SYK inhibitor 
to control early allogeneic response. Further study will be needed to assess the 







This study hypothesised that regulation of the early phase of the allogeneic 
reaction could be achieved by controlling monocytes/macrophages functions, 
including their co-stimulation and Ag presentation capacity. Furthermore, the 
study aimed to define the effects of the highly selective SYK inhibitor, PRT0603, 
on monocytes/macrophages activation, cytokine production and the allogeneic 
response.  
1.12 Aims: 
The early activation of APCs is a crucial event during the initiation of GVHD. Thus, 
monocytes/macrophages are involved triggering inflammation by presenting the 
allo-Ag to T cells, which   results in T cells activation and proliferation, as well as 
the secret ion of cytokines. The study aims to investigate monocyte derived 
macrophage function in the allogeneic culture (mixed leukocyte’s reaction - MLR). 
Furthermore, the allogeneic culture was modulated with cytokines. This was 
achieved by administration of Th1 (IFN-γ) and Th2 (IL-4) cytokines, and their 
effects on monocytes/macrophages in the early allogeneic response were 
evaluated. Finally, the therapeutic effect of using SYK inhibitor (PRT0603) in 
controlling monocytes/macrophages during early phase of allogeneic response 
was  investigated. 
1.13 Objectives: 
• Monocyte/macrophage function was evaluated by measuring the expression 
of the surface markers, including co-stimulatory molecule (CD86), Ag 
presentation function (HLA-DR), marker for classical, intermediate monocyte 
subtype (CD64 and CD32B), recognition of apoptotic cells (CD36 and 
CD204), complement receptor (C3aR) and adhesion molecule expression 
(CD11b) using flow  cytometry analysis. 
• CD3 and CD4 T cell activation was investigated by measuring median 
fluorescence intensity (MFI) expression of CD25 and proportion (%) of the 
CD69 surface marker. 
• The level of inflammation was evaluated by measuring the concentrations of 
the cytokines (TNF-α, IFN-γ, IL-2 and IL-6) using ELISA. 
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2 Material and Methods: 
2.1 Materials: 
2.1.1 Reagents, chemicals, and supplier information: 
Table 2. 1: Details of the chemicals and reagents used and which supplier they were purchased 
from. 
Reagent Manufacturer 
Annexin V -FITC BD Biosciences (USA). 
Dimethyl sulfoxide (DMSO) Thermo fisher (USA). 
Dulbecco’s Phosphate Buffered Saline (DPBS) Thermo fisher (USA). 
Ethanol (100%) Thermo fisher (USA). 
Fatal Calf Serum (FCS) Thermo fisher (USA). 
Fc Blocking BD Biosciences (USA). 
Gluta Max Thermo fisher (USA). 
Fixation buffer BD Biosciences (USA). 
Human IFN-γ DuoSet ELISA Development system Thermo fisher (USA). 
Human IL-2 DuoSet ELISA Development system Thermo fisher (USA). 
Human IL-6 DuoSet ELISA Development system Thermo fisher (USA). 
Human TNF-α DuoSet ELISA Development system Thermo fisher (USA). 
Heparin tube Thermo fisher (USA). 
Hyclone Thermo fisher (USA). 
APC Mouse anti-human CD3 Antibody BD Biosciences (USA). 
APC Mouse anti-human CD4 Antibody BD Biosciences (USA). 
APC Mouse anti-human CD14  Antibody BD Biosciences (USA). 
PE Mouse anti-human CD11b Antibody BD Biosciences (USA). 
PE Mouse anti-human CD25 Antibody BD Biosciences (USA). 
PE Mouse anti-human CD32 Antibody BD Biosciences (USA). 
PE Mouse anti-human CD36 Antibody BD Biosciences (USA). 
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PE Mouse anti-human CD64 Antibody BD Biosciences (USA). 
PE Mouse anti-human CD69 Antibody BD Biosciences (USA). 
PE Mouse anti-human CD86 Antibody BD Biosciences (USA). 
PE Mouse anti-human CD204 Antibody BD Biosciences (USA). 
PE Mouse anti-human C3R Antibody BD Biosciences (USA). 
PE Mouse anti-human HLA-DR Antibody BD Biosciences (USA). 
Mouse IgG1, κ Isotype Ctrl Antibody BD Biosciences (USA). 
Mouse IgG2b, κ Isotype Ctrl Antibody BD Biosciences (USA). 
Penicillin/Streptomycin Thermo fisher (USA). 
Recombinant Human Interleukin 4 (rhIL-4) (molecular weight 
15 kDa) 
R&D systems (USA). 
Recombinant Human Interleukin 6 (rhIL-6) (molecular weight 
20.3 kDa) 
R&D systems (USA). 
Recombinant Human Interferon gamma (IFN-γ) (molecular weight 
16.9 kDa) 
R&D systems (USA). 
RBCs lysing buffer BD Biosciences (USA). 
Rosewell Park Memorial Institute media (RPMI) Thermo fisher (USA). 
Staining reagent BD Biosciences (USA). 
PRT0603 (anti- SYK inhibitor molecular weight 340.43 kDa) Synkinase (USA). 
2.1.2 Flow cytometer antibodies: 
All antibodies used were purchased from BD Biosciences (USA). 
Table 2. 2: Details of antibodies used for flow cytometry. Fluorochrome and conjugation antibodies 
used per 1 × 104 cells. 
Antigen Clone Conjugation 
CD3 UCHT1 APC 
CD4 RPA-T4 APC 
CD11b ICRF44 PE 
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CD14 M5E2 APC 
CD25 M-A251 PE 
CD32 FLI8.26 PE 
CD36 CB38 PE 
CD64 10.1 PE 
CD69 FN50 PE 
CD86 2331 PE 
CD204 U23-56 PE 
HLA-DR TU36 PE 
C3aR Hc3Arz8 PE 
2.1.3 Cell culture complete media: 
Cell culture media, RPMI Gluta MAX (Thermo Fisher Scientific, MA, USA), was 
supplemented with 10 % foetal bovine serum (R&D Systems, Abingdon, UK) and 
1 % penicillin/streptomycin (Sigma-Aldrich, Poole, UK). 
2.1.4 Consumables for tissue culture: 
15 ml and 50 ml sterile polypropylene centrifuge tubes, falcon 5 ml round bottom 
polystyrene tubes, cryovials, 24 well plates, pipettes, and sterile tips were 
purchased from Thermo Fisher Scientific (MA, USA). 
2.1.5 Stimulus/inhibitor reconstitution: 
2.1.5.1 Recombinant human IFN-γ protein: 
IFN-γ (200 µg) powder, was obtained from R&D Systems, Abingdon UK, 
reconstituted using 1000 µl of sterile PBS and stored at -20 oC. This generates the 
stock solution of 200 µg/ml). The working solution was prepared by diluting the 
stock solution 1:20 with sterile PBS on the day of experiment. This generates 
diluted solution of 10 µg/ml. The final concentration of 100 ng/ml (0.1 µg/ml) was 
achieved by further 100x dilution of the 10 µg/ml working solution in tissue culture 
well. Typically, this was done by adding 10 µl of working solution (IFN-γ 10 µg/ml) 




2.1.5.2 Recombinant human IL-4 proteins: 
10 µg of IL-4 protein was reconstituted in 1000 µl of sterile phosphate buffered 
saline (PBS) with 0.1 % serum and stored at -20 oC (stock solution 10 µg/ml). A 
100 ng/ml for IL-4 final concentration was prepared by diluting the stock solution 
100x or 200x in tissue culture wells on the day of the experiment. 
2.1.5.3 PRT0603 SYK inhibitor: 
The SYK inhibitor PRT0603 (Mw = 340.4) is soluble in DMSO, and the stock of 5 
mg was aliquoted by weighing 0.6808 mg of the substance and dissolving it into 
1ml of DMSO. This provides 2 mM solution, which is further diluted 1:10 in RPMI 
to obtain 0.2 mM (200 µM) working solution. This is followed by pipetting 10 µl of 
this solution into 1 ml of cell culture to achieve final inhibitor concentration of 2 µM. 
Notably, the reported IC50% values for SYK inhibitors, including PRT0603, 
depend on the experimental model and vary from nM to µM concentrations. As 
this study uses whole blood culture, higher range of inhibitor concentrations is 
necessary, in contrast to experimental models that use isolated cells or cell lines. 
In a study by Nani et al., PRT0603 was used at 1 µM (Nani et al., 2014) which is 
comparable to concentration used in this study. 
2.1.6 ELISA: 
2.1.6.1 Reagent diluent and washing buffer: 
R&D ELISA kit provided x10 reagent diluent and x10 washing buffer, these were 
diluted freshly on the day of experiment 1:10 with distilled water. 
2.1.7 Samples: 
Buffy coat samples were provided from the National Health Service, blood, and 
transplantation service (NHSBT, London, UK). 
2.2 Methods: 
2.2.1 Buffy coat sample: 
Two samples of Buffy coat were received weekly and used in this study. The blood 
provided from NHSBT. All samples were labelled as non-clinical use and tested 
negative for human immunodeficiency virus (HIV), hepatitis C virus (HCV), current 
hepatitis B infection (HBsAg) and syphilis. All blood donors had signed informed 
64 
 
consent, which was provided by NHS, regarding the use of the donors’ blood for 
training and education purposes, to ensure that the samples were ethically 
approved (NHSBT, 2015). Institutional approval was obtained (ETH1617-0362), 
All samples preparation was carried out in sterile conditions in a class II safety 
cabinet. 
2.2.2 Samples preparation: 
86 samples used in this study were fresh, and 14 samples were excluded as they 
collected one day before they were received. As 2 Buffy coat samples were 
received each week, a randomly selected bag was chosen to be the responder 
cells and the second sample was selected as the stimulatory cells. 
2.2.3 Cell count: 
Trypan blue (Sigma, UK) was used to assess cell viability and carry out the cell 
count. 20 μl of cell suspension was mixed with trypan blue dye in a 1:1 dilution. 
Cell counting was performed using a Neubaur chamber. Typically, >85 % of cells 
were viable when counted in the four large squares of the chamber. Cell viability 
and cell counts were calculated using the formulas: 
Calculate cells viability = count average live cells / total number of cells x 100 
Calculate cell density (cell/ml) = average of live cells x dilution factor/ volume of 
square 
2.2.4 Preparation of responder cells (Res) and stimulatory cells: 
The Buffy coat bag was swabbed with 70 % ethanol prior to some being 
transferred to a 6 ml heparin tube, which was gently inverted 6-8 times to allow 
mixing of the sample with the anticoagulant. Lysis of the RBCs was carried out 
with lysis buffer (BD Biosciences, USA). Cell number was analysed using a cell 
count, then in a 15 ml falcon tube, the sample was diluted 1/2 or 1/5 with complete 




Figure 2. 1: Responder and stimulatory cell preparation and cell counting. 
2 Buffy coat samples were randomly selected to prepare Responder cells and Stimulatory cells, 
samples were transferred to 6 ml heparin tubes followed by RBCs lysis, the cell pellet was 
resuspended in RPMI and cells were counted to decide the dilution factor for the stimulatory and 
responder required. Created with BioRender.com 
2.2.5 Cell culture preparation: 
2.2.5.1 Culture the responder cells (Res): 
Buffy coat samples were diluted 1/2 or 1/5 with complete RPMI to achieve a cell 
count of 10x106 cells/ml. 500 µl of the responder cells sample was added to each 
well of the 24 well plate and incubated for D1, D2 and D3 at 37 oC with 5 % CO2. 
Samples were analysed on D1 and D2 for monocyte activity and on D3 for T cell 









2.2.5.2 Mixed leukocyte reaction (MLR) preparation: 
450 µl of responder cells were added to 50 µl of stimulatory cells in a 10/1 ratio 
with 500,000 cells/well in total.  500 µl of the cellular mix was placed in each well 
of the 24 well plate and incubated for D1, D2 and D3 at 37 oC with 5 % CO2. 
Samples were analysed by flow cytometry on D1 and D2 for monocytes activity 
and D3 for T cells activity (Figure 2.2). MLR without any additional cytokines was 
the optimal +ve allogeneic control. 
 
Figure 2. 2: Res and MLR preparation and incubation: 
Responder and stimulatory cells were resuspended in complete RPMI at 10x106 cells/ml. In column 
1 Res cells were seeded (500,000 cells/well) and column 4 MLR, which is mix of responder   cells 
and stimulatory cells diluted 10/1 to have 500,000 cells/well were seeded. Created with 
BioRender.com 
2.2.6 Stimulating cells culture: 
2.2.6.1 Optimising IFN-γ concentration: 
MLR culture was prepared (Section 2.2.5.2) to optimise the IFN-γ concentration. 
In MLR, three different concentrations were added (10 ng/ml, 50 ng/ml, and 100 
ng/ml) and samples were incubated and analysed by flow cytometry after D1 and 
D2 of incubation.   
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2.2.6.2 Optimising IL-4 concentration: 
MLR culture was prepared as explained earlier (Section 2.2.5.2). To optimise IL-
4 concentration in MLR, three different IL-4 concentrations were tested by adding 
10 ng/ml, 50 ng/ml, and 100 ng/ml to 3 MLR samples which were incubated and 
analysed by a flow cytometer after D1 and D2 of incubation. 
2.2.6.3 MLR stimulated with IFN-γ and IL-4: 
MLR culture was prepared as explained earlier (Section 2.2.5.2) by mixing two 
diluted Buffy coat samples in 24 well plate, cells count was around 500,000 
cells/well (Figure 2.3). The optimised 100 ng/ml IFN-γ or 100 ng/ml IL-4 were 
added to MLR during culture preparation, and the samples were incubated and 
analysed by flow cytometry after D1, D2 and D3 of incubation. 
2.2.6.4 Responder cells stimulated with IFN-γ and IL-4: 
500,000 cells/well responder cells (Res) added to 24 well plate supplemented with 
100 ng/ml of recombined IFN-γ protein or 100 ng/ml IL-4 (R&D systems, USA), on 
day of tissue culture preparation (Figure 2.3). Res IFN-γ which was used as - ve 





Figure 2. 3: Res IFN-γ/IL-4 and MLR IFN-γ /IL-4 preparation diagram: 
Responder and stimulatory cells were resuspended in complete RPMI to have 10x106 cells/ml. In 
column 1 and 2 Res were seeded (500,000 cells/well) and in column 4 and 5 500,000 cells/well of 
MLR, which is mix of responder cells and stimulatory were seeded. The additional treatment of 100 
ng/ml IFN-γ or IL-4 was added to Res in column 2 to make Res IFN-γ or Res IL-4 similarly IFN-γ 
or IL-4 added to MLR in column 5 to make MLR IFN-γ or MLR IL-4. Created with BioRender.com 
 
2.2.7 Inhibiting the stimulated cells cultures: 
2.2.7.1 Inhibition of MLR IFN-γ and MLR IL-4 with anti-SYK: 
MLR IFN-γ and MLR IL-4 cultures was prepared (Section 2.2.6.3) with the addition 
of 2 µM of PRT0603 daily on D0, D1, and D2 (Figure 2.4). The MLR IFN-γ SYK, or 
MLR IL-4 SYK       culture was incubated for three days at 37 oC with 5 % CO2. 
Analysis performed on day D1, D2 and D3 using flow cytometry. The MLR IFN-γ 
SYK or MLR IL-4 SYK results were compared to the corresponding MLR IFN-γ, or 
IL-4, Res IFN-γ or IL-4 and Res IFN-γ SYK or Res IL-4 SYK to evaluate the 
inhibitory effect of the anti-SYK treatment. 
2.2.7.2 Inhibition of Res IFN-γ and Res IL-4 with anti-SYK: 
Res IFN-γ and IL-4 cultures were prepared (Section 2.2.6.4) with the addition of 2 
µM of anti-SYK on D0, D1, and D2 to make Res IFN-γ SYK or Res IL-4 SYK. The 
culture incubated for three days at 37 oC with 5 % CO2 (Figure 2.4). Analysis was 
carried  out on D1, D2 and D3 using flow cytometry. The Res IFN-γ SYK or Res IL-
4 SYK results were compared to the corresponding Res IFN-γ or Res IL-4, MLR 
IFN-γ or MLR IL-4 and MLR IFN-γ SYK or IL-4 SYK to evaluate the inhibitory effect 




Figure 2. 4: Figure: inhibiting Res IFN-γ and MLR IFN-γ by anti-SYK diagram: 
Responder and stimulatory cells resuspend in complete RPMI to have 10x106 cells/ml. In column 
1 and 2 Res IFN-γ (500,000 cells/well) was seeded with 100 ng/ml IFN-γ. In column 4 and 5 MLR 
IFN-γ (500,000 cells/well), a mixture of responder cells and stimulatory was treated with 100 ng/ml 
IFN-γ. Cells in columns 2 and 5 were supplemented with 2 µM of PRT0603 to make Res IFN-γ SYK 
and MLR IFN-γ SYK, respectively. PRT0603 treatment was applied on D0, D1and D2. Created 
with BioRender.com 
 
2.2.8 Flow cytometer: 
The sample analysis was performed using a CyAn ADP flow cytometer (Beckman 
Coulter, USA) which has two excitation lasers: a blue laser 488 nm and a red laser 
640 nm. Minimum of 5,000 events were acquired for monocytes/T cells. The data 
were analysed by using the Summit software (version 4.3). 
2.2.9 Cell surface phenotyping: 
The procedure of cell surface phenotyping was performed in capped, round 
bottom polystyrene flow cytometer tubes (FACS tubes) after one, two and three 
days of MLR incubation. Four FACS tubes were used as set-up tubes and a 
minimum of four tubes were used as sample tubes (depending on number of MLR 
conditions). 20 µl of the selected antibodies (Table 2.3) conjugated anti-human 
CD14 APC, conjugated anti-human CD86-PE, conjugated anti-human HLA-DR 
PE, conjugated anti-human CD64-PE, conjugated anti-human CD32-PE (BD 
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Biosciences, USA), conjugated anti-human CD11b-PE (BD Biosciences, USA), 
conjugated anti-human CD36-PE (BD Biosciences, USA) conjugated anti-human 
C3R-PE and conjugated anti-human CD204-PE (BD Biosciences, USA) were 
added to identify monocytes/macrophages. 
For T cell immunophenotyping (Table 2.3), 20 µl of conjugated anti-human CD3- 
APC (BD Biosciences, USA), conjugated anti-human CD4-APC (BD Biosciences, 
USA), conjugated anti-human CD69-PE (BD Biosciences, USA), conjugated anti- 
human CD25-PE (BD Biosciences, USA), and conjugated anti-human annexin V 
FITC (BD Biosciences, USA) were used to detect the different markers. 
The experimental sample tubes for monocytes/macrophages were all treated with 
Fc blocking (Section 2.2.12) before the addition of the conjugated antibodies. The 
conjugated antibodies were mixed in the FACS tubes with 100 µl of sample 
(100,000 cells/tube) collected from the 24-well plates and incubated for 20 minutes 
in the dark at room temperature (RT). All samples were washed with 2 ml of PBS, 
vortexed and centrifuged (1500 RPM for 5 minutes at RT), and this was repeated 
twice. The supernatant was removed and finally cells were resuspended in 200 µl 
of fix buffer (BD Biosciences, USA). 
2.2.10 Controls: 
Negative control: also known as unstained control, was used to identify the 
negative population, to set the negative gate and to eliminate the autofluorescence 
cells in flow cytometry. 
Setup tube: single stain sample run before the experimental run to adjust the 
voltage of each channel, APC, PE and FITC. 
Isotype control: used to remove any background or non-specific antibody (Ab) 
binding of the expressed monocyte and macrophage cell surface antigens; the 
isotype was used in this study to match the host species, fluorophore, and Ig 
subclass for both IgM, k to match CD36 (BD Biosciences, USA), PE IgG2ak (BD 
Biosciences, USA), and HLA-DR (BD Biosciences, USA). PE IgG1, k(BD 































2.2.11 Fc blocking: 
Following the manufacture’s protocol, 100 µl (100,000 cells) was suspended in 
100 µl of staining buffer (BD Biosciences, USA) with 2.5 µl of Fc blocking buffer 
(BD Biosciences, USA), and incubated for 10 minutes at room temperature before 
immunophenotyping. 
2.2.12 Cell viability test: 
Annexin V conjugated to FITC used to evaluate cell viability, Annexin V binds to 
PS, the early marker for apoptotic cells. It was essential to check cell viability as 
this study aimed to activate monocytes and T cells. All Annexin +ve cells were 
exclude from the monocytes and T cells gated population. 
2.2.13 Cytokine quantification: 
2.2.13.1 Sample collection: 
Cytokines produced in the cell culture supernatant were collected in cryo-vials. 
200 µl was collected from each experimental condition supernatant: responder 
cells (Res), Res IFN-γ, Res IFN-γ SYK, Res IL-4, Res IL-4 SYK, MLR, MLR SYK, 
MLR IFN-γ, MLR IFN-γ SYK, MLR IL-4 and MLR IL-4 SYK after D2 of incubation. 
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All samples were stored at -20 oC until the day of analysis. 
2.2.13.2 Cytokine quantification by enzyme-linked immunosorbent assay 
(ELISA): 
All samples thawed at room temperature. Standards and all samples were diluted 
1:2 with reagent diluent (50 µl of the sample + 50 µl of reagent diluent) then added 
to the 96 well plate in duplicate. TNF-α, IFN-γ, IL-2 and IL-6 sandwich ELISA 
protocol was provided by the manufacturer (R&D system, USA). 69 well plate 
coated with capture Ab then the plate blocked with reagent diluent before adding 
the samples. After adding samples detection Ab added to 69 well incubate at RT. 
Then streptavidin-HRP added to 69 well plate avoiding direct light, followed by 
adding substrate solution and finally stop solution to stop the reaction. (Each well 
aspirated and three time washing with wash buffer between each step). 96 well 
ELISA plates were analysed using the ELISA reader (SPECTRO star Nano) from 
BMG Labtech, the reader wavelength set to 450nm, wavelength correction 570. 
2.2.14 Statistical analysis: 
Statistical analysis was performed using GraphPad Prism version 8.0 (Graph Pad 
software, CA, USA). The data in this report were analysed by parametric tests. 
The first assumption in the data analysis by parametric tests, is normality (Maxwell 
and Delaney, 2004), which was verified using the Shapiro-Wilk test. The Shapiro-
Wilk test was selected due to the low number of repeats in this study. Namely, the 
experiments were repeated 6 times or less, and the Shapiro test requires 3 or 
more values to assess the normality, also it requires that every value is unique. In 
contrast, the D'Agostino test requires 8 or more values to perform the normality 
test, thus the D'Agostino test was not used in the data analysis for this thesis. 
Importantly, the normality tests used in this study have reported that all the values 
were sampled from a population that follows a Gaussian distribution. If the data 
did not follow Gaussian distribution, Dunn’s multiple comparisons tests would be 
used. 
Quantile-Quantile plot (QQ plot) is a scatter plot generated by plotting two sets of 
quantiles. For the QQ plot the X axis is the actual values, and the Y axis is the 
predicted values. QQ plot was used as a visual normality tool to show if the data 
were sampled from a Gaussian distribution (Maxwell and Delaney, 2004). The 
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CD86 expression on monocytes/macrophages, (data collected from Res and MLR 
cultures after Day 1 (D1) of incubation) data presented on (Figure 2 .1. A) showed 
normality: The data points fall in line which gave a visual indication that the 
samples were collected from a normally distributed population. Similarly, the QQ 
plot (Figure 2.5.B) showed normality of TNF-α concentration, (data collected on 
D2 from culture supernatant for Res and MLR). The points for MLR and Res fall 
in line which gave a visual indication that the TNF-α data were normally 
distributed. The QQ plot (Figure 2 .5.C) illustrated that CD25 expression on T cells, 
(data collected on D3 of incubation from Res and MLR). Formed a straight line 
which shows that the CD25 data were collected from Gaussian distribution. 
 
Figure 2. 5: Quantile-Quantile plot (QQ plot) shows A) MFI data for CD86 expression, B) TNF-α 
concentration and C) MFI data for CD25 expression measured from MLR culture and Responder 
cells controls.  
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The data were analysed on Day 1 (D1) in graph A, on D2 of incubation in graph B, and analyses 
performed on D3 in graph C. The X-axis is the actual values, and the Y-axis is the predicted values 
(assume Gaussian distribution). The data collected from responder cell culture are present as grey 
dots and data collected from MLR as grey squares. The distribution of data points was following 
the line, which gave a visual indication that the data collected from MLR, and Responder cells were 
derived from normally distributed populations. 
The second assumption required for parametric tests is homogeneity of variance, 
and in this thesis, sphericity was selected, as the data were analysed by repeated 
measures ANOVA. The assumption of sphericity means that the sample was 
collected from a population with identical standard deviation (variance is square 
SD, if the SDs are equal, so are the variances). In other words, sphericity assume 
the differences between treatment groups are equal (Maxwell and Delaney, 2004). 
Deviations from sphericity in repeated measures ANOVA can be quantified by 
Mauchly`s test to calculate the value known as epsilon. However, Maxwell and 
Delaney reported that for small sample sizes repeated measure data sphericity, is 
usually violated (the F-statistic is positively biased and raised the risk of a Type I 
error). Thus, it is recommended to use Geisser Greenhouse correction to calculate 
epsilon by correcting the degrees of freedom for the F-distribution, to correct the 
bias that occur in the F-table (Maxwell and Delaney, 2004). When more than one 
independent categorical data was compared to one dependent variable, the data 
were processed by repeated measures one-way ANOVA. This included T cell 
activation analysis and cytokine levels comparison. However, when more than two 
independent categorical data were compared to two dependent variables, the data 
were processed by repeated measures two-way ANOVA. This included 
monocytes/macrophages phenotype analysis as the experiments were repeated 
on day 1 (D1) and day 2 (D2) of incubations with several treatments performed in 
parallel. Thus, both factors (time and treatment) were repeated measures, as the 
initial blood samples were cultured continuously throughout the experiment. The 
analysis of experiments with several cell cultures conditions, and treatment 
options included post hoc analysis test, such as Tukey or Sidak methods, where 
comparisons of multiple groups were addressed. Tukey or Sidak tests used 
compares every mean with every other mean and is used when the n number was 
identical in all the experimental groups (Kim, H 2015). When comparing means of 
two independent variables, Welch’s test was used (Ruxton D., 2006, 
Wilcox.,2012). Welch’s test was used to analyse T cells activities and cytokine 
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concentrations in the first result chapter. Welch’s test requires the data to be 
normally distributed, but do not expect the homogeneity of variance. Notably 
Welch’s test controls type I errors when the assumption of the homogeneity is 
violated and sample sizes are small comparing to student t-test (Zimmerman, D 
2010, Delacer et al., 2017). One of limitations in this study is the small sample 
size, therefore Welch’s test was used for analysis. All measured variables were 
presented as mean, and error bars represent standard deviation (SD). P values 
below 0.05 were considered significant. In this thesis, mismatched blood samples 
were used, thus fluctuation of the level of HLA and miHA mismatch resulted in 




3 Results (Part 1): 
3.1 Introduction: 
Monocytes are myeloid precursors cells, that occur in the circulation of healthy 
people       for up to 3 days. Notably, once these cells move to tissues, they 
differentiate to macrophages or dendritic cells (DCs) based on the tissue 
microenvironment (Duque & Descoteaux, 2014, Tacke & Randolph 2006, 
Sprangers et al., 2016). The differentiation from monocytes to monocyte derived 
macrophages (monocytes/macrophages) involves an increase in cellular size and 
more complex organelles, with more phagocytic capacity (Duque & Descoteaux, 
2014). Monocytes and macrophages are part of innate immune response and act 
as alarm generators to activate the immune system (Visentainer et al., 2003). 
Monocytes and macrophages cell surfaces are covered   with many receptors to 
support their function such as FcR, scavenger receptors, TLRs and complement 
receptors (Hong et al., 2020, Martinez et al., 2020). Macrophages are one of the 
professional APCs, with functions including Ag recognition, Ag internalisation, 
phagocytosis, Ag processing, loading of MHCI/ MHCII   with peptides to present 
self or non-self Ag to T cells (Chakraverty & Sykes 2007, Hong et al., 2020). 
Furthermore, following TBI and tissue injury, monocytes/macrophages activation 
results in a cytokine storm (Chakraverty & Sykes 2007). Naive donor T cells 
interact with both donor and host macrophages to recognise polymorphic 
alloantigens, that result in T cells alloactivation (Chakraverty & Sykes 2007, Blazar 
et al., 2013). In order to activate T cells three signals are required, the first signal 
involves co-stimulation, followed by Ag presentation through MHCI, MHCII and 
finally cytokines that are predominantly secreted by APCs (Blazar et al., 2013, 
Junker et al., 2020). 
This chapter addresses the early phase of monocytes/macrophages role in the 
allo-reactive T cell response using 2-way MLR. This involved optimising the two-
way MLR   by evaluating the monocytes/macrophages function, T cell activation 
and production of cytokines. The effects of the presence of allogeneic cells, using 
the MLR model, was assessed by flow cytometry. All samples were analysed after 
D1 and D2 of incubation, then compared to the control responder cell culture. This 
allowed differences in CD86, HLA-DR, CD64, CD32, CD36, CD204, C3aR and 
CD11b expression on CD14+ cells in the MLR culture to be determined using the 
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expression on CD14+ cells in the responder cells culture as the negative control in 
the absence of allogeneic cells. The expression of CD86 was measured as it is an 
essential co-stimulatory   molecule that plays a key role in T cell activation (Ke et 
al., 2016, Bajnok et al., 2017). The expression of HLA-DR was also measured to 
assess the Ag presentation capacity of the selected monocytes/macrophages 
(Zheng et al., 2004, Blazar et al., 2013, Duque & Descoteaux, 2014). Several 
studies confirmed that high expression of CD86 and HLA-DR enhanced T cell 
activation and proliferation (Zheng et al., 2004, Blazar et al., 2013, Duque & 
Descoteaux, 2014). CD64 (FCγRI) expression was selected to evaluate the 
phagocytic capacity of monocytes/macrophages and their activation state. Also, 
CD64 could be used as an activation marker for classical type of monocytes 
(Duque and Descoteaux, 2014, Boyette, 2016). CD32B (FCγRIIB) was selected 
for analysis in this study, as an inhibitory receptor that is expressed on 
monocytes/macrophages, and plays a role in the regulation of cytokine production 
and differentiation into dendritic cells (Junker et al., 2020). 
Clearance of apoptotic cells during inflammation is an important step to maintain 
tissue homeostasis, and this is mainly mediated by phagocytic cells (Madrena & 
Godson, 2003, Gorden & Pluddemann, 2018). The functionality of monocytes/ 
macrophages to clear apoptotic cells was assessed by measuring the expression 
of the scavenger receptors CD204 and CD36 (Hufford & Ravichandran, 2013). The 
complement receptor C3aR as a macrophage activation marker and CD11b was 
selected as a monocyte/macrophage adhesion molecule and maturation marker 
(Mathern & Heeger, 2015).CD11b is molecule linked with macrophages 
differentiation (Ma et al., 2019). 
T cells are the key players in the generation of alloresponse (Blazar et al., 2013, 
Markey et al., 2014, Sprangers et al., 2016, Zeiser et al., 2016). The activation of 
CD3 T cells and Th CD4 cells were analysed by measuring expression level (MFI) 
of CD25, and a proportion (%) of CD69 positive cells after three days of incubation. 
Cytokines production in cell cultures, supernatants were collected after two days 
of where, TNF-α, IFN-γ, IL-6 and IL-2 concentrations were measured using ELISA. 
After optimising MLR as an in vitro model of alloresponse, the second part of this 
chapter focused on treating MLR culture with highly specific SYK inhibitor 
(PRT0603), to determine the inhibitory effects of PRT0603 on 
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monocytes/macrophages function, T cells activation, TNF-α, IFN-γ, IL-6 and IL-2 
concentrations. 
Therefore, the aims of this chapter were: 
• Determine monocytes/macrophages viability and CD14+ expression. 
• Investigate the role of the monocyte/macrophage activation in the 
alloresponse. 
• Investigate the ability of the monocytes/macrophages to present Ag by 
measuring the level of expression of HLA-DR. 
• Investigate the development of the classical and intermediate monocyte 
phenotypes in the MLR. 
• Investigate the expression of phagocytic markers on monocytes in  the MLR 
culture. 
• Evaluate the levels of cytokines produced in the MLR culture. 
• Examine therapeutic potential of PRT0603 by targeting SYK pathway   in 
monocytes/macrophages in the alloresponse. 
• Investigate the effect of PRT0603 in MLR culture to determine if SYK   
inhibitor could reduce T cell activity. 















3.2.1 Investigating the early phase of allogeneic reaction in two-way MLR: 
CD14+ monocyte activation was analysed using triple staining for CD14-APC, 
Annexin V-FITC and CD86-PE. All samples were treated with Fc blocking and the 
results were compared to the isotype control to determine background non- 
specific antibody binding. The monocyte populations were gated (Figure 3.1.A) 
based on morphology in forward scatter and side scatter (FSC/SSC), which 
represents the distribution of cells based on size and intracellular complexity. The 
plot showed that the monocytes have a medium to large size with moderate 
granularity. The cell viability was checked by Annexin V- FITC staining after D1 
and D2 of incubation (Figure 3.1.B); the D1 results showed 85 % of the gated 
population were negative for Annexin V, thus 85 % of the gated cells were viable. 
Similar viability levels were also observed after D2 of incubation (data not shown). 
To detect the proportional of the CD14+ cells population compared to the CD14- 
cells CD14-APC stating was used for the monocyte’s phenotype determination 
(Figure 3.1.C). The staining produced a bimodal histogram with 45 % of gated 
cells (R1) expressing CD14+ on their surface. 
 
Figure 3. 1: Analysis of monocyte viability and CD14+ expression. 
Day 1 of incubation A) Monocytes population is gated on (FSC/SSC) in region R1. B) The 
histogram shows Annexin V negative (viable cells) and Annexin V positive, non-viable cells. C) 
 
A       B 
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The histogram shows CD14- and CD14+ cells (45% of cells) populations. 
 
3.2.2 Analysis of monocytes/macrophages co-stimulation capacity: 
To measure the co-stimulation capacity of the monocytes, the levels of expression 
(MFI) of CD86+ on CD14+ cells (CD14+ CD86+) were measured. The results 
(Figure 3.2.A) suggest that mixing stimulatory cells with responder cells generated 
an allogeneic response within a 2-way MLR, with enhanced CD86 expression on 
the surface of CD14+ monocytes when compared to responder cells culture. There 
was a significant increase of CD86 expression in the MLR when compared with 
the responder cells after D1 (p=0.0319) and D2 (p=0.0025) of incubation, 
respectively.  
3.2.3 Analysis of monocytes/macrophages Ag-presentation capacity: 
To determine Ag presentation potential of monocytes, HLA-DR (MHCII) was 
selected as the marker for this function. Interestingly, the data (Figure 3.2.B) 
showed significant up-regulation of the MFI values for HLA-DR on the surface of 
CD14+ in MLR culture when compared to responder cells. The significant changes 
in the HLA-DR expression levels after D1 and D2 of incubation were (p=0.0317 
and p=0.0283) respectively.  
3.2.4 Analysis of the Fc receptor expression on CD14+in the early phase of 
MLR: 
In order to determine the phagocytic function, the expression of CD64+ (FCγRI) was 
measured, as it is involved phagocytosis result in antigen presentation (Brandsma 
et al., 2018). The results (Figure 3.2.C) indicate that CD14+ monocytes express 
higher levels of CD64 in MLR on D1, however, the difference did not reach statistical 
significance. In contrast, the increase in CD64+ expression was statistically 
significant in MLR when compared to responder cells on D2 of incubation (p = 
0.0224). This suggests that up-regulation of FCγRI in the early phase of MLR (D2) 
could influence key functions, including antigen capture and phagocytic activity. 
Furthermore, the expression of CD32B+ (FcγRIIB) on CD14+ monocytes was 
measured, it is believed that monocytes/macrophages which express CD32B (Fcγ 
RII-B) are mainly involved in inhibitory response and tissue repair function 
(Brandsma et al., 2018, Junker et al., 2020). The data (Figure 3.2.D) showed non-
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significant up-regulation of CD32B on CD14+ cells in MLR compared to the 
responder cell control on D1 of incubation. However, on D2 of incubation the 
CD14+ cells lost the expression of CD32B in MLR. 
 
Figure 3. 2: Analysis of A) CD86, B) HLA-DR, C) CD64, D) CD32B expression on CD14+ monocytes 
measure by flow cytometer after one (D1) and two days (D2) of incubation. 
The X axis shows incubation days, whereas Y axis present MFI values (levels of expression) for 
each marker. The data shown represent means and the error bars are SD (n = 6). Black bar 
represents Res = Responder cells as a negative control, red bar represents MLR = Mixed leukocyte 
reaction. Statistical significance was analysed using repeated measure (RM) two-way ANOVA with 
Geisser -Greenhouse correction and Sidak multiple comparisons test, p values < 0.05 were 




3.2.5 Analysis of scavenger receptors on monocytes/macrophages in early 
phase MLR: 
The expression of CD36 and CD204 scavenger receptors were measured to 
detect the ability of CD14+ cells to capture apoptotic cells in D1 and D2 culture that 
included allogeneic cells. Both markers have dual function as they induce 
inflammation or immunotolerance (Kelley et al., 2014). The data (Figure 3.3.A) 
showed that the levels of CD36+ expression were lower in MLR compared to 
responder cells on D1 and D2 incubation. However, the differences were not 
statistically significant. 
The results for CD204 expression (Figure 3.3.B) showed that on D1 of incubation, 
there was a significant increase of expression of this marker in CD14+ in the MLR 
culture compared to responder control (p=0.017). These results suggest that 
CD14+ monocytes/macrophages in the early phase of allogeneic setting (MLR 
culture on D1) respond to the presence of allogeneic cells and up-regulate CD204, 
which could recognise and clear apoptotic cells. In contrast, on D2 of incubation, 
CD204+ expression on CD14+ monocytes were reduced in MLR and increased in 
the responder control, but the difference was not statistically significant. This may 
indicate that the dynamic of the clearance of apoptotic cells differs for allogeneic 
cells compared to the cell culture of self/responder cells. 
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3.2.6 Analysis of C3aR expression on CD14+ in the early phase of MLR: 
The complement receptor plays an essential role in immune complex binding by 
monocytes/macrophages. The results (Figure 3.3.C) showed that on D1 of 
incubation, there was a significant increase in C3aR expression on CD14+ 
monocytes in the MLR setting (p < 0.0001) when compared to the control culture 
conditions, responder cells only. Notably, C3aR expression was reduced in D2 
which is similar to the results for CD204. These data reveal that the presence of 
allogeneic cells strongly affect C3aR expression in the early phase of MLR culture. 
3.2.7 Analysis of CD11b expression on monocytes/macrophages in the early 
phase of MLR: 
The measurements of CD11b expression on CD14+ cells are important, as this 
adhesion molecule indicates differentiation between different subsets of 
macrophages. The results (Figure 3.3.D) show that CD14+ cells in the MLR culture 
express higher levels of CD11b+ on D1 and D2 of incubation when compared to 





Figure 3. 3: Analysis of A) CD36, B) CD204, C) C3aR and D) CD11b expression on CD14+ 
monocytes measured by flow cytometry after one (D1) and two days (D2) of incubation. 
The X axis shows incubation days, whereas Y axis presents MFI value (level of expression) for 
each marker. The data shown represent means and the error bars are SD (n = 6). Black bar 
represents Res = Responder cells as a negative control, red bar represents MLR = Mixed leukocyte 
reaction. Statistical significance of data was analysed using repeated measure (RM) two-way 
ANOVA with Geisser -Greenhouse correction and Sidak multiple comparisons test, p values < 0.05 
were consider significant *= p < 0.05, ****= p < 0.0001.  
3.2.8 Analysis of T cell activation in the allogeneic setting: 
T cell activity was checked on D3 by assessing the activation state of CD3+ and CD4+ T 
cells and the results were compared to the T cell activity observed in responder cells 
culture (negative control for allogenic reaction). The proportion of CD69 positive cells (%) 
and the MFI for CD25 were selected as markers to detect T cells activation in the MLR.   
The data for CD25 (Figure 3.4.A), showed that there was a significant increase in   the 
CD3+CD25+ MFI in MLR when compared to the responder cells (p=0.056). For the 
analysis of CD69 positive cells (Figure 3.4.B), the CD3+ cells showed significantly 
elevated CD69 (%) in the MLR culture compared to responder cells culture (p=0.0029). 
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The investigation of the CD4+ T helper cell activity (Figure 3.4.C) showed CD4+CD25+ 
MFI significantly increased in MLR when compared to the responder cells (p=0.0113). 
The results for CD4+ helper T cells followed the same trend for CD69 expression 
(Figure 3.4.D) and showed significantly higher proportional of CD4+CD69+ (%) in MLR 
than in responder cells (p=0.0060).  
 
Figure 3. 4: Analysis of T cells activation measured by flow cytometry after three days of incubation. 
A) MFI values for CD3+CD25+ T cells where Y axis shows MFI values for CD25 expression, B) 
Percent of CD3+CD69+ T cells where Y axis shows proportion (%) of CD69-positive T cells. C) MFI 
values for CD4+CD25+ T helper cells, and D) percent of CD4+CD69+ T helper cells, where the 
Black bar represents Res = Responder cells as a negative control, red bar represents MLR = Mixed 
leukocyte reaction culture (n=6). Statistical significance of data was analysed using Welch’s tests, 
p values below 0.05 were considered significant, * = p < 0.05, ** = p < 0.01. 
3.2.9 Measurement of cytokines in allogeneic media: 
To detect inflammatory response in the MLR, the level of TNF-α, IFN-γ, IL-6 and 
IL-2 cytokines were measured sample supernatant collected on D2 of incubation 
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from MLR compared to Res, measured by ELISA. The ELISA results for TNF-α 
(Figure 3.5.A) showed that the concentration of this   cytokine on D2 of incubation 
in the MLR culture were significantly higher than responder cells supernatant 
(p=0.0021). Furthermore, the IFN-γ data (Figure 3.5.B) revealed that the MLR 
culture generated significantly higher levels of IFN-γ compared to responder cells 
(p=0.0026). The IL-6 data (Figure 3.5.C) showed that in the responder cell 
supernatant the concentration of IL6 was below the detection limit, whereas the 
concentration in the MLR culture in D2 was significantly higher (p=0.0020). The 
same trend could be seen for IL-2 (Figure 3.5.D) as the concentration of IL-2 was 
below the detection limit in the responder cell supernatant and was significantly 
higher in the MLR cell culture (p=0.0023). These data have revealed that the MLR 
culture resulted in higher levels of production of inflammatory cytokines than the 

















Figure 3. 5: Measuring inflammatory cytokines in MLR cultures after two days of incubation. 
A) TNF-α, B) IFN-γ, C) IL-6 and D) IL-2. X axis shows comparison of two conditions: Res= 
responder cells culture, MLR = Mixed leukocyte reaction culture. Y axis shows the cytokine 
concentrations in pg/ml. Scatter Dot plot show five repeats (n = 5 except TNF-α n=7). Statistical 
significance of data was analysed using Welch’s test, p values below 0.05 were considered 










3.2.10 Effects of the inhibition of the SYK pathway in monocytes/ 
macrophages in MLR culture: 
MLR culture versus MLR treated with 2 μM SYK inhibitor (MLR SYK) were 
analysed for CD86, CD64 and HLA-DR expression on CD14+ monocytes. From 
the previous section, the data indicates that alloresponse in MLR shows CD14+ 
monocytes/macrophages up-regulation of co-stimulation (CD86), Ag presentation 
(HLA-DR level) and FcγRI (CD64) expression. This section focused on the 
inhibition of monocyte-mediated co-stimulation and Ag presentation in the 
alloresponse (MLR culture) setting. 
The data (Figure 3.6.A) showed that CD14+ monocytes/macrophages down 
regulated CD86 in MLR SYK compared to MLR however, the result did not reach 
statistical significance on D1 or D2 of incubation. The only significant differences 
observed were between MLR and Res (responder cell culture) (p=0.028) and Res 
SYK (p=0.032), which supports the idea that the difference in CD86 expression is 
due to the allogeneic response. 
Significant reductions of HLA-DR expression (Figure 3.6.B) on CD14+ were 
observed in MLR SYK (p = 0.034) compared to MLR on D1 of incubation. Whereas 
the difference did not reach statistical significance on D2. MLR showed 
significantly higher HLA-DR levels compared to Res (p=0.0028) and Res SYK (p = 
0.0004) on D1, Res (p=0.0029) and Res SYK (p=0.0012) on D2. Importantly, the 
data revealed that treating MLR with SYK inhibitor significantly down regulated 
HLA-DR expression on CD14+ monocytes/macrophages in allogeneic culture with 
no effect on responder cells. 
The data (Figure 3.6.C) demonstrated significant reduction of CD64 expression in 
MLR SYK compared to MLR on D1 (p=0.0044) and on D2 (p=0.035). Again, MLR 
showed significantly higher CD64 expression compared to Res (p = 0.0012) and 
Res SYK (p=0.0006) on D1, Res (p < 0.0001) and Res SYK (p < 0.0001) on   D2. 
Therefore, treating MLR with SYK inhibitor down regulated monocyte/macrophage 
Ag capture, possibly by targeting the FcγRI (CD64) signalling pathway. The SYK 
treatment modulating monocytes/macrophages function in allogeneic culture. 
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Figure 3. 6: Analysis of A) CD86, B) HLA-DR and C) CD64 expression on CD14+ in MLR culture 
with/without SYK inhibitor. 
Monocytes on D1 and D2 of incubation, co-stimulation, Ag presentation functions and FcγRI 
expression. The X axis shows the four experimental conditions, black bar represent Res = response 
cells, dark grey bar with dot pattern represents responder cell treated with 2 μM SYK inhibitor, 
orange bar represents  MLR = Mixed leukocyte culture, and light orange with dots pattern bar 
represents MLR SYK = MLR treated with 2 μM of SYK inhibitor. The Y axis shows MFI values in 
arbitrary units. Data shown are mean and the error bars are SD (n = 4). Statistical significance of 
data was analysed using repeated measure (RM) two-way ANOVA with Geisser-Greenhouse 
correction and Tukey’s multiple comparisons test, p values < 0.05 were consider significant *=p < 
0.05, ** = p < 0.01 and ***=p < 0.001.  
3.2.11 Analysis of the effects of the SYK inhibitor on CD3+ and CD4+ T cells: 
The analysis of T cells was performed after three days of incubation. Based on 
the monocytes/macrophages data, it was postulated that in the MLR setting, 
CD14+ cell activity was down regulated by 2 μM SYK inhibitor on D1 and D2 of 
incubation (Section 3.2.10). Consequently, it would be expected that 
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monocytes/macrophages were not able to co-stimulate and present antigens to T 
cells on D1 and D2 of MLR culture. Thus, MLR cultures were incubated for 3 days 
to analyse changes in T cells activity and the results were compared to those 
observed in MLR treated with 2 μM SYK inhibitor daily. The double gated 
CD3+CD25+ T cells were measured, and the median MFI is presented. Also, the 
double gated CD3+CD69+ T cells were measured and presented as the 
number/proportion of positive cells. 
The data (Figure 3.7.A) showed that the MLR culture treated with 2 μM SYK 
inhibitor significantly down-regulated CD25 (IL-2 receptor) expression on CD3+ T 
cells (p=0.0403) compared to MLR. Significant down regulation was reported due 
to allogeneic culture in MLR compared to Res (p=0.033), Res SYK (p=0.032). Also, 
the proportion (%) of CD3+CD69+ activated T cells (Figure 3.7.B) showed 
significant down regulation in the MLR treated with 2 μM SYK inhibitor when 
compared to the MLR (p=0.031). Significant reductions in T cells activities were 
observed again due to allogeneic culture in MLR compared to Res (p=0.012), Res 
SYK (p=0.011). 
The results for the CD25 expression on CD4+ helper T cells (Figure 3.7.C) showed 
that the MLR culture treated with 2 μM SYK inhibitor down-regulated CD25 
expression, but the decrease did not reach statistical significance. The only 
significance difference was the reduction between MLR and Res (p=0.045). The 
proportion (%) of positive CD4+CD69+ T cells (Figure 3.7.D) were slightly lower 
(but not statistically significant) in the MLR treated with SYK inhibitor when 
compared to MLR. Thus, these results confirmed that treating MLR with 2 μM 
PRT0603 SYK inhibitor has reduced CD3+ T cells activity. 
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Figure 3. 7: T cells inhibition in the presence of SYK inhibitor on D3 of incubation. 
A) MFI values for CD3+CD25+ T cells where Y axis shows MFI values for CD25 expression, B) 
Percent of CD3+CD69+ T cells where Y axis shows proportion (%) of CD69-positive T cells. C) MFI 
for CD4+CD25+ and D) Percent (%) CD4+CD69+ cells, black bar represents Res= responder cell 
culture, grey bar with dots pattern represents = Res SYK= responder cells treated with SYK, dark 
orange bar represents MLR = Mixed leukocyte reaction culture and light orange with dots pattern 
bar represents MLR treated with 2 μM of SYK inhibitor. Data shown are mean values and the error 
bars are SD (n = 3). Statistical significance of data was analysed using repeated measure (RM) 
two- way ANOVA with Geisser-Greenhouse correction and Tukey’s multiple comparisons test, p 
values < 0.05 were consider significant * =p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
3.2.12 Analysis the inhibitory effect of PRT0603 SYK on the production of 
inflammatory cytokines: 
Cell culture supernatants were collected from MLR and MLR treated with SYK 
inhibitor (MLR SYK) after two days of incubation and TNF-α, IFN-γ, IL-6 and IL-2 
concentrations were measured by ELISA to determine the inhibitory effects of 
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PRT0603 SYK inhibitor on the production of the inflammatory cytokines. 
The data (Error! Reference source not found..A) showed that the TNF-α 
concentration was significantly reduced in the MLR treated with SYK inhibitor 
compared to the MLR (p = 0.011). As previously observed, significant differences 
were evident in the allogeneic culture (MLR) compared to responder cells (Res) 
(p=0.031) and Res SYK (p= 0.031). The data for IFN-γ concentration (Error! 
Reference source not found..B) showed a significant drop of IFN-γ levels in the 
MLR treated with SYK compared to the MLR (p=0.008). Also, allogeneic culture 
(MLR) showed significant differences compared to Res (p= 0.007) and Res SYK 
(p=0.007). For IL-6 (Error! Reference source not found..C) there was a 
significant reduction in concentration in the MLR SYK compared to MLR only 
(p=0.047).  Furthermore, modest but significant differences were detected in MLR 
compared to Res (p = 0.048) and Res SYK (p=0.048).  
The data (Error! Reference source not found..D) for IL-2, showed significantly 
lower concentrations in the MLR treated with SYK inhibitor in comparison to the 
MLR (p=0.082). Also, significant differences in MLR culture compared to Res 
(p=0.002) and Res SYK (p=0.002) were confirmed.  
Overall, these results highlight that PRT0603 SYK inhibitor successfully reduced 
the inflammatory cytokine concentrations in the allogeneic cell cultures. Also, the 




Figure 3. 8: Concentrations of inflammatory cytokines in MLR cultures after two days of incubation 
in the presence of SYK inhibitor. 
A) TNF-α, B) IFN-γ, C) IL-6 and D) IL-2. X axis shows comparison of two conditions, Mixed 
leukocyte reaction (MLR) and MLR treated with 2 μM of SYK inhibitor (MLR SYK). Y axis shows 
the cytokine concentrations in pg/ml. Scatter dot plots show mean values of 3 independent repeats 
(n = 3). Statistical significance of data was analysed using repeated measure (RM) two- way 
ANOVA with Geisser -Greenhouse correction and Tukey’s multiple comparisons test, p values < 







3.3 Discussion (Part 1): 
Monocytes make up 5-10 % of total WBCs count but they play an important role 
in innate and adaptive immunity (Tacke & Randolph, 2006, Sprangers et al., 2016). 
Monocytes have a short half-life in human circulation, after 3 days monocytes based 
in the microenvironment differentiate to macrophages or DC (Tacke & Randolph, 
2006). The aim of this study was to investigate the role of 
monocytes/macrophages in whole blood allogeneic culture, in contrast to most 
other studies that isolated monocytes to study their function. In this study whole 
blood, MLR was used to evaluate monocytes/macrophage function in the early 
allogeneic reaction. The MLR culture used in this study allows activation, 
stimulation, and proliferation of both populations stimulatory cells and responder 
cells. The benefit of using whole blood was to preserve the cellular interactions 
including neutrophils, monocytes, and T cells. Using MHC mismatched in 
vitro culture could not represent the exact setting in matched GVHD patients. 
However, the data in this report showed that to activate monocytes in vitro strong 
activation stimulus is required, similar to that present in the complete MHC 
mismatched blood samples. It has been reported that during the innate immune 
response neutrophils first arrive at the affected area, recognise the pathogen via 
PAMPS/DAMPS, neutrophils then release their granular content and generate 
reactive oxygen species (ROS) (Zeise R, 2019). This enhances the recruitments 
of monocytes/macrophages to the site of infection, where later 
monocytes/macrophages will phagocytose the pathogen, the apoptotic neutrophil, 
and present antigens to T cells (Zeise, R 2019). Therefore, monocytes activation 
and macrophages polarisation are controlled by neutrophils degranulation. 
Interestingly, it has been reported that Lactoferrin, which is a neutrophil granule 
product, controls formation of M1 macrophages with a consequent 
proinflammatory response. Whereas IL-13 that is released by neutrophils 
polarises macrophages to M2, which results in anti-inflammatory response (Kumar 
et al., 2011). Monocytes/macrophages responses that could be either pro-
inflammatory or anti-inflammatory are involved in the early phase of GVHD (Zeise 
R, 2019). Similarly, platelets-monocytes interaction mediates the proinflammatory 
response and cytokine release by monocytes (Passacquale et al., 2011). 
Therefore, this study has optimised the histo-incompatible model to activate host 
(stimulatory) and donor (responder) monocytes, maintaining the cellular 
95 
 
interactions, which is important for a strong immune activation. Then the effects of 
allogeneic cells on the monocytes/macrophages function, T cell activation and 
cytokine production in the MLR culture were evaluated. The second part of this 
study evaluates the efficacy of the SYK inhibitor PRT0603 to control 
monocytes/macrophages. Indeed, if the inhibitor has a potential to reduce the 
early allogeneic response in this MHC mismatched model with a strong activation 
stimulus, this could highlight their potential to control immune response in a 
challenging GVHD setting. Thus, whole blood, MHC mismatched MLR culture 
could be used for future studies, as a model that simulates early immune response 
in GVHD, and this could complement rather than replace the current mouse 
models.  
The alloresponse was investigated using following experimental conditions: MLR 
(mixed leukocyte reaction) and Res (-ve control, responder cells only). For the flow 
cytometry immunophenotyping all samples were treated with Fc blocking and the 
results were compared to the isotype control to eliminate any background of 
nonspecific antibody binding. As 80 to 85 % of monocytes in the gated population 
were Annexin V -ve this confirmed cell viability on D1 and D2 of incubation, 
respectively.  
Monocytes/macrophages function was assessed by evaluating the expression 
level of surface markers. CD86 and HLA-DR were measured, reflecting co-
stimulation capacity and Ag presentation, respectively. Based on published 
studies, high expression of CD86 and HLA-DR are essential to prime T cells, 
enhance T cell activation and proliferation (Zheng et al., 2004, Blazar et al., 2013, 
Markey et al., 2014, Duque & Descoteaux, 2014). As FcRs links the innate and 
adaptive immune response (Brandsma et al., 2018, Junker et al., 2020), the levels 
of CD64 (FcγRI) and CD32B (FcγRIIB) were measured alongside CD36, CD204, 
C3aR and CD11b to evaluate the capability of the monocytes, to capture 
phagocytes and opsonise immune complexes (Gorden & Pluddemann, 2018, 
Mathern & Heeger, 2015).  
The results showed a significant increase of monocytes CD86, HLA-DR, CD64, 
CD204 and C3aR expression in MLR compared to the responder cells (raw data 
for CD86 are presented in the appendix Figure S.1.3). Thus, the data in this study 
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could show that monocytes in MHC mismatched MLR are strongly activated, 
which supports the concept that the allogeneic cell culture up-regulates 
phagocytosis, co-stimulatory and Ag presentation capacity of 
monocytes/macrophages. This agrees with previous reports that during early 
aGVHD, host and donor APCs up-regulate co-stimulation and Ag presentation 
markers (Chakraverty & Sykes, 2007, Markey et al., 2014). This observation is 
discussed in detail in this chapter. 
CD64 is an FcγRI receptor expressed on monocytes/macrophages and other 
cells, CD64 has a well-established role in inflammation and autoimmune diseases 
(Brandsma et al., 2018). These data could link CD64 up-regulation on 
monocytes/macrophages with increased HLA-DR expression. It is generally 
accepted that CD64 is involved in inflammation, as ligation of CD64 to the immune 
complex or opsonised Ag activates the downstream signalling of CD64. This 
includes SYK phosphorylation, Ag internalisation, Ag processing and presentation 
via MHCII (Junker et al., 2020, Brandsma et al., 2018). Intracellular signalling 
triggered by FcγR results in degranulation and secretion of pro-inflammatory 
cytokines by macrophages (Brandsma et al., 2018). Furthermore, the research 
study reported by Tacke and Randolph (2006) proposed that classical monocytes 
express CD14+ CD16- CCR2+ CD64+ markers (Tacke & Randolph, 2006). Thus, 
the findings in this work, with CD14+ CD64+ phenotype in MLR culture, broadly 
could supports the concept that early alloresponse promoted development of a 
classical monocyte subtype.  
CD32B is a low affinity Fcγ RIIB, that binds to the IgG complex, and is expressed 
in human circulating monocytes (Hepburn et al., 2004, Brandsma et al., 2018). 
More importantly, CD32B expression is involved in inhibitory immune response 
(Hepburn et al., 2004, Brandsma et al., 2018). In MLR culture, the changes in 
monocyte CD32B expression were modest and cannot be associated with either 
pro-inflammatory or inhibitory effects. The intermediate monocytes phenotype 
was described as CD14+CD16+CD32+HLA-DR++ (Tacke & Randolph 2006, Lee et 
al., 2017). In this study, the characterisation of monocyte subtypes was 
incomplete, due to limited 3 colours analyses by flow cytometry. This needs to be 
considered in future work to allow the analysis of the subtypes of monocytes. 
However, the current observation of up-regulation of CD14+CD64+ and modest 
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down regulation of CD14+CD32B+ on D2 suggests that monocytes/macrophages 
in MLR culture are more likely to develop into the classical subtype. 
In MLR culture, scavenger receptors CD36 and CD204 were assessed to evaluate 
the functional ability of monocytes/macrophages to capture apoptotic cells. 
Clearance of apoptotic cells by phagocytes is essential to control inflammatory 
response (Hufford & Ravichandran, 2013). Notably, these two markers, CD36 and 
CD204, have dual function, as they could induce both inflammation and immune 
tolerance (Kelley et al., 2014). Therefore, the data reported here indicate that 
although allogeneic cells trigger inflammatory response in MLR culture, this was 
not accompanied by changes in CD36 expression on CD14+ 
monocytes/macrophages. Remarkably, a previous study showed that the 
monocytes/macrophages that did not regulate CD36 could still prime alloreactive 
T cells in GVHD patients (Perry et al., 2018). 
The second scavenger receptor selected in this study is CD204, that can increase 
macrophages recruitment to the site of injuries (Kelley et al., 2014). The ligation 
of CD204 results in phagocytosis, inflammatory response, and secretion of 
cytokines, including TNF-α (Pombinho et al., 2018). Furthermore, CD204 is 
involved in the uptake of apoptotic cells (Maderna & Godson, 2003, Kelley et al., 
2014), which could be particularly relevant for MLR culture and GVHD. A study by 
Knouma et al. (2018) demonstrated that high levels of CD204 expression on 
monocytes/macrophages was linked to tissue fibrosis in GVHD patients (Knouma 
et al., 2018). From the data it could be concluded that clearance of apoptotic cells 
in allogeneic cell culture on D1 of incubation maybe controlled by CD204 and not 
by using the CD36 receptor. These data question the role of the different monocyte 
subtypes in the GVHD pathology, as increased expression of CD204 on non-
classical monocytes was reported to induce cGVHD (Kanuma et al., 2018). 
However, CD14+ monocytes in this study showed characteristics of the classical 
monocyte subtype, and yet reveal up-regulation of CD204 expression in the early 
phase of allogeneic reaction.  
This finding highlights the role of allogeneic cells in inducing C3aR expression in 
monocytes, which is followed by up-regulation of co-stimulation and antigen 
presenting capacity as both markers were up-regulated on D1 of MLR culture. It 
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has been previously reported that C3aR is up-regulated on APCs in response to 
complement pathway stimulation (Raedler & Heeger 2011). The ligation of C3a to 
C3aR on APCs results in intracellular signalling that involves phosphorylation of 
AKT (protein kinase B), which in turn controls expression of co-stimulatory 
molecules (Raedler & Heeger 2011). Furthermore, C3aR ligation mediates IFN-γ 
and IL-2 secretion by T cells (Nguyen et al., 2018). Thus, ligation of C3aR appears 
to be involved in the pathology of GVHD (Nguyen et al., 2015, Nguyen et al., 
2018). Although, a previous study showed that ligation of C3aR on APCs controls 
CD86 and MHCII expression on DCs and this results in T cells activation in GVHD 
(Nguyen et al., 2018), this could be the first report of such effects in monocytes, 
and in the early phase of alloresponse.  
Surface expression of CD11b on CD14+ monocytes was measured in this study, 
as the CD11b is crucial for cell adhesion and phagocytosis of pathogens (Lukácsi 
et al., 2017, Gavin et al., 2019). CD11b is also considered as a macrophage 
differentiation marker with the low levels of expression on pro-inflammatory M1, 
whereas M2 anti-inflammatory macrophages express CD11bhigh (Ma et al., 2019). 
The data in this report showed that CD11b was not-significantly up-regulated in 
MLR on D1 and D2 of incubation when compared to responder cells.  Therefore, 
it appears that CD11b expression is not involved in inflammation induced by 
allogeneic cells. To confirm this conclusion, larger number of repeats will be done 
in future work.  
Although the monocytes subtypes were not fully characterised in this study, the 
phenotype observed in the early phase of allogeneic cell culture, 
CD14+CD86++HLA-DR++CD64++, broadly could aligns with a classical subtype. 
However, the monocyte phenotype in MLR culture appears to be complex and 
dynamic with rapid changes in marker expression on D1 and D2 of incubation. 
Furthermore, the monocytes tend to differentiate into macrophages, and the line 
of transition between the different cell types is not clear. Therefore, it could be 
argued that monocyte subtypes are artificial, and that observed cell phenotype 
represents a transitional stage of monocyte development rather than a stable, 
defined cell type. 
The activation levels of CD3+ and CD4+ T cells were analysed by measuring the 
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intensity (MFI) for CD25 expression, and the proportion (%) of CD69+ cells on D3 
of incubation. It is generally accepted that T cells are the key mediators of 
alloresponse (Blazar et al., 2013, Markey et al., 2014, Sprangers et al., 2016, 
Zeiser et al., 2016). Notably, in this study the levels of CD25 expression and the 
proportion of CD69 positive cells were significantly up regulated in MLR culture on 
D3+ and CD4+ T helper cells compared to responder cells control. These findings 
indicate that activation of monocytes/macrophages precedes a strong, 
measurable T cell alloresponse, including both total CD3+ T cells and helper CD4+ 
T cells on D3 of MLR culture. This could be supported by the monocyte data 
described above. Based on the generally accepted concepts and the data from 
this study, the alloresponse is likely to be initially triggered by the recognition of 
allogeneic cells by TCR, as TCR is the only molecule that can detect polymorphic 
alloantigens (Ferrat et al., 1991, Blazar et al., 2013). However, this early event 
appears difficult to detect. Indeed, this study has shown there is a lack of 
measurable T cell activation on D1 and D2 in the MLR culture (data not shown). 
Nevertheless, an activation of monocytes is clearly detectable at this early stage 
of alloresponse, suggesting that a subtle signal generated by T cells and possibly 
combined with the presence of cell injury and inflammation results in a strong 
activation of APCs/monocytes. Subsequently, co-stimulatory signals and 
cytokines generated by CD14+ monocytes/macrophages could play a critical role 
in enabling a full T cell activation that is detected on D3 of MLR culture.  
To detect inflammatory response in the MLR, the level of TNF-α, IFN-γ, IL-6 and 
IL-2 cytokines were measured. Activated monocytes/macrophages release 
cytokines to cause an inflammatory response (Deeg, H 2001, Duque & 
Descoteaux, 2014). Indeed, it is thought that cytokines storm originates from the 
innate immune response that is activated in aGVHD (Blazar et al., 2013, Markey 
et al., 2014, Duque & Descoteaux, 2014). The samples from MLR culture and the 
control responder cells supernatants were collected on D1, D2 and D3 of 
incubation. The cytokine concentrations with consistent values above detection 
limits were observed on D2, which were analysed by ELISA and presented in this 
report. The results showed that the concentrations of TNF-α and IFN-γ in the MLR 
culture were significantly higher than the responder cells culture. This could 
indicate the presence of the inflammatory conditions in the early phase of 
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alloresponse/MLR culture. The origin of these cytokines (the producing cells) has 
not been determined, due to lack of intracellular staining, which is considered in 
future work. Based on the current data, it could be assumed that activated 
monocytes/macrophages make a substantial contribution to the cytokine 
generation due to their early activation, observed on D1 and D2 of incubation. In 
contrast, T cells were not measurably activated on D1 and D2 and are unlikely to 
play a major role in cytokine production determined on D2, with a possible 
exception for IL-2. Indeed, it has been reported that both TNFα and IFN-γ were 
secreted in the early stage of aGVHD by activated APCs (Blazar et al., 2013, 
Markey et al., 2014, Duque & Descoteaux, 2014, Sprangers et al., 2016). Notably, 
the high concentrations of TNF-α demonstrated in this study could explain the up-
regulation of the CD86, HLA-DR and CD64 on the surface of 
monocytes/macrophages observed in the early MLR culture. This is supported by 
the reported role of TNF-α in the control of CD86 expression and subsequent 
priming of T cells in aGVHD (Markey et al., 2013, Sprangers et al., 2016, Zhang 
et al., 2017). As discussed above, activated monocytes in the early MLR culture 
show some features of the classical subtype. The classical monocytes are 
regarded as the main source of TNF-α cytokines. This is based on the data 
reported by several studies, where activation of classical monocytes results in the 
secretion of TNF-α (Deeg, H 2001, Sprangers et al. 2016, Boyette et al., 2016).  
It is thought that IFN-γ promotes monocyte differentiation into macrophages, and 
polarisation towards the M1 phenotype with high Ag presentation capacity 
(Delneste et al., 2002, Lee et al., 2017, Murray, 2017, Obrien et al., 2019). 
Furthermore, several studies have shown that exposing naïve monocytes to IFN-
γ encourages development of classical CD14+ monocytes, which can then secrete 
pro-inflammatory cytokines, including TNF-α, IL1-β, IL-6, IL-12, and IL-23, and this 
promotes T cell proliferation (Duque & Descoteaux, 2014, Sprangers et al., 2016, 
Lee et al., 2017). Whereas stimulating monocytes with TNF-α and IFN-γ increases 
CD64 expression and allows binding/phagocytosis of the immune complex 
(Brandsma et al., 2018). A study has suggested that IFN-γ production plays a vital 
role during the generation of GVHD, and that IFN-γ is mainly produced by T cells 
and NK cells to control the recruitment of classical monocytes and their 
differentiation into macrophages (Sprangers et al., 2016). This supports the 
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findings in this study, where CD14+ monocytes in the MLR culture, and due to the 
secretion of IFN-γ, showed some of the features of the classical phenotype. 
Furthermore, it has been proposed that once classical monocytes are stimulated 
with IFN-γ, they become highly phagocytic M1 macrophages (Galan et al., 2015).  
Importantly, IL-6 and IL-2 concentrations were below the detection limit in the 
responder cells on D2 of incubation, whereas, in the MLR culture, IL-6 and IL-2 
had significantly higher concentrations. It has been reported that activated 
classical monocytes are the main producers of IL-6 (Boyette et al., 2016). The 
secretion of IL-6 in MLR culture could be linked with the up-regulation of CD64 
expression on CD14+ monocytes, as a previous study in rheumatoid arthritis 
showed that IL-6 cytokine controls CD64 expression in classical and intermediate 
monocytes (Luo et al. 2018).  
IL-2 is Th1 cytokine that controls T cells activation and proliferation in immune 
response in general and GVHD in particular (Kumar et al., 2017, Nassereddine et 
al., 2017). The data in this study showed high concentrations of IL-2 in the early 
phase of MLR culture, thus clearly confirming the role of this cytokine in 
alloresponse. Indeed, the IL-2 cytokine could control CD25 expression and 
increase the proportion of CD69+ T cells in MLR culture, as observed in this study 
on D3 of incubation. This interpretation of the data is supported by a recent study 
that showed that IL-2 controls early and late activation markers on T cells (Bajnok 
et al., 2017). Furthermore, the role of IL-2 in controlling the alloresponse could 
include its effects on TNF-α secretion by macrophages, which may result in the 
skin and tissue damage in GVHD (Kumar et al., 2017, Nassereddine et al., 2017). 
In summary, allogeneic reaction in the early MLR culture resulted in the increased 
co-stimulation capacity (CD86 expression), enhanced Ag presentation potential 
(HLA-DR expression), stimulation of the complement pathway (C3aR expression) 
and a strong phagocytosis function (CD64 and CD204 expression) by 
monocytes/macrophages. This striking activation of monocytes/macrophages 
appears to be induced by T cell alloreactivity and cytokine production. These data 
suggest that the use of whole blood MLR culture as an in vitro model for GVHD 
provides valuable data on the role of monocytes/macrophages in the early phase 
of allogeneic culture. The second part of this chapter focused on controlling 
102 
 
monocytes/macrophages function, T cells activation by treating MLR culture with 
a specific SYK inhibitor. As controlling GVHD by immunotherapy has been 
extensively studied for T cell activation, whereas there is limited data available 
about controlling monocytes/macrophages co-stimulation and Ag presentation, as 
well as cytokine production (Leonhardt et al., 2012). Evaluation obtained by 
observing the expression of CD64 (FcγRI), CD86 and HLA-DR on 
monocytes/macrophages. It has been reported that SYK activation is involved in 
monocytes/macrophages inflammatory response such as phagocytosis, Ag 
presentation, co-stimulation, and cytokines secretion. Thus, SYK inhibition is 
expected to suppress monocytes/macrophages inflammatory response (Yi et al., 
2014, Coffey et al., 2017). PRT0603 is a highly selective SYK inhibitor that has 
been shown in a murine model to block FcγRII in platelets to prevent heparin 
induced thrombocytopenia and thrombosis (Reilly et al., 2011). Interestingly, 
PRT0603 has selectively inhibited SYK signalling in B cells which resulted in 
deactivation of B cells, in a CLL model (Hoellenriegel et al., 2012). PRT0603 is a 
parent compound for PRT0626, which is highly selective for SYK molecules and 
showed complete suppression of BCR and FcRs signalling that resulted in 
reduced inflammation in rheumatoid arthritis patients (Coffey et al., 2013). To 
determine the potential effects of SYK inhibitor PRT0603 in controlling 
monocytes/macrophages during the allogeneic reaction, samples from MLR were 
compared to MLR with SYK treatment. Furthermore, to detect the potential toxicity 
of SYK, the control responder cells were treated with 2 µM of PRT0603 and 
compared to untreated samples of responder cells culture. Optimising SYK 
concentration extensively studied in this work, the optimal concentration selected 
showed an inhibitory effect on monocytes function. That was when the MLR 
culture treated daily with 2 µM. The results indicated that treatment of the MLR 
cultures with 2 µM SYK inhibitor significantly lowered CD64 and HLA-DR 
expression on monocytes and reduced the cytokine concentration, followed by 
decrease of T cells activities. Interestingly, the data showed that the SYK pathway 
deactivated in MLR SYK as CD64 expression diminished in both days of 
incubation, because PRT0603 is a highly selective SYK inhibitor that could target 
FCγRI signalling. It has been reported that CD64 controlled inflammation by up-
regulation of MHCII expression to enhance Ag presentation (Brandsma et al., 
2018). Interestingly, the results showed SYK inhibitor mediated down regulation 
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of HLA-DR observed on D1. This may suggest that due to suppression of SYK, 
downstream signalling CD14+ in monocytes/macrophages the Ag presentation 
capacity reduced. However, no significant down regulation of CD86 was observed 
(raw data presented in appendix Figure S.1.3), thus the SYK inhibitor did not 
control co-stimulation on CD14+ monocytes. To confirm this observation additional 
experiments are needed to determine the interaction of SYK and other signalling 
pathways in regulation of the CD86 expression on monocytes.  Furthermore, no 
changes in CD86, HLADR and CD64 expression were observed between Res and 
Res SYK. This indicates the inhibitory effect of SYK worked only in allogeneic 
culture. 
As stated earlier, three signals are important to activate T cells (Ka et al., 2016, 
Junker et al., 2020). Targeting SYK by the SYK inhibitor in MLR culture impaired 
Ag processing that could reduce Ag presentation capacity by 
monocytes/macrophages. This could affect at least one of the signals necessary 
for the full activation of T cells in alloresponse. 
Notably, the data showed on D3 in the presence of PRT0603 there was a 
significant reduction of CD25+ expression levels and percent of CD69+ positive 
cells among CD3+ T cells in MLR SYK compared to the MLR (raw data provided 
in the appendix Figure S.1.2). These results fit with studies that have shown that 
SYK phosphorylation plays a role in T cell allo-activation in GVHD (Leonhardt et 
al., 2014). This has confirmed the potential of the SYK inhibitor to reduce activation 
of CD3+ T cells, and suggests the possible mechanism: namely, targeting of the 
monocytes FcγRI, as the main pathway affected by SYK inhibition in the MLR 
culture. This could result in down regulation of the key monocyte/macrophage 
functions ultimately leading to a reduced T cell alloresponse. This highlights that 
early Ag presentation provided by monocytes/macrophages was reduced, as the 
most likely indirect effect on T cells alloreactivity in D3 of incubation. This is 
supported by the recent study that showed that targeting FcγR resulted in inhibited 
Ag presentation, which could affect T cells activation (Junker et al., 2020). As 
CD3+ T cells represent both T cell helper CD4+ cells and cytotoxic CD8+ cells, the 
effects of SYK inhibitor are broad and affect the total T cell population. However, 
the effects of the SYK inhibitor on CD4+ T helper cells were modest and did not 
reach statistical significance. 
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Importantly MLR treated with the SYK inhibitor had significantly reduced 
concentrations of TNF-α, IFN-γ, IL-6 and IL-2 cytokines compared to the untreated 
MLR. The results are in accordance with studies that showed that Fostamatinib 
(non-specific SYK inhibitor) lowered the concentration of IFN-γ and IL-6 in GVHD 
(Leonhardt et al., 2014). However, unlike Fostamatinib, PRT0603 significantly 
reduced TNF-α. It has been reported that the activation of the SYK pathway is 
involved in the control of TNF-α production by macrophages (Su Yi et al., 2014). 
The data in this report highlighted that deactivation of SYK by PRT0603 is the 
likely mechanism responsible for the reduced TNF-α production by 
monocytes/macrophages. TNF-α is mainly released by macrophages in GVHD to 
up-regulate co-stimulatory molecules and to stimulate T cells (Markey et al., 2013, 
Zhang et al., 2017). The previous data revealed a reduction of CD86 expression 
on monocytes/macrophages, due to reduction of TNF-α, as a result T cells 
alloreactivity being reduced after PRT0603 treatment. This explanation is 
supported by other studies which reported that low TNF-α concentrations are 
linked with a low risk of GVHD (Kumar et al., 2014). However, in this study the 
data showed a reduction of TNF-α with non-significant changes on CD86 
expression which could be due to the limited number of repeats. Reduction of IFN-
γ levels could deactivate monocytes/macrophages (Ashkar et al., 2018, Rahimi et 
al., 2019). IL-6 is mainly released by classical monocytes (Boyette et al., 2016). 
In GVHD IL-6 controlled T cell maturation and differentiation (Tawara et al., 2011, 
Tvedet et al., 2017). The data in this study highlighted that a reduction of IL-6 and 
IL-2 concentration in MLR after PRT0603 treatment could explain the reduction of 
T cells activity. This data was supported by studies that showed low IL-2 
concentrations are associated with lower GVHD incidences (Blazar et al., 2013, 
Kumar et al., 2017). In MLR, the results showed that SYK inhibitor was able to 
control cytokine secretion and that demonstrated its potency to reduce 
inflammation in alloresponse. Indeed, targeting cytokines is a valid therapeutic 
approach to control inflammation (Coffey et al., 2013).  
In summary, it is difficult to clearly characterise the monocytes subtypes in 
allogeneic response, the data indicated that early MLR culture activates 
monocyte/macrophages to show an inflammatory phenotype. The activated 
CD14+ could be the minor secretory cells of TNF-α, IFN-γ and IL-6 cytokines on 
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D2. Consequently, this early monocytes/macrophage activation could contribute 
to priming /alloresponse of T cells on D3 of cell culture. Importantly, these findings 
could highlight that the monocytes/ macrophages in the MHC mismatched MLR 
could react like monocytes in the matched model. In addition, the data may 
suggest that targeting SYK by 2 μM PRT0603 in MLR culture modulated 
monocytes/macrophages function and reduced cytokine secretion which is 
followed by interference with T cell allo-reactivity. Indeed, reducing the 
inflammation driven by cytokines that are produced during the allogeneic reaction 
could be an important therapeutic approach. Thus, the primary data revealed that 
the SYK inhibitor PRT0603 could be considered as a therapeutic option to control 




4 Results (Part 2): 
4.1 Introduction: 
IFN-γ is a cytokine produced by Th1 and NK cells. IFN-γ promotes monocytes 
differentiation into macrophages and polarisation towards the M1 phenotype with 
high Ag presentation capacity (Deeg, 2001, Wang et al., 2014, Lee et al., 2017, 
Lee & Ashkar, 2018). It is thought that in GVHD, tissue injury that occurs post TBI 
is accompanied by bacterial product (LPS) release from GIT epithelium, and this 
triggers macrophages activation and production of inflammatory cytokines such 
as TNF-α and IFN-γ (Chakraverty & Sykes, 2006). In GVHD, patients’ serum 
contains high concentrations of IFN-γ, however, this does not reflect GVHD 
severity. Nevertheless, IFN-γ stimulates the secretion of TNF-α and IL-6, which 
could contribute to pathology (Nakamura et al., 2000). The alloresponse is started 
by T cells after recognising the foreign Ag presented by APCs (Leonhardt et al., 
2012, Heller et al., 2017, Poe et al., 2018). This study investigated the effects of 
IFN-γ on monocytes function in the in vitro model of early allogeneic response. 
Furthermore, the effects of SYK inhibitor, PRT0603, on MLR in the presence of 
IFN-γ were assessed. This therapeutic approach could control alloresponse, 
inhibit monocyte function and T cells activation, leading to a decrease in cytokine 
production. 
Therefore, the aims of this chapter were to: 
• Investigate the effect of IFN-γ on monocytes/macrophages function and 
activation in alloresponse.  
• Investigate the effect of IFN-γ on T cell activity.  
• Evaluate the effect of IFN-γ on cytokine production in MLR culture.  
• Examine the effect of SYK inhibitor, PRT0603 on CD86, HLA-DR and CD64 
expression on monocytes/macrophages in MLR culture in the presence of 
IFN-γ.  
• Investigate the effect of PRT0603 on T cells activity in MLR culture in the 
presence of IFN-γ.  
• Evaluate the effect of SYK inhibitor on cytokine production in MLR culture in 




4.2.1 Optimising the IFN-γ concentration: 
10 ng/ml, 50 ng/ml, and 100 ng/ml IFN-γ were added to MLR, and the expression 
levels (MFI value) of CD86, HLA-DR and CD64 were measured by flow cytometry 
after D1 and D2, of cell culture. The cell viability was checked by Annexin V. 
staining. Notably, 80-85% of cells were viable on D1 and D2 (data not shown). All 
samples were treated with Fc blocking and the results  were compared to the isotype 
controls to eliminate any background of non-specific antibody binding (isotype raw 
data provided in the appendix figure S.1.3). 
The results (Figure 4.1.A and Figure 4.1.C) show that the expression of CD86 and 
CD64 were increased after treatment with 100 ng/ml IFN-γ when compared to the 
other concentrations for both days of incubation, but the differences were not 
significant. The results for HLA-DR (Figure 4.1.B) revealed slight changes in 
expression on the CD14+ monocytes/macrophages after D1, however, after D2 
the CD14+ cells treated with 100 ng/ml and 50 ng/ml IFN-γ maintained the same 
expression level. Therefore, 100 ng/ml of IFN-γ was selected as the optimal 




Figure 4. 1: Analysis of the level of expression (MFI) for A) CD86, B) HLA-DR and C) CD64 on 
CD14+ monocytes measured by flow cytometry after one (D1) and two days (D2) of incubation. 
The X axis shows incubation days, Y axis presents MFI expression. Data shown are mean and the 
error bars are SD (n = 3). Blue bar = MLR treated with 10 ng/ml IFN-γ, green bar = MLR treated  with 
50 ng/ml IFN-γ and pink bar = MLR treated with 100 ng/ml IFN-γ. Statistical significance of data 
was analysed using RM two-way ANOVA with Tukey`s multiple comparisons test and Geisser 
Greenhouse, p values below 0.05 were considered significant. 
4.2.2 Monocytes/macrophages co-stimulation capacity in MLR culture with 
addition of IFN-γ: 
To further investigate the effect of 100 ng/ml IFN-γ on monocyte co-stimulation 
capacity, four conditions were compared: Res (responder cells negative control), 
MLR (alloresponse control), MLR treated with 100 ng/ml IFN-γ (experimental 
condition, alloresponse in the presence of cytokine) and Res IFN-γ (responder 
cells treated with 100 ng/ml IFN-γ control for the effects of the cytokine). The 
results for D1 (Figure 4.2.A) revealed that the presence of IFN-γ did not affect 
CD86 expression on CD14+ monocytes in allogeneic culture. Indeed, the only 
statistically significant difference in CD86 expression on D1 was observed 
between MLR and responder controls (p = 0.0071), MLR IFN-γ Vs Res (p = 0.042) 
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and Res IFN-γ (p = 0.043). Notably, CD86 expression had increased in all cell 
culture conditions on D2. However, the effects of IFN-γ were modest when added 
to MLR culture and resulted in a slight, non-significant increase compared to MLR 
without cytokine. In contrast, addition of IFN-γ to responder cells culture resulted 
in lower levels of CD86 expression compared to responder cells only culture. 
Consequently, the statistically significant difference on D2 was observed between 
MLR IFN-γ culture compared to responder cells treated with IFN-γ (p = 0.0087) 
and Res control (p = 0.023) on D2 of incubation. These data suggest that IFN-γ 
has neutral effects on CD86 expression in monocytes. Furthermore, the combined 
presence of allogeneic cells and IFN-γ did not result in significant changes in 
monocyte/macrophages CD86 expression. Thus, the presence of IFN-γ did not 
boost alloreactive response by increasing co-stimulation via CD86 in the early 
phase of MLR culture.  
Conversely, the addition of IFN-γ did not interfere with the MLR-induced CD86 
expression, as the CD86 up-regulation on the monocytes was mainly due to the 
allogeneic response. It could be concluded that effects of IFN-γ on monocyte are 
not focused on their co-stimulatory capacity and that other monocyte functions are 
more likely targets of this cytokine. 
4.2.3 Monocytes/macrophages Ag presentation capacity in MLR culture    with 
addition of IFN-γ: 
The same four experimental conditions were investigated for Ag presentation 
capacity by measuring HLA-DR expression on monocytes/macrophages. The 
data (Figure 4.2.B) showed that CD14+ monocytes/macrophages expressed 
slightly more of HLA-DR in the MLR treated with 100 ng/ml IFN-γ compared to 
MLR only on D1 and D2, however, the difference was not significant. On D1 of cell 
culture the significant difference was observed between MLR IFN-γ vs. Res IFN-
γ (p=0.040) and Res control (p=0.0118). Similarly, on D2 of incubation the HLA-
DR expression was significantly increased in MLR IFN-γ culture compared to Res 
IFN-γ (p=0.0052) and Res control (p=0.0010). 
In contrast, it appears that IFN-γ has no   effect on monocyte HLA-DR expression 
in the absence of alloresponse (responder cells culture in the presence of IFN-γ) 
compared to responder cells only. These findings suggest that the monocytes up-
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regulated Ag presentation due to the alloresponse, and IFN-γ presence results in 
a modest further increased of HLA-DR+ expression on CD14+ monocytes. Thus, it 
could be concluded that IFN-γ stimulates HLA-DR expression in monocytes only 
if monocytes were already activated by alloresponse. 
4.2.4 Analysis of CD64 (FCγRI) and CD32B (FCγRIIB) expression on 
monocytes CD14+ in MLR treated with IFN-γ: 
The same four experimental conditions were investigated for CD64+ (FCγRI) and 
CD32B (FCγRIIB) expression. The data (Figure 4.2.C) showed that CD14+CD64+ 
expression was significantly increased in MLR IFN-γ compared to the other 
experimental conditions on D1 (p = 0.0075 vs. Res, p = 0.017 vs. MLR) and D2 (p 
= 0.0004 vs. Res and p = 0.0012 vs. MLR). Notably, on D1 and D2 in Res IFN-γ 
the expression of CD14+CD64+ was significantly higher than Res (p = 0.029 for 
D1 and p = 0.013 for D2) The results highlight the strong stimulatory effects of 
IFN-γ on monocyte expression of CD64, and the synergy between IFN-γ and early 
alloresponse leading to further increase in the expression of CD64.  
The data for CD32B expression (Figure 4.2.D) showed high levels of variability on 
D1 of incubation. Thus, there were no clear trends for changes in monocyte 
CD32B expression in the presence of allogeneic cells, IFN-γ or both stimuli. On 
D2 of incubation, the expression of CD32B was lower on D1 in all four 
experimental conditions. Furthermore, there were no effects of IFN-γ or 
alloresponse on monocyte CD32B expression. Thus, it appears that CD14+CD32+ 
expression is decreasing during the cell culture regardless of the addition of IFN-




Figure 4. 2: Analysis of expression levels on CD14+ monocytes after IFN-γ stimulation after D1 
and D2 of incubation. A) CD86, B) HLA-DR, C) CD64, D) CD32B. 
The X axis shows incubation days, Y axis presents MFI expression level. Data shown are mean 
and the error bars are SD (n = 6). Black bar represents Res = Responder cells as a negative control, 
orange bar represents MLR = Mixed leukocyte reaction, pink bar represents MLR treated with 100 
ng/ml IFN-γ, and purple bar represents Responder cells treated with100 ng/ml IFN-γ. Statistical 
significance of data was analysed using RM two-way ANOVA with Tukey`s multiple comparisons 
test and Geisser-Greenhouse correction, p values below 0.05 were considered significant, * = p < 
0.05, ** = p < 0.001, and *** = p < 0.0001. 
4.2.5 Analysis of CD36 and CD204 expression on CD14+in the presence   of 
allogeneic cells and IFN-γ: 
The expression of the scavenger receptors CD36 and CD204 were measured in 
the same four conditions to determine functional changes in 
monocytes/macrophages and their potential to clear apoptotic cells. The results 
(Figure 4.3.A) showed that the expression of CD14+CD36+ was similar in all four 
conditions on D1 of incubation. Interestingly, on D2 of incubation, CD14+ in the 
control, responder cells culture had higher expression of CD36 compared to MLR, 
MLR IFN-γ and Res IFN-γ, although the differences did not reach statistical 
significance. These data suggest that the expression of CD36 on 
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monocytes/macrophages is not affected by the presence of allogeneic cells, IFN-
γ or both stimuli combined. 
The results for CD204 expression on CD14+ cells (Figure 4.3.B) showed that on 
D1 of incubation, there was a significant increase in expression in the MLR (p = 
0.034), and in MLR IFN-γ (p = 0.021) when compared to responder cells. These 
results suggest that IFN-γ stimulate CD14+ monocytes to up-regulate CD204+ 
scavenger receptor. The effects of early D1 alloresponse (MLR culture) on 
monocyte/macrophages CD204 expression were also significant, compared to 
responder cells. However, the presence of two stimuli, MLR IFN-γ compared to 
MLR, resulted in a modest further increase in CD204 expression. Thus, IFN-γ and 
alloresponse show modest, non-significant synergy in respect to 
monocyte/macrophages expression of CD204 biomarker. It could be argued that 
IFN-γ upregulates CD204 on monocytes/macrophages in order to improve 
recognition and clearing of the apoptotic cells. However, these effects of IFN-γ and 
alloresponse on CD204 expression appeared to be short lasting, as on D2 of 
incubation, CD14+CD204+ expression was reduced in MLR and MLR IFN-γ 
settings and increased in the responder cell control. Indeed, on D2 there was a 
statistically  significant increase in responder cells expression of CD204 compared 
to Res IFN-γ (p=0.018). 
4.2.6 Analysis of Ca3R expression on CD14+ in the presence of allogeneic 
cells and IFN-γ: 
The effect of IFN-γ and alloresponse on the complement receptor C3aR was 
investigated in the four experimental conditions described above. The results 
(Figure 4.3.C) showed that MLR culture resulted in striking significant increase in 
C3aR expression on D1 of incubation compared to responder cells (p < 0.0001), 
MLR IFN-γ (p < 0.0001) and Res IFN-γ (p < 0.0001). Furthermore, MLR IFN-γ had 
significantly up-regulated C3aR expression compared to the negative control of 
responder cells only (p = 0.021). These data suggest that an early alloresponse 
(D1) showed a dramatic effect on monocyte C3aR expression. In contrast, the 
effects of IFN-γ on monocyte/macrophage C3aR expression were modest. More 
importantly, IFN-γ appeared to interfere with stimulatory effects of alloresponse, 
as shown by significant decrease in monocyte/macrophage C3aR expression in 
early (D1) MLR IFN-γ culture compared to MLR. 
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Although the prominent feature of D2 data was a large increase in 
monocyte/macrophage C3aR expression in the control, responder cell culture, the 
apparent inhibitory effect of IFN-γ on the expression of this complement receptor 
was still observed.Indeed, D2 results showed that CD14+C3aR+ expression in 
MLR was significantly increased compared to MLR IFN-γ (p < 0.0001) and Res 
IFN-γ (p < 0.0001). Notably, the control responder cells expressed CD14+C3aR+ 
at a higher level than   MLR IFN-γ (p < 0.0001) and Res IFN-γ (p < 0.0001). Overall, 
these data demonstrate a strong stimulatory effect of early alloresponse on 
monocytes/macrophages C3aR expression, whereas IFN-γ reduced the 
expression of this complement receptor. 
4.2.7 Analysis of CD11b expression on CD14+ monocytes in the presence of 
allogeneic cells and IFN-γ: 
CD11b expression on CD14+ was also analysed using the four experimental 
conditions, as described above. The results (Figure 4.3.D) revealed that the 
monocytes/macrophages in MLR and MLR IFN-γ showed a similar level of 
CD14+CD11b+ expression with no significant differences. This indicates   that 
neither IFN-γ or early alloresponse play a significant role in controlling CD11b on 
monocytes/macrophages. Although, CD11b in MLR and MLR IFN-γ was 
expressed at a slightly higher level than in responder cells, particularly on D1, the 
difference did not reach statistical significance. As CD11b is a well-established 
marker of monocyte adhesion and migration, it appears that this important function 




Figure 4. 3: Analysis of the expression CD36, CD204, C3aR and CD204 on CD14+ monocytes 
after IFN-γ stimulation on D1 and D2 of incubation. 
A) CD36, B) CD204, C) C3aR and D) CD11b. The X axis shows incubation days, Y axis is MFI 
expression. Data shown are mean and the error bars are SD (n = 3). Black bar represents Res = 
Responder cells as a negative control, orange bar represents MLR = Mixed leukocyte reaction, 
pink bar represents MLR treated with 100 ng/ml IFN-γ, and purple bar represents Responder cells 
treated with100 ng/ml IFN-γ. Statistical significance of data was analysed using RM two-way 
ANOVA with Tukey multiple comparisons test and Geisser-Greenhouse correction, p values below 
0.05 were considered significant, * = p < 0.05** = p < 0.01, and *** = p < 0.001. 
4.2.8 Activation of T cells in MLR treated with 100 ng/ml IFN-γ: 
T cell activity was investigated on D3 by assessing the percent (%) of CD3+CD69+ 
and CD4+CD69+cells and the level of expression (MFI) of CD3+CD25+ and 
CD4+CD25+ T cells was determined in the four conditions described above 
The data (Figure 4.4.A) showed a significant increase of MFI values CD3+CD25+ 
in the MLR IFN-γ compared to Res IFN-γ (p=0.0013) and Res (p=0.0024). The 
results for CD3+ population (Figure 4.4.B) showed a significantly elevated 
percentage (%) of activated, CD69+ T cells in MLR IFN-γ when compared to Res 
IFN-γ (p=0.019) and Res (p=0.021). Similar trends for increased CD69+ T cells 
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were observed for MLR culture when compared to Res (p = 0.014) and Res IFN-
γ (p = 0.019). Although proportion of CD69+ T cells in MLR IFN-γ was slightly 
increased when compared to MLR, the difference was not statistically significant.  
Thus, it can be concluded that IFN-γ on its own did not activate CD3+ T cells, as 
demonstrated by the analysis of the expression of CD69 and CD25 markers on 
D3 of incubation. Furthermore, adding IFN-γ to MLR culture had modest, non-
significant effects on T cell activation.   
For the population of CD4+ T helper cells, the level of expression (MFI) of CD25 
(Figure 4.4.C) was significantly increased in MLR compared to Res (p=0.046) and 
Res IFN-γ (p=0.046). Notably, CD4+CD25+ expression was slightly lower in MLR 
IFN-γ than MLR, although difference was not significant. For CD69 expression 
(Figure 4.4.D), the results showed the high level of variability with a significant 
increase in the proportion (%) of activated CD4+T cells in MLR IFN-γ compared to 
Res IFN-γ (p=0.043). However, the difference was not significant between MLR 
and MLR IFN-γ cultures. These findings for CD4+ T helper cells suggest that MLR 
culture on D3 of incubation results in T cell activation, as demonstrated by 
increased levels of CD25 expression and a higher proportion of CD69+ T cells. In 
contrast, the addition of IFN-γ did not boost T cell activation on D3 of incubation 





Figure 4. 4: Analysis T cells activation measured by flow cytometry after three days (D3) of 
incubation. 
A) MFI values for CD3+CD25+ T cells where Y axis shows MFI values for CD25 expression, B) 
Percent of CD3+CD69+ T cells where Y axis shows proportion (%) of CD69-positive T cells. C) MFI 
values for CD4+CD25+ T helper cells, D) Percent of CD4+CD69+ T helper cells. Data shown are 
mean and the error bars are SD (n = 3). Black bar represents Res = Responder cells as negative 
control, orange bar represents MLR = Mixed leukocyte reaction culture, pink bar represents MLR 
treated with 100 ng/ml IFN-γ and purple bar represents responder cells treated with 100 ng/ml IFN-
γ. Statistical significance of data was analysed using RM one-way ANOVA with Geisser-
Greenhouse correction and Tukey multiple comparison values below 0.05 were considered 





4.2.9 Measurement of cytokines in MLR treated with IFN-γ: 
TNF-α, IL-2 and IL-6 concentration were measured by ELISA after two days of 
incubation analysis determined in the four conditions described above, to 
determine the effects of IFN-γ and the features of inflammatory reaction in 
allogeneic   culture. The results for TNF-α (Figure 4.5.A) showed that on D2 of 
incubation in MLR IFN-γ levels of this cytokine were significantly higher than in the 
control Res culture (p=0.0069) and Res IFN-γ (p = 0.015). The levels of TNF-α in 
MLR culture were significantly higher than in the Res (p=0.028) and Res IFN-γ cell 
cultures (p=0.0105). Furthermore, the concentration of TNF-α in MLR IFN-γ was 
higher than MLR, but the result was not statistically significant.  
The results (Figure 4.5.B) for IL-2 in MLR IFN-γ were clearly measurable and were 
significantly higher than Res (p=0.043) and Res IFN-γ (p=0.032). Notably, MLR 
IFN-γ showed slightly higher IL-2 concentrations compared to MLR, however the 
difference was not significant. 
For IL-6 (Figure 4.5.C) the levels of IL-6 cytokine in MLR were detectable and 
significantly increased compared to Res (p=0.029) and Res IFN-γ (p=0.016). 
Interestingly, the levels of IL-6 in MLR culture were significantly higher than in MLR 
IFN-γ cell culture (p=0.016). Also, IL-6 concentrations were significantly higher in 
MLR IFN-γ than in the Res (p=0.061) and Res IFN-γ (p=0.011). These data 
indicate that the presence of IFN-γ interferes with the stimulatory effects of 
alloresponse on IL-6 production.  
In summary, the results presented above highlight that the inflammatory cytokines 
such as TNF-α, IL-2 and IL-6 were induced in early alloresponse (D2 of 
incubation), as MLR culture showed significantly increased levels of these 
cytokines. However, addition of IFN-γ to MLR culture resulted in a modest synergy 
with a trend for a slight increase in the production of TNF-α and IL-2. In contrast, 
IFN-γ showed strong antagonistic effects on IL-6 production even in the presence 
of the stimulatory allogeneic response, MLR culture. Regarding the source of 
cytokines in a complex cell culture, at this early stage of alloresponse (D2), 
monocytes/macrophages were clearly activated, thus it could be postulated that 
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TNF-α and IL-6 were likely to be secreted by these cells. On the other hand, IL-2 
could be produced by T cells, despite the markers of T cells activation such as 
CD25 and CD69 being negative at this stage (D2 of incubation) of alloresponse. 
Thus, intracellular analysis will consider in future work. 
 
 Figure 4. 5: Measuring inflammatory cytokines on D2 of incubation with/without IFN-γ  treatment. 
A) TNF-α, B) IL-2, and C) IL-6 concentrations. X axis shows comparison of four conditions: Res 
= responder cells, MLR = Mixed leukocyte reaction, MLR IFN-γ = MLR treated with 100 ng/ml IFN- 
γ and Res IFN-γ = Responder cells treated with 100 ng/ml IFN-γ. Y axis shows the cytokine 
concentrations in pg/ml. Scatter dot plots show repeats (n = 3 and 5 for TNF-α). Statistical 
significance of data was analysed using RM one-way ANOVA with Geisser-Greenhouse correction 
and Tukey multiple comparison, p values below 0.05 were considered significant, * = p < 0.05, ** = 




4.2.10 Effects of SYK inhibitor on CD14+ in MLR treated with IFN-γ: 
The expression levels (MFI values) of CD86, HLA-DR and CD64 were measured 
for the four test conditions:  MLR IFN-γ (+ve control MLR treated with 100 ng/ml 
IFN-γ), MLR IFN-γ SYK (experimental condition MLR treated with 100 ng/ml IFN-
γ and 2 μM anti-SYK), Res IFN-γ (control responder cells treated with 100 ng/ml 
IFN-γ) and Res IFN-γ SYK (inhibitor effects on control responder cells treated with 
100 ng/ml IFN-γ and 2 μM anti- SYK). 
The results (Figure 4.6.A) showed that there was a modest reduction in CD86+ 
expression on CD14+ monocytes in the MLR IFN-γ treated with SYK inhibitor when  
compared to the MLR IFN-γ on D1 and D2 of incubation, however the difference 
was not significant. The data also confirmed stimulatory effects of MLR as 
demonstrated by significant higher levels of CD14+CD86+ expression in MLR IFN-γ 
compared to Res IFN-γ (p=0.0042) and Res IFN-γ SYK (p= 0.0046). following the same 
trend significant difference of CD86 expression in MLR IFN-γ SYK compared to Res 
IFN-γ (p= 0.034) and Res IFN-γ SYK (p=0.039). These data confirm strong  effects of 
MLR on the expression of monocyte/macrophages co-stimulatory molecule CD86, 
modest effects of IFN-γ and a trend for slight inhibitory effects of anti SYK that did 
not reach statistical significance. 
For HLA-DR expression (Figure 4.6.B), a reduction of MFI was observed for MLR 
IFN-γ compared to MLR IFN-γ with SYK inhibitor on D1 and D2 of incubation, 
although difference was not statistically significant. The trend for significant 
reduction in HLA-DR was seen in Res IFN-γ (p = 0.040) and Res IFN-γ with SYK 
inhibitor (p=0.030) compared to MLR IFN-γ on D1. Similarly significant difference 
in HLA-DR expression was seen in Res IFN-γ (p=0.045) and Res IFN-γ with SYK 
inhibitor (p=0.032) compared to MLR IFN-γ on D2. This is a consequence of the 
lower HLA-DR expression in the presence of IFN-γ in responder cells compared 
to the combined stimulatory effects of IFN-γ plus MLR. Also, SYK inhibition could 
contribute to low HLA-DR expression in Res IFN-γ with SYK inhibitor culture, thus 
SYK pathway could modulate monocytes/macrophages Ag presentation in certain 
inflammatory settings.  
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For CD14+CD64+ expression (Figure 4.6.C), the data revealed that there was a 
modest down regulation after treatment of MLR IFN-γ with 2 μM of SYK inhibitor 
on D2 of incubation, and in Res IFN-γ SYK compared to Res IFN-γ on D1 of 
incubation. However, the difference did not reach statistical significance. 
 
Figure 4. 6: Analysis of A) CD86, B) HLA-DR and C) CD64 expression on CD14+ monocytes on 
D1 and D2 of incubation in the presence of IFN-γ, MLR and SYK inhibitor. 
The X axis shows incubation days, Y axis is MFI expression. Data shown are mean and the error 
bars are SD (n = 5). Dark purple bar represents Res IFN-γ = Responder cells cell treated with 100 
ng/ml IFN-γ as a negative control, light purple bar with dot pattern represents responder cell treated 
with 100 ng/ml IFN-γ and 2 μM SYK inhibitor, pink bar represents MLR IFN-γ = Mixed leukocyte 
reaction treated with 100 ng/ml IFN-γ, and light pink with dot pattern bar represents MLR treated 
with 100 ng/ml IFN-γ and 2µM SYK inhibitor. Statistical significance of data was analysed using 
RM two-way ANOVA with Geisser-Greenhouse correction and Tukey multiple comparison test, p 








4.2.11 Effects of SYK inhibitor on T cell activity in MLR treated with IFN-γ: 
CD3+ and CD4+ T cells were analysed after three days of incubation for CD25 
expression levels (MFI values), and  proportion (%) of CD69 positive cells in four 
conditions described above. Cell viability was   checked using Annexin V FITC and 
more than 80 % of the cells were Annexin -ve  after gating for the T cell population 
(data not shown). 
The data (Figure 4.7.A) revealed that CD3+CD25+ T cells in MLR IFN-γ showed 
significantly higher levels of expression than Res IFN-γ (p=0.041) and Res IFN-γ 
SYK (p=0.043). Importantly, treatment with 2 μM SYK inhibitor (MLR IFN-γ SYK) 
significantly reduced CD3+CD25+ expression compared to MLR IFN-γ culture (p = 
0.024).  
Following the same trend, the results (Figure 4.7.B) for the % of CD3+CD69+ T 
cells showed significant reduction in MLR IFN-γ treated with 2 μM SYK inhibitor 
compared to MLR IFN-γ (p=0.045). Also, MLR IFN-γ cell culture showed 
significantly higher proportion (%) of CD69+ T cells than Res IFN-γ (p=0.011) and 
Res IFN-γ SYK (p=0.032).  
For CD4+ cells (Figure 4.7.C) there was a slight reduction in CD4+CD25+ 
expression for MLR IFN-γ treated with SYK inhibitor when compared to MLR IFN-
γ. However, the difference did not reach statistical significance. Interestingly, 
CD4+CD25+ expression levels were significantly higher in MLR IFN-γ than in Res 
IFN-γ SYK (p=0.034).  
The results (Figure 4.7.D) for CD4+CD69+ showed similar proportion of CD69+ T 
helper cells for MLR IFN-γ compared to cell culture in the presence of inhibitor 
MLR IFN-γ SYK. Notably, CD4+CD69+ proportion (%) was higher in MLR IFN-γ 





Figure 4. 7: Analysis of T cell activation by flow cytometry on D3 of incubation with IFN-γ and SYK 
inhibitor. 
 A) CD3+CD25+, B) CD3+CD69+, C) CD4+CD25+ D) CD4+CD69+. Y axis is MFI expression in A 
and C and % in B and D. The X axis shows treatment, dark purple bar represents Res IFN-γ = 
Responder cells treated with 100 ng/ml IFN-γ, light purple bar with dot pattern represents responder 
cells treated with 100 ng/ml IFN-γ and 2 µM SYK inhibitor, pink bar represents MLR IFN-γ = Mixed 
leukocyte reaction treated with 100 ng/ml IFN-γ and light pink with dot pattern bar represents MLR 
IFN-γ SYK = MLR treated with 100 ng/ml IFN-γ and 2µM of SYK inhibitor. Data shown are mean 
and the error bars are SD (n = 4). Statistical significance of data was analysed RM one-way ANOVA 
with Geisser-Greenhouse correction and Tukey multiple comparison, p values below 0.05 were 







4.2.12 Measuring cytokines concentrations in MLR culture treated with IFN-γ 
and   SYK inhibitor: 
The samples were collected on D2 of incubation from four conditions were 
described above. All samples were analysed by sandwich ELISA for TNF-α, IL-2 
and IL-6 cytokines concentrations.  
The results  (Figure 4.8.A) revealed that SYK inhibitor significantly decreased the 
TNF-α concentration in MLR IFN-γ SYK compared to MLR IFN-γ (p=0.0017). Also, 
significant differences were observed in MLR IFN-γ compared to Res IFN-γ 
(p=0.013) Res IFN-γ SYK (p=0.045). 
For IL-2 (Figure 4.8.B), there was a significant reduction in IL-2 concentration due 
to SYK inhibitor, MLR IFN-γ SYK compared to MLR IFN-γ (p=0.032). Also, 
significant differences were observed in MLR IFN-γ compared to Res IFN-γ 
(p=0.023) Res IFN-γ SYK (p=0.024).  
For IL-6 (Figure 4.8.C) the results showed a significant reduction in the presence 
of inhibitor in MLR IFN-γ SYK compared to MLR IFN-γ (p=0.081). Significant 
differences in IL-6 concentration were seen in MLR IFN-γ compared to Res IFN-γ 
(p=0.021) Res IFN-γ SYK (p=0.025).  
Overall, SYK inhibitor significantly reduced concentrations of TNF-α, IL-2 and IL-




Figure 4. 8: Measuring proinflammatory cytokines on D2 of incubation in the presence of allogeneic 
cells, IFN-γ and SYK inhibitor. 
A) TNF-α, B) IL-2 and C) IL-6 concentrations. X axis shows comparison of four conditions: Res 
IFN-γ = Responder cell culture with 100 ng/ml IFN-γ, Res IFN-γ SYK = Responder cell culture with 
100 ng/ml IFN-γ and 2 µM of SYK inhibitor, MLR IFN-γ = Mixed leukocyte reaction with 100 ng/ml 
IFN-γ, and MLR IFN-γ SYK = MLR treated with IFN-γ and 2 µM of SYK inhibitor. Y axis shows the 
cytokine concentration in pg/ml. Scatter Dot plot shows triplicate repeats (n = 3). Statistical 
significance of data was analysed using RM one-way ANOVA with Geisser-Greenhouse correction 
and Tukey multiple comparison, * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
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4.3 Discussion (Part 2): 
In the context of GVHD development, IFN-γ is regarded as a proinflammatory 
cytokine that is released from activated APCs in response to allo-Ag (Wang et al., 
2014, Lee & Ashkar, 2018). IFN-γ is known as a Th1 cytokine, as it is mainly 
produced by Th1 cells and NK cells, and it control monocyte/macrophage 
activation (Nakamura et al., 2000, Murray, 2012, Raphael et al., 2014, Rahimi et 
al., 2019). Binding of IFN-γ to the IFN-γ receptor on the surface of 
monocytes/macrophages, will activate JAK-STAT signal transduction. This 
controls gene transcription and many monocyte functions, including Ag capture 
Ag processing, Ag presentation, anti-microbicidal function and anti-viral response 
(Schorder et al., 2003). It is thought that IFN-γ promotes differentiation of 
monocytes towards M1 macrophages with a high phagocytic capacity (Nakamura 
et al., 2000, Duque & Descoteaux, 2014, Raphael et al., 2014, Lee et al., 2017). 
However, the exact role of IFN-γ is still debated as it can act as an inhibitor of 
inflammation (Yong et al., 1998, Raphael et al., 2014, Nassereddin et al., 2017). 
Also, its association with GVHD pathogenesis remains controversial (Nakamura 
et al., 2000, Visentainer et al., 2003). In the previous chapter, MLR culture was 
shown to activate monocytes/macrophages and T cells. This is likely to involve 
contribution of multiple cytokines produced by the activated immune cells, 
however, the role of an individual cytokine such as IFN-γ needs to be defined. 
Therefore, this chapter investigated the role of IFN-γ in the early phase of 
response to allogeneic cells. 
This chapter aimed to analyse two areas, first was to evaluate the effects of IFN-
γ on the monocyte/macrophages function, T cell activation and cytokines 
production in MLR culture. The second area was to investigate the effects of SYK 
pathway inhibition in MLR treated with IFN-γ, by evaluating changes in the CD14+ 
monocytes phenotype, T cell activation and cytokine production.  
The initial, extensive study of the effects of various concentrations of IFN-γ (from 
1 to 100 ng/ml) on the early phase of alloresponse/MLR showed that a relatively 
high concentration, 100 ng/ml of this cytokine ensured a stable response without 
affecting cell viability. Although this concentration of IFN-γ is much higher than the 
levels that were observed in GVHD patients (Nakamura et al., 2000, Visentainer 
126 
 
et al., 2003). It is important to note that the reported systemic (serum) 
concentration of this cytokine does not represent the actual levels in the local, 
inflamed tissues. Furthermore, the inflamed tissue is likely to provide a continuous 
supply of newly produced cytokines, which compensates for the physiological, 
short half-life of these unstable molecules. In contrast, in vitro or ex vivo 
experimental conditions need to ensure the optimal presence of a cytokine in a 
challenging environment where cytokine stability and bioavailability is difficult to 
monitor. Indeed, the complex experimental conditions such as those based on the 
whole blood culture used in this model, represent a distinct setting where the 
cytokines are exposed to enzymes released by neutrophils, platelets, and other 
blood cells. Thus, the whole blood MLR culture used in this study cannot be 
directly compared to in vivo conditions or experimental models based on the use 
of isolated peripheral blood mononuclear cells (PBMCs). As the relevant, tissue 
levels of IFN-γ remain speculative and the in vitro stability of cytokine depends on 
the specific cell culture conditions, it could be argued that using a relatively high 
concentration of the cytokine ensures its presence during the 1-3 days of 
incubation. This approach was evaluated by confirming the known stimulatory 
effects of IFN-γ, such as an increased CD64 expression on monocytes and 
demonstrated the lack of negative effects on cell viability. Similar to this report, the 
study by Bayik et al. (2017) on human monocyte maturation has used 500 ng/ml 
of IFN-γ after optimising the cytokine concentration for cell culture conditions 
(Bayik et al., 2017). This is 5 times more than the levels of cytokine used in this 
study. Furthermore, using a mouse model by Brok et al. (1998) reported that high 
dose of IFN-γ immediately after transplantation was crucial for the prevention of 
GVHD (Bork et al., 1998). In that study, treatment with 50,000 IU (International 
Units) of IFN-γ (approximately 10 µg (10,000 ng) twice weekly for a period of 5 
weeks was required to prevent GVHD in a fully MHC-mismatched 
model. Therefore, based on these published reports and the extensive 
optimisation experiments, it was concluded that the optimal concentration of IFN-
γ was 100 ng/ml, and therefore this concentration was used in all subsequent 
experiment. Nevertheless, a high concentration of cytokines appears to be a 
limitation for the in vitro monocytes studies, as most of the studies required a high 
pharmacological concentration of cytokines to achieve phenotype changes.  
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The effects of the addition of IFN-γ to MLR culture were investigated using four 
experimental conditions: MLR IFN-γ (MLR treated with 100 ng/ml IFN-γ), MLR 
only (alloresponse control), Res (-ve control, responder cells only) and Res IFN-γ 
(control for IFN-γ effects). For the flow cytometry immunophenotyping all samples 
were treated with Fc blocking and the results were compared to the isotype control 
to eliminate any background of nonspecific antibody binding (raw data shown in 
the appendix figure S.1.4). Notably, 80 to 85 % of monocytes in the gated 
population were Annexin V -ve, thus confirming acceptable cell viability on D1 and 
D2, respectively.  
This study has used the MLR model where stimulatory cells were not irradiated or 
treated by mitomycin c. Consequently, both populations, stimulator and responder 
cells could respond to the presence of allogeneic cells. Nevertheless, the large 
numerical advantage of responder cells (10:1 ratio) favours this population. 
Indeed, the control experiments using carboxy fluorescein diacetate succinimidyl 
ester (CFSE) labelled stimulator cells have shown minimal contribution of 
stimulator cells to the overall MLR response (data not shown Sabine Broc, 
unpublished findings). 
Recently, it has been reported that the skin lesion from GVHD patients contain 
large numbers of activated macrophage infiltrates, derived from the donor 
circulatory monocytes (Jardine et al., 2020). Thus, donor (responder) APCs are 
involved in the initiation of GVHD (Jardine et al., 2020). Therefore, this study could 
argue that the MLR model described in this report might reflects the allogeneic 
response in the GVHD setting, regardless of the differences in MHC matching 
between this model and HSCT patients.   
Monocyte/macrophage function was assessed by evaluating the expression levels 
of the surface markers by measuring MFI values for CD86, HLADR, CD64, 
CD32B, CD36, CD204, C3aR and CD11b. The MLR culture in the presence of 
100 ng/ml IFN-γ compared to control conditions. The data revealed that IFN-γ up-
regulate the expression of CD64 and downregulated C3aR expression 
significantly. Interestingly, IFN-γ antagonised IL-6 concentrations in allogeneic 
culture. Non-significant difference observed in CD86 and HLA-DR expression that 
could be due to the small sample size. Although MLR IFN-γ culture showed a 
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significant up-regulation of CD86 and HLA-DR expression on CD14+ monocytes 
when compared to Res IFN-γ and Res control, this can be attributed to the 
predominant effects of allogeneic cells/MLR, rather than effects of the IFN-γ 
cytokine. Therefore, these findings indicate that IFN-γ has a modest effect on 
CD86 and HLA-DR expression in monocytes in allogenic/MLR culture, and that 
IFN-γ did not show any synergistic effects with the allogeneic response. Notably, 
these data question the previously proposed role of IFN-γ in controlling co-
stimulation in circulatory monocytes in GVHD (Deneys et al., 2001, Delneste et 
al., 2003, Zheng et al., 2004, Zeiser et al., 2016). Thus, this study supports the 
concept that the effects of IFN-γ on monocytes/macrophages in the early 
allogeneic culture are not focused on their co-stimulatory capacity and the other 
monocytes/macrophages functions are more likely targets of this cytokine.  
The presence of allogeneic cells stimulates HLA-DR and IFN-γ slightly enhanced 
expression of this maker for Ag presentation capacity. This could suggest that IFN-
γ stimulates HLA-DR expression in monocytes/macrophages only if CD14+ 
monocytes were already activated by the alloresponse. This finding supports the 
importance of donor derived IFN-γ to control HLA-DR and CD86 expression in the 
MLR/GVHD. Indeed, it has been reported that donor derived IFN-γ plays a role in 
controlling GVHD initiation (Young et al., 1998). And the donor derived MHC 
molecules could be involved as well (Poe et al., 2018). This data could be 
explained as the following, in the MLR culture both stimulatory and responder cells 
could involve in the Ag presentation and cytokines secretion. 
It has been reported by previous studies that release of IFN-γ in the early phase 
of GVHD up-regulated MHCII expression (Nakamura et al., 2000, Deeg, H 2001, 
Markey et al., 2013). This could lead to formation of M1 macrophages, as several 
studies have reported that IFN-γ induced MHCII on monocytes and controlled M1 
formation (Murray & Wang 2012, Raphael et al., 2014, Lee et al., 2017). However, 
in this report the effect of IFN-γ on HLA-DR expression is weak to moderate. 
Therefore, it could be argued that the IFN-γ mediated increase in Ag presentation 
may prepare monocytes for defence against pathogens without prominent 
inflammatory response. These results are supported by previous studies, which 
reported elevated level of serum IFN-γ in GVHD patients was linked to viral 




The Fc receptor, CD64 is high affinity IgG receptor, that is saturated with IgG 
monomer (Brandsma et al., 2018). In the previous chapter significant up-
regulation of CD64 observed due to allogeneic response. The data in this study 
showed significantly increased expression of CD64 on CD14+ monocytes in the 
MLR IFN-γ culture when compared to control conditions (MLR, Res and Res IFN-
γ) on D1 and D2 (data presented in the appendix Figure S.1.4). The explanation 
of these results could be that the binding of the IFN-γ cytokine to the cytokine 
receptor on the surface of CD14+ monocytes caused the clustering of CD64 on 
the surface of monocytes/macrophages (Brandsma et al., 2018). More importantly 
the clustering of CD64 induces downstream signalling leading to ITAM 
phosphorylation, followed by the recruitment of SYK (Kiefer et al., 1998, Coffey et 
al., 2016). Similarly, the cross-linking of opsonised Ag led to CD64 internalisation, 
processing of the Ag and loading of the processed Ag to MHC molecule (Junker 
et al., 2020). Thus, the up-regulation of CD64 could be linked to the increase of 
HLA-DR expression in MLR culture. Interestingly, this was only observed during 
allogeneic culture/MLR not with the responder cell culture. Although, this study 
cannot confirm SYK activation as intracellular staining was not performed, it could 
be assumed that the up-regulation of CD64 and increase of HLA-DR expression 
could be SYK pathway dependent (Coffey et al., 2016). The treatment of CD14+ 
monocytes in MLR culture with IFN-γ resulted in a strong up-regulation of CD64 
expression. This could have an important role in monocytes/macrophages 
phagocytosis and defence against pathogens (Delneste et al., 2003). Indeed, in 
this study IFN-γ appears to promote the monocyte response aimed at clearing the 
pathogens. However, the effects of the early alloresponse on CD64 expression 
and the synergy with IFN-γ are novel observations, and the mechanisms 
responsible are not fully understood. It is plausible that early interaction of TCR 
with allogeneic cells results in a stimulatory T cell-monocyte molecular interaction 
or the secretion of yet undefined inflammatory mediators by T cells that trigger an 
increase in CD64 expression. Importantly, as in this study relatively high 
concentrations of IFN-γ were used, it is unlikely that any additional secretion of 
IFN-γ by T cells could have an additive/synergistic effect by simply increasing the 
total concentration of this cytokine. 
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CD32B (FcγRIIB) is a low affinity IgG receptor, generally considered as an 
inhibitory FcγR, which is expressed on monocytes/macrophages, mast cells, 
eosinophils, and B cells (Junker et al., 2020). The results collected from MLR IFN-
γ culture showed a modest, non-significant down regulation of CD32B expression. 
Indeed, it has been previously reported that during inflammation CD32B 
expression on CD14+ cells was reduced due to the presence of IFN-γ (Anania et 
al., 2019). Interestingly, the results in this study suggest that 
monocytes/macrophages in MLR IFN-γ culture up-regulated the expression of 
stimulatory FcγRI (CD64) but not the inhibitory FcγRII (CD32B), which indicate an 
inflammatory nature of the response in allogeneic culture treated with IFN-γ.  
Further analysis to evaluate the ability of the monocytes/macrophages to capture 
apoptotic cells and immune complexes was carried out by investigating CD36, and 
CD204 expression on the CD14+ monocytes. In the previous chapter data suggest 
that the clearance of apoptotic cells during early alloresponse is mainly conducted 
by CD204, and not CD36 molecule (D1 of incubation). In this chapter expression 
of CD36 and CD204 on monocytes is not affected by both stimuli (the presence 
of allogeneic cells and IFN-γ). This contrasts with the previous study that reported 
IFN-γ mediated inhibition of CD36 expression on monocytes (Zhong et al., 2019). 
Interestingly, it has been reported that inhibition of CD36 does not affect 
phagocytosis of bacteria by human macrophages (Cooper et al., 2016, Wang et 
al., 2019). Similarly, this result disagrees with previous studies that reported IFN-
γ caused down regulation of CD204 expression (Yoichi Ohtaki et al., 2010, Obrien 
et al., 2019). The role of expression of CD36 or CD204 in early alloresponse 
combine with IFN-γ is not clear. That could be due to the small sample size, future 
work will overcome this limitation that may cause difference in the current result.   
The effects of IFN-γ and the alloresponse on the complement receptor, C3aR, 
were also investigated. C3aR is expressed on APCs and T cells (Raedler & 
Heeger, 2011), and it has been reported that up-regulation of C3aR expression 
on APCs and T cells is involved in alloreactivity and transplant rejection (Raedler 
& Heeger, 2011). In this study, the data demonstrated a strong stimulatory effect 
of the early alloresponse in C3aR expression on monocytes. Notably, it has been 
demonstrated that APCs up-regulate C3aR, as an early sign of aGVHD (Nguyen 
et al., 2018). Although monocytes and macrophages highly express C3aR during 
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innate immune response (Mommert et al., 2018), the current understanding of the 
molecular pathways that control C3aR expression is limited. Thus, the links 
between TCR recognition of allogeneic cells and rapid upregulation of C3aR on 
the surface of monocytes/macrophages remain poorly defined. Interestingly, MLR 
IFN-γ culture significantly reduced expression of CD14+C3aR+ compared to MLR 
culture. This observation reveals that the early alloresponse and IFN-γ have 
opposing effects on C3aR expression in monocytes /macrophages. Previous 
studies reported that FcγR and C3aR are co-expressed on the surface of 
monocytes to mediate the inflammatory response, and the ligation of FcγR with 
IgG controlled C3aR either to inhibit or amplify the C3aR response (Mommert et 
al., 2004). In this study, a dramatic increase of CD14+CD64+ expression was 
observed in MLR IFN-γ culture and that could be responsible for down-regulating 
C3aR expression. The inhibitory effects of IFN-γ on C3aR expression in 
monocytes/macrophages may have important functional consequences. A 
possible scenario could be that binding of C3a to C3aR results in activation of 
APCs and T cells, followed by IFN-γ release by the Th1 cells. The high local 
concentration of IFN-γ could result in the reduction of inflammation, down 
regulation of C3aR and increase in T cell apoptosis due to induction of Fas/FasL 
expression (Raedler & Heeger, 2011, Mathern & Heeger, 2015). As this study 
used high, pharmacological IFN-γ concentrations, this may contribute to the 
reduction of C3aR expression, which could be linked to reduced inflammatory 
response provided by monocytes/macrophages. 
CD11b is regarded as an important differentiation marker, for macrophage 
subsets. Notably, CD11b was expressed slightly more in the allogeneic 
culture/MLR when compared to the responder cells. This could indicate that CD14 
monocytes in MLR and MLR IFN-γ cultures were in a similar differentiation stage, 
as monocytes derived macrophages. Interestingly CD11b is crucial for cell 
adhesion, and phagocytosis of pathogens, apoptotic cells, and complement-
opsonised cells by monocytes, but this process does not always involve 
inflammation (Gavin et al., 2019, Lukácsi et al., 2017). Therefore, it appears that 
CD11b expression is not involved in inflammation triggered by allogeneic cells.  
T cell activations were analysed on D3 of incubation, by evaluating the expression 
of MFI CD25 and % of CD69+. Notably, IFN-γ did not act synergistically with the 
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allogeneic response to enhance T cells activation. It has been reported that 
activated monocytes/macrophages control T cells priming (Bajnok et al., 2017, 
Murray, 2017). The data in this study showed that IFN-γ activated 
monocytes/macrophages appeared to have enhanced phagocytosis on D1 and 
D2 of incubation due to higher levels of CD64 expression. This was accompanied 
by a modest increase of Ag presentation (HLA-DR expression) and co-stimulatory 
capacity (CD86 expression). Also, the addition of IFN-γ to MLR culture has modest 
effects on T cell activation and failed to act synergistically with the early phase of 
alloresponse. It has been reported that IFN-γ could limit alloreactive T cells 
expansion in allogeneic culture, by up-regulation of apoptotic receptors (Wang & 
Yang, 2014, Via et al., 2017). Although these studies support the findings reported 
here, additional investigations are needed to establish if the modest effects of IFN-
γ on T cell activation could reach statistical significance with a larger number of 
experimental repeats.  
The levels of cytokines (TNF-α, IL-6 and IL-2) in MLR culture with/without the 
addition of IFN-γ were measured. The cell culture supernatant samples were 
collected on D1, D2 and D3. However, the only results with consistent values 
above detection limits were on D2, which were presented in this report. Notably, 
this corresponded with the increased levels of expression of the activation markers 
on monocytes/macrophages that were also at their peaks on D2 of incubation.  
The data in this study have shown that MLR culture in the presence of IFN-γ 
produced only slightly more TNF-α and IL-2 when compared to the MLR. Indeed, 
a significant difference was only observed in MLR IFN-γ when compared to Res 
and Res IFN-γ. Based on the expression of the cell surface markers at this early 
stage of alloresponse/MLR culture, monocytes/macrophages were clearly 
activated. Thus, it could be postulated that TNF-α is likely to be secreted by these 
cells on D1 and D2 of incubation. On the other hand, IL-2 is likely to be produced 
by T cells, however, the source of cytokines remains speculative, which highlights 
the need for intracellular cytokine staining to determine which cells produce each 
cytokine.  
The data in this report revealed that IFN-γ had modest effects on TNF-α secretion 
in allogeneic cell culture. This is in contrast with previous studies that reported that 
133 
 
IFN-γ strongly stimulated TNF-α production from APCs (Nakamura et al., 2000), 
which was attributed to functional characteristics of classical monocytes (Wang et 
al., 2014, Spragers et al., 2016). Furthermore, the increased production of IL-2 in 
the early phase of the alloresponse could explain the modest up-regulation of 
CD69 in both CD3+ and CD4+ T cells. Indeed, a previous study showed that CD69 
is an early T cells activation marker was induced by IL-2 cytokine (Bajnok et al., 
2017). Interestingly, this study showed a decrease in IL-6 concentration in MLR 
IFN-γ when compared to the MLR culture. IL-6 is a pleiotropic cytokine that has 
proinflammatory and anti-inflammatory functions (Duque & Descoteaux, 2014). 
The data in this study highlights that early administration of IFN-γ negatively 
regulated IL-6, which is opposite to what has been reported previously and 
interpreted as IFN-γ induced classical monocytes that differentiate in to M1 
macrophages to produce IL-6, IL-2, IL-12, and IL-23 (Nakamura et al., 2000, Wang 
et al., 2014). The apparent inhibitory effects of IFN-γ on the alloresponse and 
reduced IL-6 production implied that IFN-γ antagonise IL-4 by inhibiting IL-6 
production, which could be linked to suppression of cytokine signalling mediated 
by STAT6 inhibition (Delneste et al., 2002). These data highlight the link between 
the effects of IFN-γ, IL-4 and IL-6 in the early allogeneic culture. Thus, IL-4 
concentration in the MLR culture could be measured to determine the interaction 
between this cytokine and IFN-γ, and their effects on the production of IL-6. 
Overall, the addition of IFN-γ to the early MLR culture resulted in increased CD64 
expression/phagocytosis function with down regulation of C3aR, slightly 
enhanced co-stimulation capacity and Ag presentation potential. The addition of 
IFN-γ to the MLR culture resulted in a cytokine production profile that broadly 
matched the classical subtype, except for IL-6 reduction. Importantly, this study 
did not focus on classifying the monocytes subtypes. The main concern was the 
function of monocytes/macrophages and the T cell activation in early MLR culture, 
which was not significantly boosted by the presence of IFN-γ. These data show 
that the presence of IFN-γ in the early phase of the alloresponse does not play a 
pro-inflammatory role (Nakamura et al., 2000, Visentrain et al., 2003). Therefore, 
the contribution of IFN-γ to GVHD pathology may need to be examined in a 
different light. Indeed, IFN-γ could drive monocyte differentiation towards 
macrophages, and defence against pathogens with limited T cell co-stimulation 
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and inflammatory potential. However, due to the small sample size and limitations 
of using an in vitro model in this study it is difficult to generalise this conclusion.  
The second part of this chapter focused on modulating monocytes/macrophage’s 
function and T cells activation by treating MLR IFN-γ culture with a SYK inhibitor. 
The SYK pathway is involved in transmitting signals from FcRs expressed on 
monocytes/macrophages that control crucial events in the development of GVHD 
(Leonhardt et al., 2012, Poe et al., 2018). It has been reported that SYK pathway 
activation controls monocytes/macrophages phagocytosis and Ag presentation 
(Su Yi et al., 2014, Coffey et al., 2017). SYK inhibitors that were tested in murine 
models and clinical trials have shown promising results in the reduction of 
inflammation in autoimmune diseases (Leonhardt et al., 2012). More importantly, 
targeting SYK signalling is an attractive concept aiming to reduce GVHD 
pathology (Leonhardet et al., 2012, Poe et al., 2018). Therefore, this study 
evaluated the effects of highly selective SYK inhibitor (PRT0603), on modulating 
monocyte/macrophage activation and production of cytokines in the early phase 
of allogeneic cell culture with/without the addition of IFN-γ. 
The findings in this study showed that CD14+ monocytes expressed high levels of 
CD64 in the MLR IFN-γ culture. Although this implies SYK pathway activation, this 
was not confirmed using intracellular staining for phosphorylated SYK protein. 
Nevertheless, it is well established that clustering of CD64 molecules on 
monocyte/macrophage surface results in ITAM phosphorylation and SYK pathway 
activation (Kefer et al., 1998, Coffey et al., 2017). In this part of the study four 
experimental conditions were compared: MLR IFN-γ (allogeneic culture with 
addition of IFN-γ), MLR IFN-γ SYK (allogeneic culture with addition of IFN-γ and 
SYK inhibitor), Res IFN-γ (control for the effect of IFN-γ) and Res IFN-γ SYK 
(control with responder cells IFN-γ and SYK inhibitor).  
Interestingly expression of CD86 HLA-DR and CD64 on CD14+ monocytes were 
slightly reduced in MLR IFN-γ SYK compared to MLR IFN-γ. However, the 
reduction was modest and non-significant. This non-significant reduction could be 
due to the small sample size. It has been reported that PRT0603 is a highly 
selective SYK inhibitor that targets intracellular signalling through FcγRI 
(Hoellenriegel et al., 2012), and targeting of this receptor affects Ag presentation 
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(Junker et al., 2020). The modest effects of PRT0603 SYK inhibitor on 
monocyte/macrophage functions such as co-stimulation and Ag presentation, 
suggest that FcγRI signalling represents a single component of the complex 
interactions between multiple pathways driven by the alloresponse and IFN-γ 
cytokine. Interestingly, the addition of IFN-γ could reduce the potency of the SYK 
inhibitor on monocytes, as in the previous chapter the SYK inhibitor significantly 
down-regulated CD64 expression. In contrast, in this chapter only a modest 
reduction of CD64 expression was observed. Nevertheless, it is feasible that 
relatively small changes in monocytes/macrophages function could lead to 
significant effects on T cells alloreactivity.  
The analysis of T cells in the presence of the SYK inhibitor was performed on D3. 
Notably, the data showed a significant reduction of CD25 expression levels and 
CD69 on CD3+ T cells in MLR IFN-γ SYK when compared to MLR IFN-γ. This has 
confirmed the potential of the SYK inhibitor to reduce activation of CD3+ T cells. 
As CD3+ T cells represent both T cell helper CD4+ cells and cytotoxic CD8+ cells, 
the effects of the SYK inhibitor are broad and affect the total T cell population. 
However, the effects of the SYK inhibitor on CD4+ T helper cells were modest and 
did not reach statistical significance (raw data are provided in the appendix figure 
S.1.5). Indeed, targeting the SYK pathway could indirectly reduce T cell activation 
(Coffey et al., 2017). More importantly, the addition of IFN-γ to the MLR culture 
did not reduce the efficacy of the SYK inhibitor. As described in the previous 
chapter, SYK inhibitor has significantly reduced T cell activation in MLR, in a 
similar way to the data presented in this chapter. 
To evaluate inflammatory response in the MLR IFN-γ culture with/without SYK, 
the concentrations of TNF-α, IL-6 and IL-2 cytokines were measured. The 
supernatant samples were collected on D2 of incubation from MLR IFN-γ, MLR 
IFN-γ SYK, Res IFN-γ and Res IFN-γ SYK cell cultures. Notably, the TNF-α, IL-2 
and IL-6 concentrations were significantly reduced in MLR IFN-γ SYK when 
compared to MLR IFN-γ. Therefore, T cell activities were reduced on D3 as both 
IL-2 and IL-6 are essential for T cells activation. Indeed, IL-2 is mainly produced 
by helper T cells, and it could be regarded as an essential growth factor for both 
CD8+ and CD4+ T cells (Blazar et al., 2013). It has been previously reported that, 
in the early period post HSCT, IL-2 concentrations are increased, which results in 
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stimulation of T cell proliferation and differentiation (Blazar et al., 2013). Therefore, 
lower concentrations of IL-2 due to PRT0603 treatment could affect T cells 
alloreactivity, leading to significant reduction of CD25 expression and a decrease 
in the proportion of CD69 positive CD3+ T cells. Indeed, it has been shown that 
low IL-2 concentrations are associated with lower rate of GVHD (Blazar et al., 
2013, Kumar et al., 2017). Similarly, it is thought that IL-6 is mainly produced by 
classical monocytes (Boyette et al., 2016). In GVHD setting it was proposed that 
IL-6 is involved in controlling T cells maturation and differentiation (Tawara et al., 
2011, Tvedet et al., 2017), and diminishing T cells apoptosis (Duque & 
Descoteaux, 2014). However, inhibition of the SYK pathway resulted in reduction 
of TNF-α concentration in the presence of allogeneic cells and IFN-γ, which did 
not influence significant effect on monocytes. As TNF-α is mainly produced by 
macrophages in GVHD, this cytokine could trigger the inflammatory response 
culminating in up-regulation of co-stimulatory molecules on APCs and activation 
of T cells (Nakamura et al., 2000, Markey et al., 2013, Zhang et al., 2017). The 
data in this study demonstrate that treatment of MLR IFN-γ culture with the SYK 
inhibitor resulted in a modest reduction of monocyte/macrophages expression of 
CD86 and HLA-DR, which is followed by a significant decrease in T cell 
activations. This confirms the importance of the SYK pathway in alloresponse 
(MLR culture) and by implication in GVHD. Although T cells are not directly 
targeted by the SYK inhibitor, it could be postulated that reduced activation of the 
B cell receptor and FcRγ in the alloresponse resulted in a significant change in the 
inflammatory milieu, which indirectly affects T cell response. Indeed, targeting 
cytokine productions is a well-established therapeutic approach to control 
inflammation (Coffey et al., 2013). 
In summary, these findings suggest that administration of IFN-γ to early MLR has 
enhanced the phagocytosis function of monocytes. This could promote monocyte 
differentiation towards a phagocytic phenotype without T cell co-stimulation and 
limited pro-inflammatory potential. Targeting the SYK signalling pathway on 
monocytes/macrophages, in the early phase of MLR IFN-γ culture results in the 
reduction of production of inflammatory cytokines and a subsequent decrease in 
T cells alloreactivity. Notably, the addition of IFN-γ did not reduce the efficacy of 
SYK inhibition in the allogeneic culture. 
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5 Results (Part 3): 
5.1 Introduction and aims: 
IL-4 is a cytokine secreted by mast cells, basophils and Th2 cells (Mosser & 
Edward, 2008, Rahimi et al., 2019). Monocytes and macrophages express IL- 4R, 
and its ligation will activate these cells to become an alternatively activated 
subtype that supports tissue repair (Mosser & Edward, 2008, Raphael et al., 2014, 
O’Brien et al., 2019), and anti-inflammatory response (Lee et al., 2017). 
Interestingly, it has been reported that IL-4 activates macrophages to up-regulate 
CD86 (Deszo et al., 2004).  However, IL-4 activated monocytes fail to present Ag 
to T cells (Mosser & Edward, 2008). Earlier studies reported that high doses (10 
µg) of IL-4 could suppress aGVHD, by antagonising IFN-γ and reducing donor Th1 
cells activities and proliferation in a murine model (Blazer et al., 2013, Via et al., 
2017). 
In this chapter, the Th2 cytokine IL-4 was selected, with the aim of investigating 
monocytes/macrophages function in the early phase of MLR culture for D1 and 
D2 of incubation in response to this cytokine. 
Therefore, the aims of this chapter were: 
• Investigate the effects of IL-4 on activation of monocytes/macrophages in the 
early phase of alloresponse. 
• Investigate the effects of MLR in the presence of IL-4 cytokine on T cell activity. 
• Evaluate the effects of adding IL-4 to early phase MLR culture on the 
production of cytokines. 
• Examine the effects of SYK pathway inhibitor on monocytes/macrophages in 
the early phase alloresponse in the presence of IL-4 cytokine. 
• Investigate the effects of selective SYK inhibitor PRT0603, on T cells 
activation in MLR culture in the presence of IL-4 cytokine. 
• Evaluate the effects of SYK pathway inhibition on cytokine production in early 




5.2.1 Optimising IL-4 concentration: 
10 ng/ml, 50 ng/ml and 100 ng/ml IL-4 were added to MLR culture, and the level of 
expression (MFI) of CD86, HLA- DR and CD64 were measured by flow cytometry on 
D1 and D2 of incubation. The cell viability was confirmed by Annexin V staining, 
where 80-85 % of cells were viable on D1 and D2. All samples were treated with 
Fc blocking and the results were compared to the isotype control to eliminate any 
background of non-specific antibody binding. 
The results (Figure 5.1.A and Figure 5.1.B) show that the expression levels of 
CD86 and HLA-DR were increased after treatment with 100 ng/ml IL-4 when 
compared  to the other concentrations mainly on D2, thought the differences were 
not statistically significant. The results for CD64 (Figure 5.1.C) revealed slight 
changes in expression on the CD14+ monocytes/macrophages on D1 and D2 of 
incubation. Therefore, 100 ng/ml of IL-4 was  selected as the optimal concentration 





Figure 5. 1: Analysis of the level of (MFI) expression on CD14+ monocytes by flow cytometry 
after D1 and D2 of incubation in the presence of with IL-4. A) CD86, B) HLA-DR and C) CD64. 
The X axis shows incubation days, Y axis is MFI expression. Data shown are mean and the error 
bars are SD (n = 3). Yellow bar = MLR treated with 10 ng/ml IL-4, green bar = MLR treated with 
50 ng/ml IL-4 and purple bar = MLR treated with 100 ng/ml IL-4. Statistical significance of data 
was analysed using RM two-way ANOVA with Tukey multiple comparisons test and Geiser -
Greenhouse correction, p values below 0.05 were considered significant. 
5.2.2 Monocyte/macrophage co-stimulation capacity in MLR culture in the 
presence of IL-4 cytokine: 
The expression of the co-stimulatory molecule CD86 was investigated in four 
conditions: responder cells (negative control), MLR (positive alloresponse 
control), MLR treated with 100 ng/ml IL-4 (experimental condition, alloresponse in 
the presence of IL-4) and Res IL-4 (control for IL-4 effects, responder cells treated 
with 100 ng/ml IL-4).  
The results (Figure 5.2.A) showed that MLR culture (alloresponse) in the presence 
of 100 ng/ml of IL-4 significantly up-regulated CD14+CD86+ expression compared 
to the responder (Res) cells (p=0.005), MLR (p=0.0020) and Res IL-4 (p=0.0027) 
on D2 of incubation. There were no significant differences between the four 
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conditions on D1. These data indicate that the presence of allogeneic cells and 
IL-4 cytokine during early phase of response resulted in a strong synergistic effect, 
leading to significant up-regulation on CD14+ monocytes co- stimulation capacity. 
5.2.3 Monocyte/macrophage Ag presentation in early MLR culture with 
addition of IL-4 cytokine: 
To investigate monocytes Ag presentation capacity, HLA-DR expression was 
determined in the four conditions described above. The results (Figure 5.2.B) 
showed that CD14+ cells expressed significantly higher levels of HLA-DR in the 
MLR with addition of 100 ng/ml IL-4 (MLR IL-4) compared to Res (p=0.044) and 
Res IL-4 (p=0.020) on D1. Following the same trend, the CD14+ monocytes in the 
MLR IL-4 culture expressed significantly more HLA-DR when compared to MLR (p 
= 0.0015), Res (p < 0.0001)  and Res IL-4 (p=0.0015) on D2 of incubation. These 
results highlight that during the early phase of alloresponse monocytes/ 
macrophages significantly up-regulate Ag presentation capacity due to the 
combined presence of allogenic   cells in MLR and IL-4 cytokine. 
5.2.4 Analysis of monocytes/macrophages CD64 and CD32B expression in 
early MLR with addition of IL-4 cytokine: 
It is generally regarded that CD64 and CD32B play important roles in 
monocyte/macrophage function, as these Fc receptors contribute to phagocytosis 
of opsonised pathogens and the capture of antibody-antigen complexes. The 
expression of these two markers of monocyte function was investigated in the four 
conditions described above. For CD64 (Figure 5.2.C), on D2 of incubation the 
MLR culture showed higher levels of CD64 expression compared to the other 
conditions with significant difference when compared to MLR IL-4 (p=0.0170), 
and Res IL-4 (p=0.001). Thus, it appears that the presence of IL-4 cytokine in 
the culture inhibits MLR-induced CD64 expression on monocytes. 
For CD32B (Figure 5.2.D) the results showed that CD14+CD32B+ expression in 
MLR IL-4 appeared increased compared to the MLR and other control conditions 
on D1 however, the difference was not significant. Interestingly, CD14+CD32B+ 
expression   down regulated in MLR on D2 compared to the other conditions, 
although the difference did not reach statistical significance. These results suggest 
that unlike CD64 marker, CD32B expression was not significantly affected by the 
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presence of allogeneic cells however, the addition of IL-4 cytokine could up-
regulate the inhibitory receptor CD32B. 
 
 
Figure 5. 2: Analysis of expression on CD14+ monocytes by flow cytometry on D1 and D2 of 
incubation in the presence of allogeneic cells (MLR) and cytokine.IL-4. 
A) CD86, B) HLA-DR, C) CD64, D) CD32B. The X axis shows incubation days, Y axis presents MFI 
expression. Data shown are means and the error bars are SD (n = 3). Black bar represents Res = 
Responder cells as control, orange bar represents MLR = Mixed leukocyte reaction, purple bar 
represents MLR treated with 100 ng/ml IL-4, and yellow bar represents Responder cells treated 
with 100 ng/ml IL-4. Statistical significance of data was analysed using RM two-way ANOVA with 
Tukey multiple comparisons test and Geiser -greenhouse correction, p values below 0.05 were 




5.2.5 Analysis of monocytes/macrophages scavenger receptors in MLR 
culture treated with IL-4 cytokine: 
The monocytes/macrophages expression of scavenger receptors was analysed 
by measuring the level of CD36, and CD204, that could be linked to the capacity 
of monocytes to clear apoptotic cells in the four experimental conditions described 
above. The results for CD36 (Figure 5.3.A) showed that in MLR IL-4 the 
expression of CD14+CD36+ was slightly higher than in the other culture conditions 
(Res, MLR and Res IL-4) on D1, however the difference did not reach statistical 
significance. Interestingly, on D2 of incubation CD14+CD36+ expression was 
reduced in the MLR compared to other experimental conditions, although the 
differences were not significant. Thus, it appears that effects of IL-4 on CD36 
expression in CD14+ are not significant. 
The results for CD204 (Figure 5.3.B) showed that on D1 of incubation, there was 
a significant increase in CD14+CD204+ expression for the MLR compared to Res 
IL-4 culture (p=0.040). There was a modest reduction of CD14+CD204+ 
expression in the MLR IL-4 compared to the MLR, although differences were not 
significant on D1 and D2 of incubation. On D2, there was a significant increase of 
CD14+CD204+ in Res compared to Res IL-4 (p=0.022). These results suggest that 
IL-4 cytokine down regulates CD14+CD204+ expression in 
monocytes/macrophages during D1 and D2 of cell culture, although the observed 
effects were modest. 
5.2.6 Analysis of C3aR expression on CD14+ monocytes in the presence of 
allogeneic cells and MLR IL-4: 
The monocytes/macrophages expression of complement receptor C3aR was 
investigated in four experimental conditions described above. The results for 
C3aR (Figure 5.3.C) showed that on D1 of incubation monocytes/macrophages 
expression of C3aR was at the highest level in MLR compared to other 
experimental conditions, including significant difference from MLR IL-4 culture (p 
< 0.0001). This demonstrates a strong stimulatory effect of early alloresponse on 
monocytes/macrophages C3aR expression and inhibitory effects of IL-4 cytokine. 
Furthermore, C3aR expression was significantly increased in the MLR IL-4 
compared to Res IL-4 (p < 0.0001) probably due to dominant effects of MLR   over 
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IL-4 mediated inhibition. Interestingly, on D2 of incubation the highest levels   of 
monocytes/macrophages C3aR expression was observed in the control 
responder (Res) culture, significantly higher than Res IL-4 (p < 0.0001) and MLR 
IL-4 (p=0.030), indicating inhibitory effects of IL-4 cytokine. Although the 
stimulatory effects of MLR were largely masked on D2 due to the high levels of 
C3aR+ expression in the control Res culture, inhibitory effects of IL-4 were still 
evident. Thus, both MLR and MLR IL-4 expressed significantly higher levels of 
C3aR than Res IL-4 culture (p=0.007 and p=0.0067, respectively). 
5.2.7 Analysis of CD11b expression on CD14+ monocytes in the presence of 
allogeneic cells and IL-4 cytokine: 
The monocytes/macrophages expression of adhesion molecule CD11b was 
investigated using four experimental conditions described above. The results for 
CD14+CD11b+ (Figure 5.3.D) on D1 revealed the strong stimulatory effects of IL- 
4 as both MLR IL-4 and Res IL-4 expressed significantly higher levels of this 
marker compared to Res control (p = 0.0027 and p = 0.0477, respectively) and 
MLR culture (p = 0.0149 for MLR IL-4 vs. MLR). 
 Following the same trend, on D2 of incubation both MLR IL-4 and Res IL-4 
expressed significantly higher levels of CD11b+ than   Res controls (p=0.0043 and 
p = 0.0054, respectively) and MLR culture (p=0.0375 and p =0.0460, respectively). 
This highlights that IL-4 up-regulated CD11 b expression, whereas the presence of 
allogeneic cells did not have significant effects on this marker of 
monocytes/macrophages functions. 
Overall, these results demonstrate distinct effects of IL-4 on 
monocytes/macrophages phenotype and function. Indeed, IL-4 cytokine 
significantly enhanced monocytes/macrophages levels of expression of CD86 and 
HLA-DR. Importantly   this, effect was synergistic with the stimulatory potential of 
alloresponse (MLR culture). Furthermore, IL-4 showed inhibitory effects on the 
expression of CD64 and C3aR during early phase of monocytes/macrophages 
culture and this could not be reversed by alloresponse. Also, IL-4 enhanced the 




Figure 5. 3: Analysis of expression on CD14+ monocytes by flow cytometry after D1 and D2 of 
incubation in the presence of allogeneic cells/MLR and IL-4 cytokine. 
A) CD36, B) CD204, C) C3aR, D) CD11b. The X axis shows incubation days, Y axis is MFI 
expression. Data shown are mean and the error bars are SD (n = 3). Black bar represents Res = 
Responder cells as negative control, orange bar represents MLR = Mixed leukocyte reaction, 
purple bar represents MLR treated with 100 ng/ml IL-4, and yellow bar represents Responder cells 
treated with 100 ng/ml IL-4. Statistical significance of data was analysed using RM two-way 
ANOVA with Tukey multiple comparisons test and Geisser -Greenhouse correction, p values below 
0.05 were considered significant, * = p < 0.05, ** = p < 0. 01, *** = p < 0.001, and **** = p < 0.0001. 
5.2.8 Analysis of T cell activity in MLR treated with IL-4 cytokine: 
After three days of incubation the proportion percent (%) of T cells that express 
CD69 (CD3+CD69+ and CD4+CD69+), and the levels of expression (MFI) of CD25 
(CD3+CD25+ and CD4+CD25+) were assessed to investigate T cells in the four 
experimental conditions: responder cells (-ve control), MLR (+ve allogeneic 
control), MLR IL-4 (experimental condition, MLR treated with 100 ng/ml IL-4) and 
Res IL-4 (control for the effects of IL-4).The data (Figure 5.4.A) showed that the 
MFI values for CD3+CD25+ in the MLR IL-4 culture were significantly lower(p = 
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0.034)  than in the MLR. 
Notably, CD3+CD25+ expression level was significantly higher in the MLR 
compared to Res (p=0.0025), which was seen previously (Figure 3.4.A) and Res 
IL-4 (p=0.0042). Therefore, a strong stimulatory effect of the presence of 
allogeneic cells (MLR) on the expression levels of CD25 in CD3+ T cells on D3 of 
culture was confirmed in this set of experiments. 
The results for CD69 expression (Figure 5.4.B) showed a modest reduction of the 
proportion (%) of CD3+CD69+ T cells in the MLR IL-4 when compared to the MLR. 
However, the difference was not statistically significant. Importantly, the percent 
of CD3+CD69+ T cells was significantly higher in the MLR compared to Res (p = 
0.0001) and Res IL-4 (p=0.0033), which confirms the stimulatory effects of MLR 
on D3 of culture. Furthermore, the proportion of CD69+ T cells was significantly 
increased in MLR IL-4 compared to Res (p=0.0062). This indicates that IL-4 has a 
modest or neutral effect on CD69 expression, as an inhibitory effect would result in 
a much lower percent of CD69+ T cells in MLR IL-4 culture and significant 
difference from MLR culture. 
For the CD4+ T helper cells, the expression levels of CD25 (Figure 5.4.C) were 
significantly increased in the MLR compared to Res (p=0.0499) and Res IL-4 
(p=0.016). Although, CD4+CD25+ expression was lower in the MLR IL-4 culture 
than MLR the difference  was not statistically significant. This indicates stimulatory 
effects of MLR on CD25   expression in helper T cells and a modest/neutral effect 
of the addition of IL-4 to MLR culture. 
For the proportion of CD69+ Th cells (Figure 5.4.D), the results showed that there 
was a modest, non-significant decrease for the MLR IL-4 compared to the MLR on 
D3 of culture. Although the percent of CD4+CD69+ cells appeared higher in MLR 





Figure 5. 4: Analysis T cells activation by flow cytometry on D3 of incubation with/without addition 
of IL-4. 
A) MFI values for CD3+CD25+ T cells where Y axis shows MFI values for CD25 expression, B) 
Percent of CD3+CD69+ T cells where Y axis shows proportion (%) of CD69-positive T cells, C) MFI 
values for CD4+CD25+ T helper cells, and D) proportion (%) of CD4+CD69+ T helper cells. Data 
shown are mean and the error bars are SD (n = 3). Black bar represents Res = Responder cells 
as negative control, orange bar represents MLR = Mixed leukocyte reaction culture, purple bar 
represents MLR treated with 100 ng/ml IL-4, and yellow bar represents responder cells treated 
with 100 ng/ml IL-4. Statistical significance of data was analysed using RM one-way ANOVA with 
Tukey multiple comparison with Geisser greenhouse correction. Values below 0.05 were 




5.2.9 Measurement of cytokines in MLR culture treated with IL-4: 
The cytokines TNF-α, IFN-γ, IL-2 and IL-6 were measured by ELISA on D2 of 
incubation, using the following four conditions: responder cells (negative control), 
MLR (positive alloresponse control), MLR IL-4 (experimental condition, MLR 
treated with 100 ng/ml IL-4) and responder cells treated with 100 ng/ml IL-4 
(control for the effect of IL-4). 
The results for TNF-α (Figure 5.5.A) showed that the concentration of this   
cytokine on D2 of incubation in the MLR IL-4 was significantly lower than in the 
MLR culture (p=0.0042). This indicates an inhibitory effect of IL-4 on MLR- induced 
TNF-α production. Furthermore TNF-α concentration was significantly higher in 
the MLR compared to Res (p=0.0041) and Res IL-4 (p=0.0062). Interestingly, the 
levels of TNF-α in MLR IL-4 were slightly higher than those in Res IL-4. Although 
the difference did not reach statistical significance, this observation suggests that 
IL-4 does not completely inhibit the MLR effects on TNF-α production. 
The results for IFN-γ (Figure 5.5.B) demonstrated that the concentration of this 
cytokine in MLR IL-4 culture was significantly reduced compared to the MLR (p = 
0.0018), thus indicating a strong inhibitory effect of IL-4. Notably, the 
concentrations of IFN-γ were significantly higher in the MLR than Res (p=0.0002) 
and Res IL-4 (p=0.0002), confirming stimulatory effects of MLR on IFN-γ 
production on D2 of culture. 
The data for IL-2 (Figure 5.5.C) showed that MLR IL-4 culture had significantly 
decreased levels of this cytokine compared to the MLR (p=0.0160). Also, IL-2 
concentrations were significantly higher in the MLR culture compared to Res (p = 
0.0017) and Res IL-4 (p=0.0015). These data indicate that MLR strongly 
stimulates IL-2 production on D2 of incubation and that this effect is significantly 
inhibited by the addition of IL-4 to MLR culture. 
The result for IL-6 concentrations (Figure 5.5.D) showed significantly lower levels 
in the MLR IL-4 compared to MLR culture (p=0.0011), implying a strong inhibitory 
effect of IL-4 on MLR-induced IL-6 production. Notably, IL-6 concentrations were 
significantly higher in the MLR compared to Res (p=0.0002) and Res IL-4 (p 




Overall, these results highlight that treatment with 100 ng/ml of IL-4 showed a 
significant inhibitory effect on the production of TNF-α, IFN-γ, IL-2 and IL-6 in the 
early phase of alloresponse, D2 of cell culture. 
 
Figure 5. 5: Measuring cytokines by ELISA on D2 of incubation in MLR culture with/without IL-4. 
A) TNF-α, B) IFN-γ C) IL-2 and D) IL-6 concentrations. X axis shows comparison of four conditions: 
Res = responder cells, MLR = Mixed leukocyte reaction, MLR treated with 100 ng/ml IL-4 and 
Responder cells treated with 100 ng/ml IL-4. Y axis shows the cytokine concentrations in pg/ml. 
Scatter Dot plots show three repeats (n = 3). Statistical significance of data was analysed using 
RM one-way ANOVA, Tukey multiple comparison with Geisser Greenhouse correction. p values 
below 0.05 were considered significant, * = p < 0.01, ** = p < 0.001 and *** = p < 0.0001. 
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5.2.10 Analysis of the effects of SYK inhibitor on monocytes/macrophages in 
MLR treated with IL-4: 
Previously in this chapter, the addition of IL-4 to MLR culture showed a distinct 
effect on monocytes/macrophage. Therefore, this section examined the effects of 
daily treatment with SYK inhibitor, 2 μM PRT0603 on co-stimulation and Ag 
presentation capacity of monocytes/macrophages. The expression of (MFI) for 
CD14+CD86+, CD14+CD64+ and CD14+HLA-DR+ were measured in the following 
four conditions: MLR IL-4 (MLR treated with 100 ng/ml IL-4), MLR IL-4 SYK (MLR 
treated with 100 ng/ml IL-4 and 2 μM anti-SYK), Res IL-4 (Responder cells treated 
with 100 ng/ml IL-4 control for the effects of IL-4) and Res IL-4 SYK (Responder 
cells treated with 100 ng/ml IL-4 and 2 μM anti-SYK). 
For CD86 (Figure 5.6.A), there was a modest reduction in the expression in the 
MLR IL-4 culture treated with anti-SYK when compared with MLR IL-4 on D1 and 
D2 of incubation, however   the difference was not significant. Furthermore, there 
were no changes of CD86 expression in Res IL-4 SYK compared to Res IL-4 on 
D1 and D2. As previously note, the presence of allogeneic cells and IL-4 cytokine 
during early phase of response resulted in a strong synergistic effect, leading to 
significant up-regulation of monocytes/macrophages co-stimulation capacity in 
MLR IL-4 compared to Res IL-4 and Res IL-4 SYK (p=0.019, p=0.026 respectively). 
Also, there were significant differences in MLR IL-4 SYK compared to Res IL-4 
and Res IL-4 SYK (p=0.018, p=0.024 respectively) on D2. 
The data for HLA-DR (Figure 5.6.B) showed similar expression in the MLR IL-4 
SYK culture compared to the MLR IL-4 on D1 and D2 of incubation. Following the 
same trend,  there were no changes in HLA-DR expression in Res IL-4 SYK 
compared to Res IL-4 on D1 and D2. Thus, it appears that the SYK inhibitor does 
not affect MLR- induced increases in HLA-DR+ expression and this is not altered 
by the presence of IL-4 cytokine. As noted in the previously described 
experiments, during early phase of the alloresponse monocytes/macrophages 
have significantly up-regulated Ag presentation capacity due to the combined 
presence of allogeneic cells in (MLR) and IL-4 cytokine. Consequently, CD14+ 
monocytes cells expressed significantly higher levels of HLA-DR in MLR IL-4 
compared to Res IL-4 (p=0.02) and Res IL-4 SYK (p = 0.04) on D2 of incubation. 
Following the same trend, the CD14+ in the MLR IL-4 SYK culture expressed 
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significantly more HLA-DR when compared to Res IL-4 (p = 0.04), Res IL-4 SYK 
(p=0.049) on D2 of incubation. 
For CD64 (Figure 5.6.C), the data revealed the MLR IL-4 with 2 μM of anti-SYK 
showed similar CD64 expression on the CD14+ monocytes compared to MLR IL-
4. Res IL-4 SYK showed same levels of CD14+CD64+ expression when compared 
to Res IL-4. Therefore, SYK inhibition did not show the effects on CD14+ CD64+ 
expression in the presence of allogeneic cells and IL-4 cytokine. 
In summary, these results reveal that although MLR and MLR IL-4 have strongly 
up-regulated   CD86 and HLA-DR on CD14+, the daily treatment with SYK inhibitor 
PRT0603 did not affect these markers. Thus, it appears that the co-stimulation 
and Ag presentation capacity of monocytes/macrophages in the presence of 






Figure 5. 6: Analysis of the expression CD86, HLA-DR and CD64 on CD14+ 
monocytes/macrophages by flow cytometry on D1 and D2 of incubation with/without IL-4 and anti- 
SYK. 
A) CD86, B) HLA-DR and C) CD64. The X axis shows incubation days and Y axis is MFI 
expression. Data shown are mean and the error bars are SD (n = 3). Yellow bar represents Res 
IL-4 = Responder cells as negative allogeneic control treated with 100 ng/ml IL-4, dark yellow bar 
with pattern represents responder cell treated with 100 ng/ml IL-4 and 2 µM anti-SYK, purple bar 
represents MLR IL-4 = Mixed leukocyte reaction treated with 100 ng/ml IL-4, and light purple bar 
with pattern bar represents MLR treated with IL-4 and 2 µM of anti-SYK. Statistical significance of 
data was analysed using RM two-way ANOVA with Tukey multiple comparisons with Geisser 
Greenhouse correction, p values below 0.05 were considered significant. * = p < 0.01, ** = p < 
0.001 and *** = p < 0.0001. 
5.2.11 Analysis of the effects of SYK inhibitor on T cell activity in the  
presence of MLR and IL-4 cytokine: 
In this section, analysis of the effects of daily treatment with SYK inhibitor (2 μM 
PRT0603) on T cells on D3 of incubation was carried out. The CD3+ and CD4+ T 
cells were analysed for the level of expression of CD25 (MFI) and percent (%) of 
CD69+ cells using four experimental conditions described above. The cell viability 
was investigated using Annexin V and showed that more than 90-95 % of cells 
were Annexin -ve after gating on the T cells population (data  not shown). 
The data for CD25 expression (Figure 5.7.A) revealed that there was almost no 
difference in CD3+CD25+ MFI values in the MLR IL-4 treated with 2 μM anti-SYK 
inhibitor and the MLR IL-4. Also, no differences were found between Res IL-4 and 
Res IL-4 SYK. 
The data for the CD3+CD69+ cells (Figure 5.7.B) showed that the proportion (%) 
of CD69+ T cells was reduced in the MLR IL-4 treated with 2 μM anti-SYK 
compared to the MLR IL-4, although the difference did not reach statistical 
significance. Following the same trend, Res IL-4 SYK showed a lower proportion 
(%) of CD3+CD69+ T cells compared to Res IL-4, with a modest difference that 
was not significant. 
For the CD4+ cells (Figure 5.7.C), there were a slight reduction in MFI values for 
CD4+CD25+ in the IL-4 treated with 2 μM anti-SYK when compared to the MLR IL- 
4, however the difference was not statistically significant. Furthermore a small 
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reduction in MFI values for CD4+CD25+ observed for Res IL-4 SYK compared to 
Res IL-4, was not significant. 
Similarly, the results for the proportion (%) of CD4+CD69+ cells (Figure 5.7.D) 
showed a modest reduction in MLR IL-4 with SYK inhibitor compared to MLR IL- 
4, however, the difference did not reach statistical significance. 
Overall, these results highlight that treatment with 2 μM anti-SYK resulted in 
slightly  lower T cell activation levels in the presence of allogeneic cells (MLR) and 
IL-4 cytokine, although the effects were not statistically significant. Thus, the 
therapeutic potential of SYK inhibitor in alloresponse in the presence of IL-4 
cytokine appears to be rather modest. 
 
Figure 5. 7: Analysis of T cells activation by flow cytometer on D3 of incubation in the presence of 
MLR, IL-4 and anti-SYK. 
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A) CD3+CD25+, B) CD3+CD69+, C) CD4+CD25+, and D) CD4+CD69+. Y axis presents MFI 
expression in A and C whereas B and D are present (%) of CD69 positive cells. The X axis shows: 
yellow bar represents Res IL-4 (responder cells treated with 100 ng/ml IL-4), yellow bar with pattern 
represents Res IL-4 SYK (responder cells treated with 100 ng/ml IL-4 and 2 µM anti-SYK), purple 
bar represents MLR IL-4 (Mixed leukocyte reaction treated with 100 ng/ml IL-4), and purple bar 
with pattern represents MLR IL-4 SYK (MLR treated with 100 ng/ml IL-4 and 2 µM of anti-SYK). 
Data shown are mean and the error bars are SD (n = 3). Statistical significance of data was 
analysed using RM one-way ANOVA Tukey multiple comparison with Geisser-greenhouse 
correction, p values below 0.05 were considered significant. 
5.2.12 Measuring cytokine concentrations in MLR treated with IL-4 and SYK 
inhibitor: 
The results presented in (Figure 5.5) showed that the addition of 100 ng/ml of IL- 
4 to MLR culture resulted in a decrease in the concentrations of TNF-α, IFN-γ, IL-
2 and IL-6 cytokines. Nevertheless, the levels of cytokines in MLR IL-4 cultures 
were higher   than in a control, responder cell cultures. Therefore, this section 
evaluated the effects of combining 100 ng/ml IL-4 and 2 μM anti-SYK daily 
treatment on the cytokine production. Thus, TNF-α, IFN-γ, IL-2 and IL-6 
concentrations were measured by sandwich ELISA and the samples were 
collected on D2 of incubation from the same four experimental conditions 
described above. 
The results for TNF-α (Figure 5.8. A) revealed that 2 µM of SYK inhibitor treatment 
significantly decreased TNF-α concentrations in the MLR IL-4 SYK when 
compared to the MLR IL-4 (p=0.0173). For IFN-γ (Figure 5.8.B), the results showed 
a significant reduction in the MLR IL- 4 SYK compared to the MLR IL-4 (p = 0.0007). 
With significant difference in MLR IL-4 compared to Res IL-4 (p=0.034) and Res 
IL-4 SYK (p = 0.021). 
Also, IL-2 (Figure 5.8.C) data showed that the concentrations of this cytokine were 
significantly reduced with 2 µM anti-SYK treatment MLR IL-4 SYK compared to the 
MLR IL-4 (p = 0.0035), significant difference in MLR IL-4 compared to Res IL-4 (p 
= 0.001) and Res IL-4 SYK (p=0.008). 
Although the result for IL-6 (Figure 5.8.D) showed a small decrease in 
concentrations of this cytokine in MLR IL-4 SYK compared to MLR IL-4, the 
difference was not significant. However, significant differences were observed in 
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MLR IL-4 compared to Res IL-4 (p=0.03) and Res IL-4 SYK (p=0.03). 
In summary, these results indicate that SYK inhibitor significantly decreased the 
production of TNF-α, IFN-γ and IL-2 cytokines in MLR culture in the presence of 
IL-4. Notably, this further reduction of cytokine production due to SYK pathway 
inhibition was evident despite the negative influence of IL-4 on the MLR-induced 
cytokine levels. Therefore, relatively modest effects of SYK inhibition on IL-4 
influenced alloresponse may still prove beneficial, as further reduction of Th1 type 
cytokines to below detection levels could result in the quenching of the initial 
inflammation. 
 
Figure 5. 8: Measuring cytokines by ELISA on D2 of incubation in the presence of MLR, IL-4 and 
anti-SYK. 
A) TNF-α, B) IFN-γ, C) IL-2 and D) IL-6 concentrations. X axis shows comparison of the two 
conditions: MLR IL-4 = Mixed leukocyte reaction treated 100 ng/ml IL-4 and MLR IL-4 SYK = Mixed 
leukocyte reaction treated 100 ng/ml IL-4 and 2 µM anti-SYK. Y axis shows the cytokine 
concentration in pg/ml. Scatter Dot plot presents triplicate repeats (n = 3). Statistical significance 
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of data was analysed using RM one-way ANOVA Tukey multiple comparison with Geisser-
Greenhouse correction, p values below 0.05 were considered significant, * = p < 0.05, ** = p < 0.01 
and ***= p < 0.001. 
 
5.3 The effects of SYK inhibitor when MLR is unmodified compared to the MLR 
culture in presence of IFN-γ and IL-4: 
To quantify the effects of the selective SYK inhibitor PRT0603, the percent of 
inhibition of the expression of monocytes/macrophages markers was calculated. 
Furthermore, the percent reduction in T cell activity and a decrease in cytokine 
concentrations were also calculated. The following formula was used: (mean of 
MFI (or cytokine concentration) with SYK/ mean of MFI (or cytokine concentration) 
without SYK x 100) -100.  
5.3.1 Evaluation of the inhibitory effects of PRT0603 on monocytes/ 
macrophages: 
In Figure 5.9 the data for unmodified MLR culture on D1 of incubation showed that 
the  percent of inhibition by SYK inhibitor treatment was 32 % for CD86 expression 
(Figure 5. 9.A), 48 % for HLA-DR (Figure 5. 9.B) and 28 % for CD64 (Figure 5. 
9.C). Similar trends were shown on D2 of incubation 29 % inhibition of CD86 
expression, 34 % of HLA-DR and 32 % inhibition of CD64 expression was 
observed. Interestingly, in the presence of cytokines, IFN-γ and IL-4, the potency 
of the SYK inhibitor was reduced compared to unmodified MLR culture. Indeed, 
the inhibition of CD86, HLA-DR and CD64 expression was 20 % or less on D1 of 
incubation. Similarly, on D2 of incubation the presence of cytokines interfered with 
the SYK inhibitor potency. Thus, the expression of CD86 was inhibited by 14 % in 
MLR IFN-γ and by 27% in MLR IL-4. The expression of HLA-DR reduced by 10 % 
in MLR IFN-γ and by 15% in MLR IL-4. The expression of CD64 decreased by 5 
% in MLR IFN-γ and by 8% in MLR IL-4. 
Overall, the presence of IFN-γ or IL-4 strongly reduced the potency of SYK 
inhibitor in controlling monocytes activities in early allogeneic culture compared to 
unmodified MLR culture. This has important repercussions for the potential clinical 
use of SYK inhibitors, as both acute and chronic GVHD are likely to involve 
production of cytokines, which could interfere with therapeutic efficacy of drugs 






Figure 5. 9: Comparing the precent of inhibition of A) CD86, B) HLA-DR and D) CD64 expression 
after SYK inhibitor treatment:  
Y axis presents the % of inhibition, X axis presents incubation day. Orange square show data 
calculated from MLR after SYK treatment, pink triangle MLR IFN-γ after SYK treatment and MLR 
IL-4 purple circle. The data calculated followed this formula (mean of MFI with SYK/ mean of MFI 
without SYK x 100) -100. 
5.3.2 Evaluation of the inhibitory effects of PRT0603 on T cells and 
cytokine concentrations: 
To compare the inhibitory effect of PRT0603 on the levels of CD25 expression 
(MFI values) on T cells and the proportion of CD69 positive T cells in unmodified 
MLR culture and in the presence of cytokines (IFN-γ or IL-4), following formula 
was used. The mean of MFI (or proportion of CD69+ cells) with SYK/ mean of MFI 
(or proportion of CD69+ cells) without SYK x 100) -100.  
The data showed (Figure 5. 10) that the SYK inhibitor reduced CD3+CD25+ MFI 
values by 42 % in unmodified MLR and by 44 % in MLR IFN-γ cultures. The 
reduction was less prominent in the MLR IL4 culture by only 15 %. For early T cell 
activation marker, CD69 expression change from negative to positive, the 
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reduction in CD3+ population was pronounced in all conditions. Indeed, the SYK 
inhibitor resulted in 65 %, 59 %, 54 % reduction in MLR, MLR IFN-γ and MLR IL-
4 respectively.  
By evaluating the effects of the SYK inhibitor on CD4+ T cell population, the data 
showed that the SYK inhibitor reduced CD25 expression levels (MFI) by 25 %, 
15% and 17% in unmodified MLR, MLR IFN-γ and MLR IL-4 respectively. The 
proportion of CD69+ cells reduced by 33 % in unmodified MLR culture, 20% in 
MLR IFN-γ and 33% in MLR IL-4. Overall, reductions of the proportion of CD69+ 
T cells were more pronounced after SYK inhibitor treatment in both CD3+ and 
CD4+ T cells. This is in contrast with the less potent inhibition of CD25 expression 
levels. This is an interesting observation, as CD25 expression is linked with both 
effector and regulatory T cells. Thus, relative sparing of CD25 expression may 
allow SYK inhibitors to preferentially target effector T cells. Notably, the presence 
of cytokines IFN-γ and IL-4 slightly affected the potency of SYK inhibitor effects 
on T cells compared to unmodified MLR culture. This finding highlights the 
importance of SYK pathway in T cell activation and suggests that IFN-γ and IL-4 
do not provide additional signals to T cells that could override SYK inhibition. This 
is in sharp contrast with the data on monocytes, where the presence of cytokines 
interferes with SYK inhibitor effects. 
In Figure 5.10.B the data presented the reduction of cytokine concentrations due 
to the SYK inhibitor treatment. TNF-α concentration were reduced by 87 % in 
unmodified MLR culture, reduced by 91 % in MLR IFN-γ and the reduction reached 
92 % in MLR IL-4. Furthermore, IFN-γ concentrations were reduced due to SYK 
inhibitor treatment by 88 % in unmodified MLR and 80 % in MLR IL-4 culture. 
Similarly, IL-2 concentration decreased due to the SYK treatment by 82 %, 79 % 
and 80 % in unmodified MLR, MLR IFN-γ and MLR IL-4 culture respectively. 
However, IL-6 concentration decreased by 90 % in unmodified MLR, whereas the 
presence of IL-4 and IFN-γ have substantially interfere with the effectiveness of 
SYK inhibitor by 55 % in MLR IFN-γ and 48 % in MLR IL-4. 
Similar to effects on T cells, the potency of SYK inhibitor to diminish the cytokine 
concentrations was not affected by the presence of cytokines IL-4 or IFN-γ added 
to MLR culture. Indeed, the SYK inhibitor mediated reduction of cytokines was 
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impressive in all investigated conditions, the unmodified MLR, the MLR IFN-γ and 
the MLR IL-4 culture. This points out that the SYK inhibitor therapy could show 
robust effects in challenging, inflammatory environment with a presence of large 
quantities of cytokines. This data will be discussed in the general discussion 
section 6. 
 
Figure 5. 10: Comparing the potency of inhibition of A) T cells activation B) cytokine concentration 
after the SYK inhibitor treatment:  
Y axis presents the % of inhibition, X axis A) T cells surface markers, B) Cytokine concentrations 
(TNF-α, IFN-γ, IL-2 and IL-6). Orange square data calculated from MLR after SYK inhibitor 
treatment, pink triangle represents MLR IFN-γ after SYK inhibitor treatment and data from MLR 
IL-4 are presented as purple circle. The data were calculated following this formula: (mean of MFI 
with SYK/ mean of MFI without SYK x 100) -100. 
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5.4 Discussion (Part 3): 
The discussion for the results presented in chapter 5 (MLR IL-4), can be divided 
into two parts. The first part evaluated the effects of IL-4 on alloresponse/MLR   
monocytes/macrophages function and, T cells activation. The second part 
evaluated the effects of combining IL-4 and treatment with the SYK inhibitor 
PRT0603 in the MLR setting. Notably, IL-4 is produced by T cells, NK cells 
basophils and eosinophils (Junttila, 2018, Via et al., 2017). IL-4 was selected in 
this study as a Th2 cytokine that could modify the inflammatory response and 
antagonise Th1 cytokines (Via et al., 2017). IL-4 controls lymphocytes function: it 
causes T cells to differentiate into the Th2 phenotype, and controls 
immunoglobulin class switching by B cells (Junttila, 2018, Zhao et al., 2018). Many 
studies have highlighted the therapeutic potential of IL-4 to control T cell activities 
(Raphael et al., 2014, Kumar et al., 2017, Junttila, 2018). The study by Via and 
colleagues (2017) showed that early administration of a high dose (10 µg) of IL-4 
control T cells alloresponse, reduced aGVHD (Via et al., 2017). Notably, the high 
doses of IL-4, above the physiological levels were needed to achieve 
pharmacological effects in GVHD setting. Furthermore, it has been proposed that 
IL-4 enhances monocyte differentiation into intermediate monocytes and to 
polarise macrophages toward the alternative macrophage (M2) type, which have 
anti-inflammatory and tissue repair functions (Duque & Descoteaux, 2014, 
Raphael et al., 2014, Murray et al., 2017). However, human monocytes or 
macrophages subsets and their functions are different, as each subset reacts 
differently, depending on the activator context (Mosser & Edwards, 2008, Boyette 
et al., 2016). IL-4 binds to two types of IL-4 receptors based on the cellular type, 
T cells mainly express IL-4RI, whereas epithelial cells expressed IL-4 RII (Junttila, 
2018, Zhao et al., 2018). Interestingly myeloid cells including monocytes and 
macrophages expressed both receptors type (Junttila, 2018, Zhao et al., 2018). 
This study evaluated monocytes/macrophage’s function and T cell activity after 
administration of IL-4 to the early allogeneic cell culture (MLR). To optimise the IL-
4 concentration in MLR setting, three different concentrations 10, 50 and 100 
ng/ml of IL-4 were used and evaluated for the expression of CD86, CD64 and 
HLA-DR. The higher dose of 100 ng/ml IL-4 was the most consistent in the whole 
blood 2-way MLR model. Importantly, none of the IL-4 concentrations used in this 
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study showed cytotoxic effects, thus the viability of cells in the culture was >85 % 
in all experimental conditions. The study by Delneste et al. (2003) on human 
monocytes differentiation in vitro used IL-4 and IFN-γ, the cytokine concentrations 
in the range of 25-100 ng/ml to achieve changes in monocytes phenotype 
(Delneste, 2003). This is remarkably similar to the concentrations used in this 
study. Furthermore, Delneste et al. (2003) used purified monocytes cell culture, 
whereas this study was based on whole blood culture. As the bioavailability of 
cytokines is affected by the presence of the complex whole blood matrix, the 
effective cytokine concentrations in this study are likely to be lower than that used 
by Delneste et al. (Delneste, 2003). It has been reported that low doses of IL-4 will 
bind to IL-4 R type I with high affinity (Junttila, 2018). However, the use of high 
concentrations of IL-4 in this report did not show any negative effects on cell 
viability, and changes in the monocyte phenotype showed similar trends across 
the full range of investigated concentrations. Therefore, it could be argued that a 
relatively high cytokine concentration could preserve its activity during several 
days of cell culture without affecting cell viability and their function. Obviously, this 
may not apply to all conditions and an optimal cytokine concentration needs to be 
evaluated in a particular experimental model. Notably, several cell cultures studies 
that activate monocytes used high non-physiological cytokine concentrations 
(Delneste, 2003, Bayik et al., 2017) 
This study evaluated the effects of treating the alloresponse/MLR with IL-4, by 
analysing the expression of CD86, HLA-DR, CD64, CD32, CD36, CD204, C3aR 
and CD11b on the CD14+ monocytes. The results observed in MLR IL-4 culture 
were compared to MLR, Res and Res IL-4. During the flow cytometer staining 
procedure, all samples were treated with Fc blocking and the results were 
compared to the isotype control to eliminate background of nonspecific antibody 
binding. Cell viability was assessed after D1 and D2 of incubation days by Annexin 
V, and 80 to 85 % of monocytes in the gated population were Annexin V negative, 
confirming that the cells were viable. However, CD14+ monocytes viability data on 
D3 showed 45 to 50 % Annexin positive cells, thus the D3 result were excluded 
from analysis. 
Interestingly, the data in this report showed that CD14+ monocytes in MLR IL-4 
culture significantly up-regulated CD86, HLA-DR and CD11b expression, with 
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significant down regulation of CD64 and C3aR expression. The explanation for 
this observation is based on the following:  when IL-4 binds to IL-4R on monocytes, 
this activates JAK1-JAK3 signalling which results in STAT6 phosphorylation. 
Subsequently, the STAT6 dimer is translocated to the nucleus, triggering 
transcriptions of the genes for HLA-DR and CD86 on APCs (Deneys et al., 2001, 
Zhao et al., 2018). Thus, IL-4 controlled CD86 and HLA-DR expression via STAT6 
pathway (Deneys et al., 2001, Deszo et al., 2003, Balce et al., 2011). Although 
this report did not address the precise mechanism of IL-4 effects on isolated 
monocytes, it could be postulated that IL-4 could trigger STAT6 phosphorylation, 
resulting in enhanced co-stimulation and Ag presentation capacity compared to 
untreated MLR control. Thus, the data from this study helped to clarify the effects 
of IL-4 in the early phase of immune response to allogeneic cells, with particular 
focus on the role of CD14+ monocytes/macrophages, highlighting that IL-4 did not 
control the inhibitory effect through co-stimulation. However, this study did not 
evaluate the expression of the co- inhibitory CD80 molecule, which needs to be 
measured in the future work. These results support previous studies that have 
showed IL-4 mediated induction of HLA-DR expression in monocytes (Roussetf et 
al., 1988, Anje et al., 1990, Lee et al., 2017). However, the data in this study 
contradicted the observation of via et al (2017), where IL-4 controlled T cell 
proliferation indirectly by reducing Ag presentation capacity in an aGVHD mouse 
model (Via et al., 2017). In this work, CD64 was selected as an activator FcγRI 
and CD32B (FcγRIIB) as an inhibitory receptor (Zhao et al., 2018). When FcγR 
binds to the Fc region of the immune complex (antibody-antigen complex), this 
controls internalisation and phagocytosis of the immune complex, and later Ag 
presentation (Brandsma et al., 2018, Zhao et al., 2018). The observations 
described here suggest that the presence of allogeneic cells (MLR) enhances 
phagocytic and antibody-antigen capture functions of monocytes. Whereas the 
addition of IL-4 cytokine to the MLR culture inhibited these effects. Furthermore, 
these results could be interpreted in the light of changes in the monocyte 
phenotype in the alloresponse/MLR triggering an increase in the classical 
monocytes, whereas IL-4 showed the opposite effects. The results reported here 
support previous studies that showed the down regulation of CD64 expression, 
due to IL-4 treatment which limited classical monocytes differentiation 
(Akinrinmade et al., 2018, Duque & Descoteaux, 2014). The reduction of CD64 
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expression could reflect the status of SYK downstream signalling. The role of 
CD64 clustering and SYK activation was already discussed in Chapter 4 (Kiefer 
et al., 1998, Coffey et al., 2016). The further analysis of intracellular staining for 
the SYK phosphorylation could be useful to show the activation state of the SYK 
pathway in this model. However, previous extensive study of SYK signalling 
(Coffey et al., 2016) enable the prediction of the effects of FcγR ligation and SYK 
pathway inhibition, without the need to repeat experiments that were already 
reported.CD32B was selected as a monocyte inhibitory marker, although its role 
in human monocytes and particularly in GVHD pathology have been less studied, 
with most research focused on CD32B expression in DCs (Brandsma et al., 2019, 
Junker et al., 2020). This study evaluated CD32B expression on 
monocytes/macrophages in early response to the allogeneic reaction and 
treatment with IL-4 cytokine. The results in MLR IL-4 cell culture showed up-
regulation of CD32B on CD14+ monocytes compared to MLR, Res and Res IL-4 
on D1 but the differences were not statistically significant (raw data are presented 
in the appendix Figure S.1.6). These results may suggest that unlike the CD64 
marker, CD32B expression was not significantly affected by the presence of 
allogeneic cells or the addition of IL-4 cytokine. Regarding the monocyte 
phenotype, the alloresponse and IL-4 on CD32B expression, which is associated 
with intermediate monocyte phenotype, did not produce significant effects. That 
could be due to limited number of experiments, that needs to consider in further 
investigation. Notably, up-regulation of CD32B is mainly involved in the monocyte 
inhibitory response (Brandsma et al., 2018). Although this study did not investigate 
monocytes subtype and CD16 expression was not determined to define 
CD14+CD16-CD64+ and CD14+CD16+CD32B+ populations, down-regulation of 
CD64 and up-regulation of CD32B+ in the MLRIL-4 culture suggest that IL-4 may 
promote an intermediate monocyte subtype. This could infer that the presence of 
IL-4 combined with alloresponse resulted in monocyte differentiation towards a 
subtype that has some anti-inflammatory features. Interestingly, monocytes that 
express CD32B (inhibitory receptor) can capture and process immune complexes 
and present the processed Ag to T cells, resulting in weak T cell activation in an 
experimental model based on murine DCs (Junker et al., 2020).  Therefore, the 
intermediate monocytes highly express MHC-II, FcγRIIB and are recruited in the 
later stages of inflammation to enhance antigen presentation, secretion of anti-
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inflammatory cytokines and chemokines, and to initiate wound healing (Tacke & 
Randolph, 2006, Belhareth & Mege, 2015).  
In this study, phenotypical analysis of CD36 and CD204 expression on CD14+ 
cells were performed to evaluate clearance of apoptotic cells. Interestingly, CD36 
is considered an important phagocytic marker expressed on the surface of M2 
macrophages to recognise apoptotic cells (Pennathur et al., 2015). The current 
data on the CD14+ monocytes expression of CD36 in the early phase of GVHD 
are limited and it is unclear if this molecule is a marker for immune tolerance or a 
strong alloresponse. Based on this study, the role of the CD36 molecule appears 
to be limited, with modest increase in its expression on monocytes observed in 
the early phase of MLR culture in the presence of IL-4 cytokine.  
The expression of CD204 on CD14+ monocytes is slightly down regulated in the 
MLR IL-4 when compared to the MLR culture. The reduction of CD14+CD204+ 
expression was also observed on Res IL-4 compared to Res. These data 
contradict a previously published study, which reported that CD204 expression 
was enhanced by IL-4 (Ohtaki et al., 2010). The possible explanation of this 
observation could be that IL-4 antagonise the effect of TNF-α, which is increased 
in the allogeneic culture. Hence, the reduction of TNF-α could result in down 
regulation of CD204. In this study, administration of IL-4 to the early MLR culture 
may have promoted the capture of apoptotic cells by monocytes via CD36 rather 
than CD204, which could affect monocyte function and their differentiation into a 
distinct phenotype. However, this concept needs to be interpreted with caution, as 
the IL-4 mediated changes in the expression of scavenger receptors were modest 
and did not reach statistical significance. Nevertheless, the monocytes expression 
of CD36 and CD204 showed large variations, thus the future work will need to 
address this by increasing the number of experimental repeats or by improving 
the methodology. 
Monocytes/macrophages expressed C3aR at high concentration (Mommert et al., 
2018). The data revealed that the addition of IL-4 to early MLR culture significantly 
down-regulated the expression of C3aR on monocytes/macrophages when 
compared to the control MLR culture on D1 of incubation. The monocyte 
expression of C3aR dropped even further on D2 of incubation, confirming that IL-
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4 treatment has negative effect on C3aR levels. The data in this study support the 
previous observation obtained using a different experimental model, which 
showed a reduction of C3aR on human M2 macrophages in an allergic reaction in 
the presence of IL-4 and histamine (Mommert et al., 2018). Notably, it has been 
reported that targeting C3aR on mice DCs lowered the Ag presentation capacity, 
APCs activation, reduced HLA-DR expression and decreases IFN-γ production 
(Nguyen et al., 2015). More importantly, C3aR deficiency on APCs reduced T cell 
priming and decreased the onset of aGVHD (Nguyen et al., 2015). Notably, the 
reduction of C3aR could be a potential sign that IL-4 could control monocytes 
activities in early allogeneic culture. However, in this study CD86 and HLA-DR 
were highly expressed on CD14+ monocytes/macrophages after IL-4 treatment. 
Thus, the role of IL-4 and the expression of C3aR on human 
monocytes/macrophages in early allogeneic cell culture requires further study, to 
confirm IL-4 function. At present, it could be postulated that IL-4 mediated 
decrease in C3aR expression which reflects the development of M2 macrophages 
and promotes an anti-inflammatory response. Nevertheless, this effect of IL-4 
cytokine needs to be balanced with a striking stimulation of 
monocyte/macrophages CD86 expression. 
CD11b is one of the key markers that are expressed on the surface of 
monocytes/macrophages particularly the M2 subtype, with an anti-inflammatory 
function (Ma et al., 2019). CD11b is also considered as a main regulator for 
monocyte migration and adhesion (Zheng et al., 2015, Lukácsi et al., 2017, Baba 
et al., 2020). Furthermore, CD11b is considered as a differentiation and activation 
marker (Sprangers 2016, Baba et al., 2020). Notably, monocytes/macrophages 
can change their response to inflammation based on the microenvironment milieu 
(Zheng et al., 2015). 
The data in this study showed that CD11b expression is mainly controlled by IL-4 
treatment, without a significant contribution by the allogeneic reaction. Thus, IL-4 
showed a strong effect on monocytes/macrophage migration and adhesion 
functions, which was not affected by the presence of allogeneic cells. The data 
reported here broadly agreed with previous studies that showed IL-4 induced 
CD11b expression on macrophages due to STAT6 activation after IL-4R ligation 
(Deszo et al., 2003, Zheng et al., 2015). Therefore, it appears that the MLR culture 
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represents a robust model of an immune response with a good insight into 
monocyte function. However, it is difficult to confirm the role of the specific 
subtypes due to monocytes plasticity in the MLR culture. However, the early 
allogeneic culture with IL-4 cytokine activated monocytes and they are mainly 
differentiated to monocytes derived macrophages, as demonstrated by CD11b 
expression, and they are capable of co-stimulation and presenting Ag to T cells. 
Furthermore, T cell activation levels were analysed on D3 of incubation by 
evaluating the proportion of (%) CD69 and expression (MFI) CD25 on the surface 
of CD3+ and CD4+ cells. Generally, CD4+T helper cells have been associated with 
early GVHD development (Hong et al., 2020). Moreover, it has been reported that 
IL-4 reduces T cell proliferation and migration in aGVHD (Via et al., 2017). The 
data in this study showed a significant reduction of CD25 expression levels (MFI 
values) on CD3+ T cells with modest non-significant decrease in CD3+CD69+, and 
CD4+CD69+, CD4+CD25+ markers in the MLR treated with IL-4 when compared to 
the control MLR culture. These findings showed that the early phase of the 
alloresponse/MLR culture, IL-4 stimulates CD14+ cells co-stimulatory and Ag 
presenting functions, while at the same time this cytokine down regulates T cell 
activation. This agrees with a previous study that reported activation of 
macrophages in vitro with IL-4, leading to enhanced Ag presentation, but failure 
to present Ag to T cells (Mosser & Edwards, 2008). Thus, the T cell response is 
mainly controlled by the cytokine environment (Junttila, 2018).  
The culture supernatants collected on D2 of incubation were measured for the 
concentrations of specific inflammatory cytokines: TNF-α, IFN-γ, IL-2 and IL-6. 
The data in this study showed that 100 ng/ml of IL-4 significantly lowered the 
concentrations of TNF-α, IFN-γ, IL-2 and IL-6 in MLR-IL-4 when compared to the 
control MLR culture, which could be a protective effect of IL-4 in controlling the 
early allogeneic response. These data agree with a previous study in a different 
model, which reported that the Th2 type response can down regulate the 
production of Th1 cytokines, resulting in reduced pathogenesis of GVHD (Kumar 
et al., 2017). In GVHD, TNF-α plays an essential role by controlling tissue damage 
and enhancing cells apoptosis (Kumar et al., 2017, Via et al. ,2017). 
Interestingly, in a mouse model, blockage of TNF-α or absence of IFN-γ showed 
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therapeutic effects in aGVHD but promoted development of cGVHD (Kumar et al., 
2017, Via et al., 2017). These results are in accordance with a study that reported 
that IL-4 reduced IFN-γ secretion and resulted in suppression of CD8 T cells 
(Raphael et al., 2014, Via et al., 2017). Whereas, in this report, the effect of IL-4 
to antagonise IFN-γ was linked to a significant reduction of CD25 level on CD3+ 
cells, which comprises CD8+ T cell population.  
In this report, the reduction of IL-2 and IL-6 could be linked with the low TNF-α 
concentration observed in the MLR IL-4 culture. It has been reported that IL-6 in 
GVHD stimulates the production of TNF-α by APCs (Deeg, H 2001, Tawara et al., 
2011, Tvedt et al., 2017, Drobyski et al., 2018). Furthermore, the antagonism 
between IL-4 and IL-2 could explain the lack of T cell activation in the MLR IL-4 
culture (Markey et al., 2014), as low concentrations of IL-2 post HSCT were 
associated with a decrease in GVHD incidence (Kumar et al., 2017). Indeed, the 
data in this report support the concept that IL-6 cytokine could be involved in the 
control of T cells activation (Tawara et al., 2011, Drobyski et al., 2018). In this 
context, reduction of IL-6 concentrations due to IL-4 treatment could result in the 
lowered levels of alloresponse, as IL-6 could be secreted by activated 
monocytes/macrophages, and this cytokine has been associated with the 
development of aGVHD (Tawara et al., 2011, Tvedt et al., 2017, Drobyski et al., 
2018, Hong et al., 2020). Notably, in some experimental models, IL-4 showed a 
protective role, such as reduced inflammation in GVHD (Kumar et al., 2017, Via 
et al., 2017). In this report, the addition of the IL-4 cytokine to the MLR culture 
generates the unique inflammatory conditions that promote monocyte/APC 
activation, while at the same time antagonised the inflammatory cytokines in MLR 
culture that result in limiting T cell response. The findings in this study suggests 
that treating MLR with 100 ng/ml of IL-4 could showed a therapeutic potential in 
the early allogeneic response. Notably, the data showed that monocytes in the 2-
way MLR with non-physiological IL-4 concentration could reacted similarly to 
monocytes in isolated cell culture.  
The second part of this chapter evaluated the effects of combining a treatment 
with 2 µM PRT0603 (anti-SYK) and 100 ng/ml IL-4 cytokine. The expression levels 
(MFI values) for CD86, HLA-DR and CD64 were measured by flow cytometry to 
evaluate the phenotype and function of the monocytes/macrophages in following 
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conditions: MLR IL-4 SYK (experimental condition, MLR treated with 100 ng/ml IL-
4 and 2 µM anti-SYK), MLR IL-4 (allogeneic response/MLR treated with IL-4), Res 
IL-4 (responder cells treated with IL-4) and Res IL-4 SYK (responder cells treated 
withIL-4 and anti-SYK). The results showed that with 2 µM of the SYK inhibitor, 
there were no changes in CD86, HLA-DR and CD64 expression. This suggests 
that the SYK pathway is involved in the control of CD86 and HLA-DR expression 
during the alloresponse and not in the IL-4 driven response. This is in contrast to 
previous observations that showed that Fostamatinib (a non-selective SYK 
inhibitor) mediated a decrease in CD86 expression on macrophages in a mouse 
model of GVHD (Flynn et al., 2015). 
 Considering that CD64 is a Fcγ receptor, which uses the SYK pathway for 
downstream signal transmission, it could be regarded as unexpected that the SYK 
inhibitor does not affect expression of this marker. However, it is feasible that IL-
4 treatment controls CD64 expression in such a way that any further inhibition by 
the SYK inhibitor is non-significant.  
Importantly, on D3 of incubation CD3+ and CD4+ T cell activation levels were 
evaluated by measuring MFI values for CD25 and percent (%) of T cells positive 
for CD69 expression. The data indicate that SYK treatment may not affect T cells 
activation levels in the MLR IL-4 culture, although the effects did not reach 
statistical significance (raw data in appendix Figure S.1.7). Thus, the data needs 
to be interpreted with caution and further study is required. Notably, the effects of 
SYK inhibitor were observed despite the low levels of TNF-α, IFN-γ IL-2 cytokine 
production in the presence of IL-4. Thus, SYK inhibition achieves further, profound 
reduction of cytokine production with values that were often below detection limits. 
This could be particularly important in GVHD setting, as even a minute increase 
in cytokine levels could trigger a spiral of inflammation leading to severe 
pathology. The data in this study support a previous report that showed that SYK 
pathway inhibition resulted in lower TNF-α secretion (Su Yi et al., 2014). 
Furthermore, significant reduction in IL-2 secretion could explain the slightly lower 
levels of T cells activation in the MLR IL-4 SYK culture. Interestingly, despite the 
reduction in TNF-α and IFN-γ concentrations, the levels of CD86 expression on 
CD14+ remained relatively high in the MLR IL-4 SYK culture. This is in contrast 
with previous studies, which reported that TNF-α is the principal factor that 
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controlled CD86 expression, whereas IFN-γ controlled HLA-DR expression and 
Ag presentation (Raphael et al., 2014, Lee et al., 2017). However, these results 
could support the concept that CD86 and HLA-DR expression is regulated by IL-
4 ligation to their receptor which does not involve SYK activation. As such, the 
SYK treatment did not control that high expression. 
In summary, addition of IL-4 cytokine to the early allogeneic culture, activated 
monocytes/macrophages, resulting in cells that highly express CD86 and MHCII 
with low phagocytosis capacity through FcR, C3aR and CD204. That caused 
neutral effects on T cells activities and as expected, IL-4 antagonise other 
cytokines in the allogeneic culture. However, using IL-4 as a treatment is not a 
safe option to control monocytes/macrophages in the allogeneic response. 
Indeed, IL-4 combined with the SYK inhibitor did not control 
monocytes/macrophages or T cells activation, although this treatment did 
significantly reduce cytokine concentrations. 
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6 General discussion: 
HSCT is a therapeutic option for many diseases (Welniak et al., 2007, Hill and 
Koyama 2020), however, infections and GVHD severely limit the successful use 
of HSCT (Deneys et al., 2001, Blazar et al., 2013, Wang and Young, 2014, Hill 
and Koyama 2020). Despite improvements in MHC matching, the inevitable 
presence of mismatched miHA antigens may stimulate a strong immune 
response by donor T cells, leading to the development of GVHD (Shlomchik, 
2007, Hill and Koyama 2020). Furthermore, activation of APCs, especially 
monocytes, in the early phase of GVHD, play a crucial role in the pathology. 
Monocytes maintain an important role in innate and adaptive immunity (Tack and 
Randolph 2006, Sprangers et al., 2016). Monocytes have short half-life in human 
circulation, after 3 days monocytes based in the microenvironment differentiate 
to macrophages or DCs (Tack and Randolph 2006). Monocyte-derived 
macrophages mainly adapt to the surrounding environment (Wang et al., 2014, 
Murray., 2017). Changes in extrinsic pathway, such as cytokine levels, could 
control macrophage polarisation, therefore, it is possible to evaluate in vitro 
monocyte-derived macrophage surface marker expression maintained by 
changing cytokines in the extrinsic pathway to control monocytes differentiation 
and polarisation towards the M1 phenotype, with high Ag presentation capacity 
(Wang and Yang, 2014, Murray, 2017). Several studies have shown that IFN-γ is 
essential for activation of monocytes that appear to adapt to the proinflammatory 
response (Blazar et al., 2013, Deneys et al., 2001, Wang and Young, 2014). It 
was proposed that after TBI, damaged tissue activated APCs that release IFN-γ 
and this cytokine control monocytes differentiation into macrophages during the 
early phase of GVHD (Deeg, 2001, Blazar et al., 2013, Murray, 2017). 
Furthermore, activated donor T helper cells secret high concentrations of IFN- γ 
in response to endotoxin (LPS) (Deeg, 2001, Murray, 2017). This in turn activates 
the innate immune response to produce additional proinflammatory cytokines 
(Wang and Yange, 2014). Notably, monocytes cultured with IFN-γ and TNF-α will 
acquired M1 morphology, however, if monocytes are cultured with IL-4, then the 
monocyte-derived macrophages will give rise to the M2 macrophages (Martinez 
and Gordon, 2014). This knowledge was obtained using either cell cultures of 
PBMCs, isolated monocytes or animal models, in contrast, this study avoided 
experimental manipulation of human monocytes by using whole blood culture and 
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a short incubation period. Although this study used high, non-physiological 
concentrations of IFN-γ and IL-4 to activate the monocytes, the dosing of these 
cytokines was based on extensive concentration optimising experiments. 
Interestingly, other papers support the use of high cytokine concentrations to 
activate monocytes in vitro. The study by Delneste et al. (2003) on human 
monocyte differentiation in vitro used IL-4 and IFN-γ cytokine concentrations in 
the range of 25-100 ng/ml to achieve changes in the monocyte phenotype 
(Delneste, 2003). These are remarkably similar to the concentrations used in this 
study. Furthermore, Bayik et al. (2017) used 500 ng/ml of IFN-γ to allow human 
monocyte maturation, which is 5 times more than the levels of cytokine used in 
this study (Bayik et al., 2017). Importantly, the data in this study showed that in 
the unmodified, whole blood MLR culture, the monocytes activation pattern 
shares many features of the monocytes obtained from inflamed tissues of GVHD 
patients (Jardine et al., 2019). The MLR culture in this study allowed activation, 
stimulation, and proliferation of both stimulatory and responder cells. 
Furthermore, the complex nature of the whole blood MLR allows interactions of 
many cells, including neutrophils, platelets, and the differentiation of monocytes 
to macrophages, depending on the cytokine milieu. This could be similar to the 
conditions in GVHD patients, where the graft T cells interact with both host and 
donor cells, including neutrophils and myeloid cells (Jardine et al., 2019).  Indeed, 
recent studies in GVHD patients have confirmed the critical role of infiltrated 
donor monocyte-derived macrophages in the affected skin, which activate 
pathogenic T cells (Jardine et al., 2019, Young et al., 2020). Thus, the data from 
this report could highlights the similarity between recent clinical observations 
(Jardine et al., 2019, Young et al., 2020) and the phenotype of activated 
monocytes in the whole blood MLR culture. Nevertheless, further studies are 
needed to confirm these findings. The current understanding of how multiple 
cytokines are integrated in the allogeneic environment remains limited. As the 
concept of cytokine therapy is well established in GVHD, this study evaluated the 
effect of IFN-γ and IL-4 on early monocyte activation that contributed to the 
response of allogeneic T cells in MLR culture.  
Signalling for both cytokines IFN-γ and IL-4 is mediated by the JAK/STAT 
pathway via STAT1/2 and STAT6, respectively (Lin and Leonard, 2019). 
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JAK/STAT signalling in monocytes/macrophages results in transcriptional 
enhancement or changes in cellular functions such as phagocytosis, Ag 
presentation and co-stimulation. A previous study has reported that these two 
cytokines can share the same STAT protein to enhance or antagonise the effects 
of each other (Lin and Leonard, 2019). This study used administration of IFN-γ 
and IL-4 to the MLR culture, followed by evaluation of the levels of expression 
(MFI) values for 8 surface receptors on monocytes/macrophages by flow 
cytometry: CD86, HLA-DR, CD64, CD32B, CD36, CD204, C3aR and CD11b, as 
each marker could be linked to one of the monocytes functions. In addition, this 
study investigated the therapeutic potential of highly selective SYK inhibitor 
(PRT0603) that targets monocytes/macrophages FcγR signalling by inhibiting the 
SYK pathway. This enabled evaluation of the role of FcγR in the early phase of 
allogeneic cell culture.  
The data collected from early MLR culture represented the allogeneic reaction. 
Notably, TCR is the only molecule that can recognise MHC I or MHC II 
polymorphisms (Ferrat et al., 1991, Blazar et al., 2013, Zeiser et al., 2016 and 
Lee et al., 2018). In this study, T cells could recognise the polymorphic Ag on D1 
that result in IL-2 secretion to activate monocytes, the activated monocytes 
released cytokines that also control the expression of monocytes markers. Thus, 
based on the data available, it could be concluded that this mechanism is likely 
to operate in all conditions: MLR, MLR IFN-γ and MLR IL-4 cultures. Notably, the 
data reveal that activated monocytes in unmodified MLR culture expressed 
several surface markers and produced cytokines that could be linked with the 
classical subtype. As monocytes share similarity to data reported by previous 
studies, where activation of classical monocytes (Deeg, H 2001, Tawara et al., 
2011, Sprangers et al. 2016, Boyette et al., 2016, Tvedt et al., 2017). 
Furthermore, based on the preceding (D1 and D2) activation of 
monocytes/macrophages in the MLR culture, it appears that the early functional 
response of monocytes plays an important role in subsequent T cells 
alloresponse (on D3 of incubation), including both total CD3+ T cells and helper 
CD4+ T cells. Notably, it has been reported that priming of the T helper cells has 
been associated with early GVHD development (Koehen et al., 2015, Zeiser et 
al., 2016 and Hong et al., 2020). The presence of inflammatory conditions in the 
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early phase of alloresponse/MLR culture due to stimulatory signals provided by 
allogeneic cells is confirmed by significant increases of TNF-α, IFN-γ, IL-6 and 
IL-2 concentrations in the MLR culture, when compared to the responder cells 
control. Although this study did not determine the origin of these cytokines, at this 
early stage of alloresponse, monocytes/macrophages were clearly activated. 
Thus, it could be postulated that TNF-α, IFN-γ and IL-6 are likely to be secreted 
by monocytes/macrophages. On the other hand, IL-2 could be produced by T 
cells. However, intracellular cytokine analysis is needed to address the limitation 
of current study in the future work.  
The results of this study revealed that the allogeneic response in whole blood 
MLR culture could activates monocytes/macrophages in a similar way to the 
reactions generated in a clinical aGVHD setting. However, due to limited number 
of monocyte markers analysed in this study, limited cytokine measurements, and 
the lack of intracellular cytokines staining, the relevance of this model to the 
clinical setting remains speculative.  Furthermore, whole blood MLR culture was 
also used to evaluate the effect of administration of IFN-γ and IL-4 cytokines on 
monocytes/macrophage’s function.  
These data indicate that the presence of IFN-γ does not play a strong pro-
inflammatory role during the early phase of alloresponse. The key contribution of 
IFN-γ to the alloresponse appears to be to drive CD14+ monocytes differentiation 
towards a defence against pathogens mode, with limited inflammatory response 
and modest effects on T cell priming. 
In contrast, administration of IL-4 to the MLR culture steers monocytes towards 
a distinct functional state, characterised by the high levels of CD86, HLA-DR and 
CD11b expression, and decreased the levels of CD64 and C3aR expression.  
However, IL-4 inhibited MLR-induced T cell activation and showed antagonistic 
effects on Th1 type cytokines. Indeed, this highlight the need of further analysis 
of Tregs in the future work, as it has been recently reported that combining IL-2 
and IL-4 could induce Treg formation (Zhou et al., 2020). Interestingly, in 
response to allo-Ag, activated APCs released IFN-γ cytokine (Wang et al., 2014, 
Lee & Ashkar, 2018). HLA-DR expression is thought to be controlled by IFN-γ 
binding to IFN-γR to activate JAK/STAT signalling, resulting in increased 
transcription of MHC II genes: HLA-DR, DP, DQ, Li and HLA-DM (Axelrod et al., 
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2019). However, in this study, the effects of IFN-γ on monocytes expression of 
HLA-DR were rather modest. This could be a distinct feature of peripheral blood 
monocytes that differs from other APCs. Alternatively, the unique environment of 
the whole blood culture may have influenced the effects of IFN-γ.  In contrast, in 
MLR IL-4 culture a strong increase in HLA-DR expression was observed, which 
highlights the role of IFN-γ independent pathway responsible for HLA-DR up-
regulation that was triggered by the ligation of IL-4 to IL-4R.  
CD86 expression is controlled by either receptor cross-linking or cytokine 
stimulation (Axelrod et al., 2019). The data in this study showed that CD86 
expression was up-regulated by different pathways, in MLR and MLR IFN-γ 
cultures CD86 could be triggered by cross-linking of MHC II to TCR during 
allogeneic recognition. However, the MLR IL-4 culture showed a strong up-
regulation of CD86 expression that could be linked to the well-known 
phosphorylation of STAT6 protein that follows ligation of IL-4R (Tugal et al., 
2013). Indeed, the data revealed that IL-4 stimulation of CD86 expression was 
much stronger than that observed in MLR and MLR IFN- γ cultures.  
The data in this study revealed that stimulating monocytes by allogeneic cells in 
MLR culture initiates inflammation due to the observed production of cytokines. 
Furthermore, it is generally accepted that the CD64 molecule is involved in 
inflammation. CD64 expression is controlled by IFN-γ binding to IFN-γ receptor. 
Indeed, the results presented here show that CD64 expression is increased in 
MLR and MLR IFN-γ cultures. Notably, the expression of CD64 was higher after 
adding IFN-γ to the MLR culture. As expected, IL-4 has opposite effects to IFN-
γ, which was confirmed by the observed significant reduction of CD64 expression 
in the MLR IL-4 culture. The likely explanation could be that IL-4 mediated STAT6 
phosphorylation which inhibits activation of a number of genes, including CD64 
(Tugal et al., 2013). This finding highlights the importance of CD64 expression on 
monocytes/macrophages as an early marker in allogeneic reaction that indicates 
the predominant effects of IFN-γ cytokine. Notably, the data showed that the 
phenotype of monocytes/macrophages in MLR-IL-4 culture could be defined as 
M2, which is different from the phenotype in MLR and MLR IFN-γ cultures.  
The allogeneic culture (MLR) significantly enhanced C3aR expression on CD14+ 
monocytes. Unexpectedly, both cytokines, IFN-γ and IL-4, appear to negatively 
control C3aR expression on monocytes, and that could lead to a defect in T cells 
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priming. Notably, CD64 and C3aR are co-expressed on the surface of monocytes 
to mediate inflammatory response (Mommert et al., 2004). Therefore, it appears 
that an increased level of expression of CD64 on monocytes is controlled by the 
administration of IFN-γ to the cell culture. Conversely, the high concentration of 
IFN-γ negatively controls C3aR expression. Furthermore, administration of the 
IL-4 cytokine to the MLR culture significantly down-regulated the expression of 
C3aR on CD14+ monocytes as monocytes in MLR IL-4 showed some anti-
inflammatory response. It has been reported that reducing C3aR could have 
beneficial effects and may down regulate the inflammatory response. This is 
supported by the previous report that showed targeting C3aR on mice DCs lowers 
their Ag presentation capacity and decreases IFN-γ production (Nguyen et al., 
2015). More importantly, C3aR deficiency on APCs reduces T cell priming and 
delays the onset of aGVHD (Nguyen et al., 2015). The data in this study showed 
that monocyte CD11b expression was not involved in the inflammatory response 
induced by allogeneic cells in MLR, or allogeneic cells treated with the IFN-γ 
cytokine in MLR IFN-γ culture. Although additional experiments may be needed 
to confirm this observation and to determine mechanisms responsible for CD11b 
expression on monocytes. However, this study indicates that CD11b was 
controlled by IL-4 signalling. These data support previous studies reporting that 
IL-4 induces CD11b expression in the cell line with characteristics of alternative 
activated M2 macrophages (Deszo et al., 2003), and in a mouse model (Zheng 
et al., 2015).  
Furthermore, based on the preceding (D1 and D2) activation of 
monocytes/macrophages in the MLR culture, it appears that early functional 
response of the monocytes plays an important role in subsequent T cells 
alloresponse (on D3 of incubation), including both total CD3+ T cells and helper 
CD4+ T cells. Moreover, the data in this study has revealed that adding IFN-γ 
cytokine to the MLR culture caused modest effects on T cell activation. There 
were no synergistic effects when the IFN-γ cytokine was combined with MLR 
stimulus. Indeed, the significant increase in T cell activity in MLR IFN-γ culture 
can be attributed to the role of allogeneic cells but not IFN-γ. Although T cells 
express IFN-γ receptors on their surface (Boehm et al., 1997), the data in this 
study showed that IFN-γ did not activate T cells directly, which highlights the role 
of allogeneic cells and monocytes/macrophages in the priming of T cells. 
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Recently, it has been reported that IFN-γ induced apoptosis of activated T cells 
and reduced proliferation of activated allogeneic cells by up-regulation of PD-1 
(Lee et al., 2017). Therefore, the findings in this study could be explained by IFN-
γ induced apoptosis of T cells, which highlights the importance of analysis of the 
expression of PD-1 on T cells and PDL-1/PDL-2 on macrophages in the future 
work. Notably, IL-4 showed opposing effects on monocyte/macrophages and T 
cells, as IL-4 enhanced monocyte/macrophages capacity to co-stimulate and 
present antigens, and at the same time it appeared to limit T cell activation. This 
could be linked to differentiation into intermediate monocytes and the 
development of M2 macrophages, which were reported to show high Ag capacity 
and co-stimulation potential, but generate weak T cells activation (Lee et al., 2017 
and Junker et al., 2020). Alternatively, it is feasible that monocyte activated by IL-
4 release IL-10, and this cytokine could inhibit effector T cells and induce 
regulatory T cells. This highlights the importance of considering measurements 
of IL-10 concentrations and T reg analysis in the future work. It has been reported 
that one of the strategies to control GVHD in early phase is reducing T cells 
priming by administration of IL-4 (Markey et al., 2014 and Via et al., 2017). 
However, it is difficult to ensure the therapeutic potential of IL-4, as it strongly 
activates monocytes/macrophages. Indeed, the finding in this study could explain 
the recent report of the limited benefits of using IL-4 to control aGVHD, and 
subsequent development of cGVHD (Via et al., 2017). 
Overall, the data in this study demonstrate the plasticity of the monocyte 
responses to the presence of allogeneic cells and to the addition of specific 
cytokines. In fact, these findings strongly argue against the oversimplified 
categorisation of monocytes into pro- and anti-inflammatory subtypes. Instead, 
based on these novel data, it could be proposed that monocyte function and 
phenotype is determined by the presence of the dominant cytokine. Thus, two 
subtypes are proposed in this study, IFN-γ and IL-4 driven monocytes. Notably, 
these two monocyte subtypes could differentiate into monocyte-derived 
macrophages and their phenotypes are clearly distinct from previously defined 
categories. Importantly, these novel, cytokine driven monocyte subtypes were 
defined using a whole blood culture and early phase of alloresponse. This 
ensures minimal alteration of monocytes and maintains conditions that could 
closely mimic the physiological setting.  
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The second part of this study investigated the effects of the SYK inhibitor, 
PRT0603, on controlling monocytes/macrophage’s function, cytokine secretion 
and T cells activation in MLR, MLR IFN-γ and MLR IL-4 cultures. SYK is a protein 
tyrosine kinase expressed on B cells, mast cells, monocytes, and macrophages. 
It controls outside/in signal transduction, resulting in distinct cellular responses 
(Leonhardt et al., 2012, Yi et al., 2014, Coffey et al., 2017, Kato et al., 2017). It is 
well established that monocytes/macrophages functions, including phagocytosis, 
Ag presentation, oxidative burst and cytokines secretion are controlled by SYK 
activation. Thus, SYK inhibition suppresses the monocytes/macrophages 
inflammatory response (Yi et al., 2014, Coffey et al., 2017, Leonhardt et al., 
2012). Importantly, SYK activation is involved in transmitting signalling from FcRs 
expressed on monocytes/macrophages, which controls crucial events in the 
development of GVHD (Leonhardt et al., 2012, Poe et al., 2018). Consequently, 
targeting SYK signalling by using an SYK inhibitor is an attractive approach to 
control GVHD pathology (Leonhardet et al., 2012, Poe et al., 2018). Notably, SYK 
inhibition appears to control T cells activation indirectly (Leonhardet et al., 2012, 
Coffey et al., 2017). The results in this study suggest that there was a significant 
increase in the levels of monocyte CD64 expression (high-affinity human IgG 
receptor, FcγRI) in allogeneic culture with and without IFN-γ, which could be 
linked to activation of SYK downstream signalling. An earlier study reported that 
ligation of FcγR on macrophages directly regulates phosphorylation signalling, 
even before the peak of phagocytosis (Kiefer et al., 1998). On the other hand, the 
MLR IL-4 culture showed a reduction of CD64 expression that may indicate 
antagonism with SYK pathway. However, intracellular staining was not performed 
in this study to confirm SYK activation status. This study used PRT0603 (a parent 
compound for PRT0626), which is a highly selective SYK inhibitor that showed 
complete suppression of BCR and FcRs signalling, resulting in reduced 
inflammation in rheumatoid arthritis patients (Coffey et al., 2013). This study 
evaluated the therapeutic potential of targeting the SYK pathway in 
monocytes/macrophages by using 2 µM PRT0603 and measuring expression of 
CD64 (FcγRI), CD86 and HLA-DR on CD14+ monocytes/macrophages.  
The data revealed that PRT0603 significantly reduced CD64 expression in MLR 
SYK culture. Furthermore, SYK inhibition resulted in a short term (observed on 
D1 of incubation) inhibition of HLA-DR expression. This could be explained by 
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PRT0603 mediated down regulation of CD64, as CD64 was reported to control 
inflammatory response by up-regulation of HLA-DR expression (Brandsma et al., 
2018). However, inhibition of SYK pathway did not significantly control expression 
of the co-stimulatory molecule CD86 on CD14+ monocytes. This could imply that 
the co-stimulatory function of monocytes/macrophages is regulated 
independently from SYK, however, this important observation needs to be 
confirmed by additional experiments and the precise mechanisms should be 
determined. Notably, the MLR IFN-γ culture treated with PRT0603 showed a 
modest, non-significant reduction in monocytes/macrophages functions, FcγRI 
expression, co-stimulation, and Ag presentation. Thus, it is feasible that the 
activation of monocytes/macrophages to support phagocytosis function is a 
component of the innate immune response induced by IFN-γ treatment, which is 
not affected by SYK inhibitor. Furthermore, the SYK inhibitor did not affect CD86, 
HLA-DR and CD64 expression on monocytes/macrophages in the MLR IL-4 
culture. Thus, it appears that co-stimulation and Ag presentation capacity of 
monocytes/macrophages in the presence of allogeneic cells and IL-4 are not 
regulated by the SYK pathway. Alternatively, IL-4 treatment reduces CD64 
expression to such an extent that any further inhibition by SYK inhibitor is non-
significant. The inhibitory effect of PRT0603 in various experimental conditions 
was compared by calculating the percent of inhibition for each marker on 
monocytes/macrophages (Figure 5.9). Overall, SYK inhibition resulted in reduced 
monocytes marker expression in unmodified MLR, however, both cytokines (IFN- 
γ and IL-4) reduced the potency of this inhibitor. Thus, SYK treatment showed 
less inhibitory effect on monocytes/macrophages when compared to unmodified 
MLR. This is an important observation suggesting a limited efficacy of this SYK 
inhibitor in controlling monocytes/macrophages activation in inflammatory 
condition, which are likely to be present in aGVHD.  
Notably, PRT0603 treatment resulted in reduced activation of CD3+ T cells in 
MLR SYK. This could be linked to the down-regulation of Ag presentation 
capacity provided by monocytes/macrophages, followed by reduction in cytokine 
concentration. Therefore, T cells alloreactivity appears to be affected indirectly by 
SYK inhibitor treatment. That agrees with the hypothesis in this study that 
controlling early monocytes/macrophages response could regulate T cells 
alloresponse. Whereas in MLR IFN-γ cultures PRT0603 treatment reduced CD3+ 
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T cells without significant changes in monocytes/macrophages activation. 
Therefore, T cells alloreactivity appears to be affected by the reduction of cytokine 
concentration. The data in this study indicate that the SYK inhibitor does not 
significantly affect T cells activation levels in the MLR IL-4 culture. However, as 
administration of IL-4 to the allogeneic culture has previously shown a reduction 
in T cells activation, it is feasible that the SYK inhibitor has a limited scope for 
effects in a condition with a minimal level of T cell activity. This observation was 
confirmed by calculating the relative inhibitory effect of PRT0603 and comparing 
the percent of inhibition of T cells in unmodified MLR, MLR IFN-γ and MLR IL-4 
(Figure 5.10. A). The presence of IL-4 cytokine in the MLR culture (IL-4 MLR) 
showed low potency of the SYK inhibitor to prevent activation of CD3+ T cells. 
That could be due to minimal T cell activities in MLR IL-4. Notably, the reductions 
of CD3+ CD25+ T cells were more pronounced after SYK inhibitor treatment in 
both unmodified MLR and MLR IFN-γ. This highlights the efficacy of controlling T 
cell activation by SYK inhibitor treatment. Furthermore, the results in this study 
indicate that the SYK inhibitor predominantly controls cytokine secretion in all 
experimental conditions, MLR, IFN-γ MLR and IL-4 MLR. That probably affected 
indirectly T cells early activation. Nevertheless, the SYK inhibitor has shown 
therapeutic potential in a new model of allogeneic response by targeting cytokine 
production to control inflammation (Coffey et al., 2013). Although SYK treatment 
did not control monocytes/macrophages functions, it resulted in the reduction of 
cytokine production, which could be considered as an important tool in controlling 
inflammation in the alloresponse in an in vitro model that could mirrors allogeneic 
reaction.  
To verify this, the precent of cytokine reduction was calculated (Figure 5.10.B). 
Interestingly, the SYK inhibitor mediated reduction of cytokines was impressive 
in all investigated conditions, the unmodified MLR, the MLR IFN-γ and the MLR 
IL-4 culture. This points out that the SYK inhibitor therapy could show robust 
effects in challenging, inflammatory environment with a presence of large 
quantities of cytokines.  
In conclusion, this study suggests that monocytes/macrophages activation in the 
early phase of allogeneic response is followed by priming of T cells. The 
difference between IFN-γ and IL-4 effects on monocytes/macrophages function 
in the early allogeneic culture appears to originate from their different stimulation 
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mechanisms: IFN-γ has enhanced phagocytosis function whereas, IL-4 cytokine 
antagonised this effect and up-regulated the co-stimulation and the Ag 
presentation on monocytes/macrophages during the early allogeneic culture. 
This study has shown that blocking of the SYK pathway results in the reduction 
of monocyte CD64 and HLA-DR expression in the unmodified MLR culture, as 
well as a profound decrease in the production of inflammatory cytokines. This led 
to a reduction in T cells activation. PRT0603 SYK inhibitor showed therapeutic 
potential in reducing cytokine concentrations that lead to T cell inhibition in MLR 
IFN-γ. When MLR culture is stimulated with IL-4 the SYK inhibitor reduced 
cytokine concentrations. Thus, PRT0603 could be therapeutic option in 
controlling the cytokine driven inflammatory response in allogeneic culture and 




7 Limitations and future work: 
7.1 Limitations: 
There are a number of limitations of this study, firstly due to the relatively small 
number of repeats for each experiment analysing monocytes/macrophages and T 
cells surface markers expression and cytokine concentrations, it is necessary to 
interpret the data with caution. Indeed, a small number of repeats could be the 
reason for loss of statistical significance in some experiments, particularly when 
this is combined with a large variation in measured values. Furthermore, the data 
which show significance with this low number of repeats may benefit from 
increased power of statistical analysis that is associated with a larger number of 
experiments. Notably, this was due to the pandemics and lockdown, which 
restricted the time available for experimental work. Furthermore, some of the 
blood samples received from the NHS were rejected due to their collection time, 
as only samples delivered within 24 hours showed acceptable level of monocytes 
viability.  
Flow cytometry instrument that was used in this study was CyAn ADP flow 
cytometer (Beckman Coulter, USA), which has two excitation lasers. 
Consequently, this instrument allows the analysis of the limited number of markers 
in a single sample. Conversely, an instrument with 3 or more lasers, such as LSR 
Fortessa, would allow in depth analysis of the cell phenotype with a large number 
of markers analysed simultaneously. For example, CD14+ monocytes could be 
analysed for the expression of CD16, CD64, CD86 and HLA-DR markers, and at 
the same time apoptotic cells could be excluded using Annexin, and the responder 
population could be distinguished from allogeneic stimulators by using CFSE 
staining. This approach could be used in the future work by introducing a more 
powerful flow cytometer instrument. 
This study uses high, non-physiological cytokine concentrations, and MHC 
mismatched blood samples in MLR cell cultures, which are not reflecting the 
conditions present in GVHD patients. However, in vitro models can rarely mimic 
in vivo environment. Indeed, MHC matched blood samples that only differ in minor 
histocompatibility antigens cannot be used for MLR cultures and analysis of 
monocytes, as the immune response develops slowly and would require 
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incubation periods of 3-4 weeks (Delaney et al., 2015). Furthermore, this study 
has used extensive optimisation of the cytokine concentrations to activate 
monocytes in MHC mismatched MLR model. The preliminary results have 
indicated that high concentration of cytokine is required to activate monocyte 
cultured in vitro in whole blood MLR model. Notably, similar concentrations of IL-
4 and IFN-γ were used by other study (Delneste, et al., 2003) or even 5 times 
more than the levels of cytokine used in this study by Bayik et al (2017). Thus, in 
order to differentiate human monocytes in vitro, a high concentration of cytokine 
appears to be needed. Importantly, high cytokine concentrations did not affect 
monocytes or T cells viability, and they showed strong allogeneic responses, 
similar to that reported in other studies (Delneste et al., 2003, Bayik et al., 2017). 
Furthermore, a limited number of surface markers were evaluated to characterise 
monocytes/macrophage’s phenotype and function. Additional markers would 
benefit the study and should be considered in the future work. The expression of 
CD80 was measures in preliminary experiments, however, no difference in the 
levels were observed between MLR culture and Responder cell control (data not 
shown). Nevertheless, the analysis of CD80 expression in other conditions such 
as IFN-γ MLR and IL-4 MLR cultures should be conducted in the future.  As this 
study has only evaluated T cells activation in MLR cultures, it would be valuable 
to determine T cells proliferation in the future work. Furthermore, there was a lack 
of cytokine intracellular staining to specify the source of cytokines and 
measurements of additional cytokines such as IL-5. IL-7, IL-12 and IL-17 could 
help in a more comprehensive evaluation of immune response in MLR model. 
Notably, IL-1β was measured, but the data were below detection limits. Thus, the 








7.2 Future work:  
In the future work, analysing the samples with BD LSR Fortessa flow cytometry 
instrument should be considered, as this will allow multicolour panel design and 
analysis of T cells and monocytes within the same sample. Thus, a single 
experimental run will provide detail characterisation of the phenotypes of the key 
cell populations and subpopulations. For example, CD14+ monocytes could be 
analysed for CD1c+ expression to exclude DCs, and monocytes subtypes could be 
determined based on the expression of CD16, CCR2 and CX3CR1 markers. The 
multi-colour panel also allows analysis of T cells populations, including Tregs that 
could be affected by the presence of IL-4 in MLR culture. Thus, Tregs could be 
analysed in MLR IL-4 and compared to unmodified MLR culture. Furthermore, the 
effects of SYK inhibitor on Tregs could be evaluated by analysing MLR SYK and 
MLR IL-4 SYK cultures. It could be valuable to analyse the expression of program 
death 1 (PD-1) marker on T cells and program death ligand 1 (PDL-1) on 
monocytes/macrophages, as these molecules are involved in immune tolerance. 
Thus, the future work could include investigation of the role of PD-1/PDL-1 
interaction in the regulation of early allogeneic culture in unmodified MLR and in the 
presence of IFN-γ, IL-4 and SYK inhibitor.  
The use of intracellular analysis with a mixed panel can be used to evaluate 
monocytes and, T cells cytokines and specify the cells that secrete TNF-α, IFN-γ, 
IL-2, and IL-6. That will help to conclude which cells are affected by SYK treatment 
and which reduced the proinflammatory cytokine concentrations. Further cytokine 
analysis will consider measuring the concentration of IL-12 and IL-17, as both are 
essential for T cell formation. Measuring the concentration of the anti-inflammatory 
cytokines IL-10 and IL-4 will evaluate if the anti-inflammatory reaction is enhanced 
after SYK treatment. 
Furthermore, T cells proliferation could be assessed using carboxy fluorescein 
diacetate succinimidyl ester (CFSE) staining.  Thus, T cells proliferation could be 
determined in unmodified MLR, and MLR culture in the presence of cytokines, IFN-




The comparison of the highly selective SYK inhibitor, PRT0603, and the less 
selective first generation SYK inhibitor Fostamatinib could reveal the importance of 
the “off-target” effects in controlling allogeneic response. Indeed, it has been 
recently reported that in addition to SYK, Fostamatinib inhibited 117 kinases, 100 of 
which had half-maximal inhibitory concentration (IC50) values within 3-fold of the 
IC50 value for SYK (Zarrinet al.,2021). The off targets for Fostamatinib include 
FLT1, vascular endothelial growth factor receptor 2 (VEGFR2), SRC, FLT3, LYN 
and LCK. Consequently, it is feasible that Fostamatinib could show more potent 
effects than PRT0603 in MLR model, however, this would also indicate potential risk 
of side effects associated with the functional roles of off-target 
pathways. Conversely, the therapeutic potential of PRT0603 could be similar to that 
of Fostamatinib, suggesting that SYK pathway plays a prominent role in allogeneic 
response, and that the use of the second generation, selective SYK inhibitors could 
represent a promising treatment option. However, the data cannot be confirmed in 
vitro as this model focused on cellular interaction, and this model did not measure 
the level of toxicity for each treatment. Thus, further study in vivo is required to 





8.1 T cells gating strategies: 
 
Figure S1. 1: Analysis of lymphocytes viability, CD3 + and CD4+ expression. 
Day 3 of incubation A) Lymphocytes population is gated on (FSC/SSC) in region 
R1. B) The histogram shows Annexin V negative (viable cells) and Annexin V 
positive, non-viable cells. C) The histogram shows CD3- and CD3+ cells (65% of 
cells) populations. D) The histogram shows CD4- and CD4+ cells (55% of cells) 
populations. 









Figure S1. 2: Analysis of CD3 T cells activation by flow cytometer on D3 of incubation. 
The dot plots comparing 4 conditions: responder cells as negative allogeneic control (Res), 
responder cells with 2µM PRT0603 negative control treated with inhibitor to check SYK toxicity 
(Res SYK), mixed leukocyte reaction (MLR) as +ve allogeneic control and mixed leukocyte reaction 
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X axis represents CD69-PE, Y axis presents CD3-APC. 
 
8.3 Analysing the expression of CD86 on CD14+ monocyte/macrophages (in 
MLR, MLR SYK, Res and Res SYK): 
 
Figure S1. 3: Flow cytometry histograms that present expression of CD86+ on CD14+ in four 
experimental conditions on D2 of cell culture. 
A) Isotype control, B) Res = responder cells as a negative allogeneic control, C) MLR = mixed 
leukocyte reaction as a positive allogeneic control, D) Res SYK = responder cells treated with 
2 µM PRT0603, E) MLR SYK = mixed leukocyte reaction treated with 2 µM PRT0603 γ, the 














8.4 Analysing the expression of CD64 on CD14+ monocyte/macrophages (in 
MLR, MLR IFN-γ, Res and Res IFN-γ): 
 
Figure S1. 4: Flow cytometry histograms that present expression of CD64+ on CD14+ in four 
experimental conditions on D2 of cell culture. 
A) Isotype control, B) MLR = mixed leukocyte reaction as a positive allogeneic control, C) MLR 
IFN-γ = mixed leukocyte reaction treated with 100 ng/ml IFN-γ, D) Res = responder cells as a 
negative allogeneic control, E) Res IFN-γ = responder cells treated with 100 ng/ml IFN-γ. the 
histograms shifted to the right when the MFI values for CD64 expression increased. 
8.5 CD4+CD25+ T cells activation analysis before and after SYK treatment (MLR 
IFN-γ, Res IFN-γ, MLR IFN-γ SYK and Res IFN-γ SYK): 
Figure S1. 5: Analysis of CD4 T cells activation by flow cytometer on D3 of incubation. 
The dot plots comparing 4 conditions: Res IFN-γ (responder cells as a negative control treated 
with 100 ng/ml IFN-γ), Res IFN-γ SYK (control for the effect of IFN-γ and PRT0603 SYK inhibitor), 
MLR IFN-γ (allogeneic control treated with IFN-γ), MLR IFN-γ SYK (mixed leukocyte reaction 
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expression on CD4+ helper T cells, X axis presents CD25 -PE and Y axis presents CD4-APC. 
8.6 Analysing the expression of CD32 on CD14+ monocyte/macrophages (in 
MLR, MLR IL-4, Res and Res IL-4): 
Figure S1. 6: Flow cytometer histograms presenting expression of CD14+CD32+ in four conditions 
on D1of incubation. 
A) Isotype control B) MLR = mixed leukocyte reaction, as allogeneic control C) MLR IL-4 = mixed 
leukocyte reaction treated with 100 ng/ml IL-4 D) Res = responder cells as a negative control E) 
Res IL-4 = responder cells as treated with 100 ng/ml IL-4. The histogram shifted to the right due 
to  the increase in MFI values for CD32 expression. 
8.7 CD3+CD69+ T cells activation analysis before and after SYK treatment (MLR 
IL-4, Res IL-4, MLR IL-4 SYK and Res IL-4 SYK): 
Figure S1. 7: Analysis of CD3+ T cells activation by flow cytometer on D3 of incubation. 
The dot plot graphs compare 4 conditions: Res IL-4 = responder cells as control treated with 100 
ng/ml IL-4, Res IL-4 SYK = responder cells treated with 100 ng/ml IL-4 and 2 µM PRT0603, MLR IL-
4 = mixed leukocyte reaction treated with 100 ng/ml IL-4, MLR IL-4 SYK = experimental condition, 
mixed leukocyte reaction treated with 100 ng/ml IL-4 and 2 µM PRT0603. To evaluate 
% of CD3+CD69+ cells, X axis represents CD69-PE and Y axis presents CD3-APC. 
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